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Abstract 
The  relationship  between  hypertension  and  cardiovascular  morbidity  has  long  been 
recognised.  However  evidence  is  mounting  implicating  hypotension  and  not 
hypertension  as  the  predominant  risk  factor  for  mortality.  I  demonstrated  a  20-30% 
prevalence of intradialytic symptoms and hypotension in children during conventional, 
4 hour haemodialysis (HD) sessions. The declining blood pressure (BP) was originally 
believed to be caused by ultrafiltration (UF) and priming of the HD circuit due to loss of 
fluid from the intravascular space.  However data, largely in adults, challenged this 
hypothesis leading to a new consensus that intradialytic hypotension has a multifactorial 
aetiology. The uraemic milieu triggers a series of events that alters the cardiovascular 
compensatory responses to haemodynamic stresses, however the extent to which these 
physiological responses are impaired and their consequences are unknown and poorly 
understood.   
 
At first I corroborated adult findings that a poor correlation existed between relative 
blood volume changes and intradialytic hypotension in children, supporting the theory 
that fluid removal alone was not responsible for cardiovascular decompensation during 
HD  and  this  assumption  was  a  gross  oversimplification  of  the  underlying  problem. 
Using  a  traditional  method  (endocardial  wall  motion)  and  a  novel  method  (Speckle 
tracking  2-dimensional  strain)  I  then  measured  the  regional  left  ventricular  (LV) 
function in children (aged 2 to 17 years) at the start of dialysis and again during peak 
stress at the end of HD. I found rising cardiac troponin I levels in 25% of the cohort and 
reduced regional LV function in all the children examined. The level of dysfunction 
significantly  correlated  with  actual  BP,  the  degree  of  intradialytic  BP  fall  and  UF 
volumes. What remains unclear however is whether the fall in BP was the cause or 
effect  of  the  ischaemic  cardiac  injury.  Finally  I  investigated  dialysis  methods  for 
abrogating intradialytic morbidy in children treated with four hour HD sessions. A step 
sodium  profile  from  148mmol/l to  138mmol/l, prophylactic  mannitol  and  sequential 
dialysis were successful, to variable degrees in attenuating intradialytic symptoms or 
hypotensive  episodes.  Intradialytic  midodrine  was  exclusively  used  in  one  patient 
resistant  to  all  other  forms  of  therapy  and  was  found  to  be  the  most efficacious  in 
supporting the BP and preventing hypotension. 
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Chapter One 
Introduction: Intradialytic Hypotension  
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1.1  Epidemiology 
During haemodialysis (HD) the objective is to remove all the sodium and water that 
accumulates in the inter-dialytic period within the few hours of treatment time. The 
major barrier to achieving this goal is the development of haemodynamic instability, 
manifesting as hypovolaemia related symptoms or intradialytic hypotension. In adults 
this occurs on average in 20-30% treatments
1 with a resultant risk of under dialysis from 
recurrent treatment interruptions and patients remaining volume overloaded. There is a 
clear  correlation  between  high  blood  pressure  (BP)  and  the  risk  of  stroke.  Several 
observational studies in patients with essential hypertension also describe a “J” shaped 
curve between diastolic blood pressure (BP) and mortality
2. The same trend has been 
described in dialysis patients, with a suggestion that hypertension is associated with 
morbidity but mortality is associated with hypotension
3. In adults, patients with pre-
dialysis systolic BP less than 110 mmHg have a fourfold increase in the relative risk of 
cardiac-related death versus those with a systolic BP between 140 to 149 mmHg. Post 
dialysis,  patients  with  systolic  BP  less  than  110  mm  Hg  had  a  2.8-fold  increase  in 
relative risk for a cardiac-related death compared with patients with systolic BP 140 to 
149 mmHg
4 (see Figure 1.1). The difficulty in dialysis patients is establishing accurate 
surrogates of interdialytic BP load. Most commonly BP targets are based solely on pre- 
and/or post-dialysis systolic BP measurements, however Agarwal et al have shown a 
steady rise in systolic and diastolic BP during the interdialytic period that reaches a 
plateau  48  hours  after  dialysis
5.  Furthermore  both  pre-  and  post-dialysis  BP 
measurements  were  found  to  be  inferior  to  home  BP  recordings  in  predicting  left 
ventricular hypertrophy and mortality
6. One could therefore postulate that the negative 
association  between  low  BP  and  adverse  outcomes  only  reflects  the  use  of  a  poor  
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SBP < 110 mm Hg v 
140 -149mmHg,   
RR = 2.62,P < 0.01 
SBP < 110 mm Hg v 
140 -149mmHg,   
RR = 2.62,P < 0.01 
SBP < 110 mm Hg v 
140 -149mmHg,   
RR = 2.62,P < 0.01 
surrogate  marker  of  afterload  or  may  represent  a  cohort  of  patients  with  cardiac 
dysfunction or impaired cardiovascular reserve during times of stress.    
 
 
 
 
 
Figure 1.1: Systolic blood pressure (SBP) post dialysis and cardio/cerebrovascular mortality in 
haemodialysis patients 
4 
 
 
 
Frequent intradialytic hypotensive episodes have also been implicated in accelerating 
decline in residual renal function and precipitaing serious vascular complications such 
as cerebral, cardiac and mesenteric ischaemia. The problem is confounded in children as 
the ultrafiltration (UF) goal is often higher from liquid nutritional supplements or poor 
adherence to fluid restrictions. In addition younger or developmentally delayed children 
may not be able to verbalize the evolution of new symptoms and therefore there can be 
very little warning of decompensation. This places a greater reliance on monitors and 
basic cardiovascular measurements during their treatments.  
 
 
 
Systolic BP mmHg 
SBP 110-119 v     
140-149mmHg,  
RR= 1.48 (p<0.01) 
SBP < 110 mm Hg v 
140 -149mmHg,   
RR = 2.62 (p< 0.01) 
  SBP >180 v  140-149mmHg,  
RR= 1.06 (p<0.05)  
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1.2  Definition 
There is no recognised definition of intradiaytic hypotension in children. Very loosely 
the term refers to a drop in BP during dialysis and has been defined by KDOQI as a 
decrease in systolic blood pressure by ≥20 mm Hg or a decrease in MAP by 10 mm Hg 
associated with symptoms
7. The former is such a non-specific, subjective definition and 
unsuitable in the research arena. The latter in our opinion is not always relevant in the 
paediatric environment. In children the evolution of symptoms can be for a number of 
reasons but if a hypertensive patient had a 25mmHg fall in systolic BP that restores their 
BP to within the normal range, despite being a clinically a favourable outcome this will 
still  be  categorised  as  an  episode  of  intradialytic  hypotension  and  thus  a  negative 
dialytic outcome. Therefore at the onset of this work I elected to develop a clinically 
valid, objective and reproducible definition relevant to paediatrics.  
 
The first task force on blood pressure control in children is the only group to report age 
and  gender  adjusted  5
th  percentile  systolic  blood  pressure  measurements  from  the 
general population
8. For the purpose of this study, I defined intradialytic hypotension as 
any BP measurement below the 5
th percentile systolic blood pressure measurements as 
this  is  equivalent  to  a  BP  below  that  expected  within  the  normal  population.  Any 
deviation from this is clearly stated in the text.  
 
 
1.3  Pathophysiology  
During  dialysis  mobilization  of  fluid  from  the interstitial  to the  intravascular  space, 
venoconstriction of capacitance vessels, increased vascular tone and active increases in 
heart rate and contractility preserve circulatory adequacy. As a result even with a UF  
 
19
volume equal to the entire plasma volume the measured blood volume only changes by 
10-20%. An impaired compensatory response causes hypotension in the face of total 
body water expansion. 
 
Most of the plasma volume resides in the veins, with a marked difference in the venous 
capacitance  between  organs.  During  UF  the  ability  to  mobilize  blood  from  the 
splanchnic venous pool is vital for preserving the central blood volume. Venous tone is 
affected  by  vasoactive  hormones,  sympathetic  nervous  system  and  upstream  filling 
pressures.  The  De-Jager  Krogh  phenomenon  refers  to  the  transmission  of  upstream 
arterial  pressure  through  the  capillaries  to  the  veins  causing  venous  distension  and 
altered venous capacitance. During arteriolar constriction the distending pressure to the 
vein is reduced and blood is extruded centrally towards the heart to maintain cardiac 
refilling.  Conversely  factors  that  cause  arterial  dilatation,  such  as  antihypertensives 
increase venous capacitance, reduce cardiac filling pressures and through transmission 
of increased hydrostatic pressure to the capillary bed inhibit vascular refilling.  
 
Vasoconstriction is mediated by an increase in sympathetic activity. In dialysis patients 
this response can be inadequate owing to an increased production of vasodilators or 
impaired  sympathetic  response  to  hypovolaemia.  Adenosine  is  an  endogenous 
vasodilator  that  is  released  by  vascular  myocytes  and  endothelial  cells.  It  is 
hypothesized  that  during  a  sudden,  non-gradual  intradialytic  hypotension  episode, 
ischaemia prevails resulting in increased consumption of adenosine triphosphate (ATP) 
and  generation  of  adenosine
9.  This  is  thought  to  augment  splanchnic  blood  pooling 
through  an  inhibitory  effect  on  norepinephrine  release  thus  causing  regional 
vasodilatation, result in arteriolar vasodilatation and depress myocardial contractility. In  
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fact,  pretreating  hypotensive  prone  patients  with  caffeine,  an  adenosine  receptor 
antagonist,  was  shown  to  lower  the  number  of  hypotensive  episodes  in  adults
10. 
Additional mediators of tone include nitric oxide and asymmetrical dimethyl arginine 
(ADMA). During dialysis elevated levels of cytokines such as interleukin 6 and tissue 
necrosis  factor  alpha  stimulate  synthesis  of  inducible  nitric  oxide  synthetase  within 
vascular smooth muscle cells and thus an increased production of nitric oxide, a potent 
vasodilator. However the increase in nitric oxide concentration is delayed by hours after 
the initial exposure to the cytokines and is also accompanied by the continued removal 
of competitive inhibitors of nitric oxide synthetase such as ADMA
11 during HD. Such 
enhancement of endothelial function hours into dialysis is though to contribute to the 
evolution of late onset intradialytic hypotension. 
 
 The sympathetic nervous system is the principle control mechanism of arteriolar tone 
and therefore of central blood pressure and patients with end stage renal disease (ESRD) 
show increased basal level of peripheral sympathetic activity
10, 12. In hypotensive prone 
patients  a  paradoxical  decrease  in  sympathetic  activity  is  seen  at  the  time  of  a 
hypotensive  episode
12  and  this  results  in  a  rapid  decline  in  the  peripheral  vascular 
resistance  and  increased  vascular  bed  capacitance.  Problems  with  sympathetic  end-
organ responsiveness and the efferent parasympathetic baroreceptor pathway have also 
been reported but the underlying mechanism remains unexplained. Some believe this 
may be a heightened manifestation of the Bezold-Jarisch reflex, a cardiodepressor reflex 
resulting  in  a  sudden  loss  of  sympathetic  tone  causing  abrupt  severe  hypotension 
accompanied by bradycardia. It is postulated that conditions associated with reduced 
cardiac refilling pressures such as left ventricular hypertrophy, diastolic dysfunction or  
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structural heart defects stimulate cardiac stretch receptors and thus maladaptively trigger 
a variant of the Bezold-Jarisch resulting in hypotension.   
   
The remaining key player and interconnecting component is plasma refilling. This refers 
to the movement of fluid from the extravascular to the vascular compartment under the 
influences of hydraulic, osmotic and oncotic pressure gradients across the capillary bed. 
If UF rates exceed refilling rates the intravascular volume will fall. There is evidence of 
increased capillary permeability in the presence of uraemia that encourages movement 
of  water  between  the  interstitium  and  intravascular  compartments
13.  Arterial 
vasoconstriction  decreases  hydrostatic  pressures  on  the  capillary  bed,  facilitating 
vascular  refilling.  The  oncotic  pressure  which  is  effectively  the  plasma  protein 
concentration promotes refilling; and plasma sodium and glucose mobilizes fluid from 
the intracellular space as a result of increased plasma tonicity
14. Plasma haematocrit 
level  has  a  positive  influence  on  refilling  rates,  however  during  dialysis  plasma 
haematocrit  levels  change  as  early  as  15mins  secondary  to  change  in  posture, 
haemodilution caused by  redistribution of water from the extra- to the intravascular 
space and redistribution of blood from the microcirculation to the central circulation, the 
Fahraeus effect
15. Finally refilling is facilitated by greater tissue hydration and occurs at 
a faster rate when the interstitial space is overloaded. 
 
There  are  also  a  number  of  additional  factors  that  may  influence  the  central  blood 
pressure during dialysis. Firstly the volume of  blood that is required to support the 
extracorporeal circuit can be a significant proportion of the effective circulating volume 
in  the  younger  patients.  Blood  and  dialyser  membrane  reactions  can  result  in  a 
significant  inflammatory  response  and  early  decompensation,  with  some  evidence  
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suggesting cellulosic membranes to be greater offenders in activating complement and a 
number of cytokine systems than synthetic membranes. The choice of anticoagulant can 
also influence intradialytic BP with reports of hypotension with regional citrate and 
prostanoid anticoagulation compared with heparin and low molecular weight heparins.  
 
In essence we know that hypovolaemia is the trigger for intradialytic hypotension but 
the pathophysiology is complex and the current explanation is incomplete. The uraemic 
milieu  impairs  compensatory  responses  to  reduced  blood  volume  with  ineffective 
venoconstriction, inadequate cardiac refilling, reduced plasma refilling and activation of 
the  sympaticoinhibitory  Bezold–Jarish  reflex  leading  to  sudden  hypotension.  The 
literature  is  dominated  by  research  in  adults  and  the  degree  to  which  this  can  be 
extrapolated to paediatrics is unknown. We have anecdotal evidence that children on 
conventional HD regimens develop intradialytic hypotension but lack published data on 
the prevalence, pathophysiology and consequences of intradialytic hypotension that is 
specific to paediatrics 
 
 
1.4  Risk Factors  
1.4.1  Dialysis Related 
The dialysate composition can influence cardiovascular stability during HD. Dialysate 
sodium generates a crystalloid osmotic pressure and promotes fluid shift between the 
different body compartments. Dialysate sodium activity is approximately equal to 97% 
of the measured sodium concentration, but varies with changes in dialysate temperature, 
pH and the presence of additional ions.  In the absence of UF, we can approximate the 
concentration of dialysate sodium to achieve isotonic dialysis by correcting the blood  
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sodium measured by direct ionometry for a Donnan factor of 0.967. Hyponatric dialysis 
causes osmotic fluid shift from the extracellular to intracellular compartment, dialysis 
disequilibrium  disorder  and  intradialytic  hypotension.  Hypernatric  dialysis  transfers 
sodium  to  the  patient,  causing  interstitial  oedema,  interdialytic  thirst  and  increased 
interdialytic weight gain but may also achieve short-term dialysis gains by improving 
cardiovascular stability.  
 
Hypocalcaemia depresses myocardial contractility and reduced vascular reactivity
16 and 
thus  increases  the  risk  of  intradialytic  hypotension.  Conversely  owing  to  fear  of 
inducing  extra-skeletal  calcium  deposition,  the  new  K/DOQI  guidelines  suggest 
maintaining plasma calcium levels in the low normal range. Using a dialysate calcium 
concentration of 1.25mmol/l permits higher vitamin D and calcium based phosphate 
binders in the management of hyperparathyroidism. In a proportion of patients this can 
lead to hypocalcaemia
17. Low magnesium dialysate baths will encourage the movement 
of  plasma  magnesium  molecules  across  the  dialysis  membranes.  Low  plasma 
magnesium levels can result in cramping and arrhythmias and higher magnesium baths 
may help to improve cardiovascular stability and intradialytic symptoms. Acetate was 
originally used as the buffer in dialysate as it was cheap, offered equimolar conversion 
to  bicarbonate  and  is  bacteriostatic.  However  high  plasma  acetate  levels  result  in 
vasodilatation, depressed left ventricular function and thus place individuals at risk of 
intradialytic  hypotension  and  hypoxaemia  particularly  in  the  first  hour  of  dialysis
18. 
Switching to bicarbonate buffers improves cardiovascular stability.    
 
During fluid removal from the vascular compartment venoconstriction of the splanchnic  
and possibly the splenic
19 vascular beds, mobilizes blood, forcing it centrally towards  
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the heart to maintain cardiac refilling. If food is consumed during dialysis, blood is 
diverted  to  the  splanchnic  circulation  and  patients  are  susceptible  to  intradialytic 
hypotension.   
 
1.4.2  Uraemic Cardiovascular Disease 
The cardiovascular mortality rate of children and young adults on dialysis is extremely 
high, at 1000 times greater than age-matched controls
20 and greater than adult dialysis 
patients.  
 
Figure 1.2: All cause cardiovascular mortality for men and women in the general population and 
those on haemodialysis 
20 
 
The pathophysiology of uraemic cardiac disease is not fully defined but patients with 
ESRD are exposed to a number of traditional and non-traditional cardiovascular risk 
factors. Cardiovascular morbidity and mortality was originally thought to be a problem 
exclusive to adult dialysis patients however opinions are changing. Children in ESRD 
share  the  full  gamut  of  uraemia  related  cardiovascular  abnormalities  as  adults  but  
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distinct  differences  exist  that  may  be  important  in  the  context  of  considering 
cardiovascular stability during HD. 
 
Children do not share the high prevalence of traditional Framingham risk factors as 
adults and neither have they developed significant classical, atheromatous, coronary and 
peripheral  artery  disease.  What  is  unclear  however  is  whether  the  absence  of 
macroscopic, atheromatous vasculopathy translates to improved dialysis morbidity over 
adults. Theoretically with less advanced cardiovascular disease children should be able 
to  tolerate  larger  UF  goals  without  decompensation  and  tolerate  a  more  aggressive 
approach towards UF without running the risk of adverse ischaemic injury. However 
there  is  clear  evidence  of  significant  cardiovascular  disease  in  children  on  dialysis. 
Mechanical  or  haemodynamic  overload
21,  22  and  altered  humoral  responses
23,  24  are 
precursors for cardiac remodeling and the development of left ventricular hypertrophy 
(LVH).  Echocardiogram  studies  have  demonstrated  significantly  worse  diastolic 
dysfunction in children on HD and peritoneal dialysis (PD)
25-27 compared with those 
with  mild-to-moderate  chronic  kidney  disease  (CKD)  or  post  transplant
27,  28  but  the 
systolic  function  is  preserved.  The  presence  of  vascular  disease  is  demonstrated  by 
reports of reduced vascular compliance
29, 30 and recent studies describing transformation 
of paediatric vascular smooth muscle cells into osteoblast-like
 cells with subsequent 
calcification  of  coronary  valves,  carotid  and  coronary  arteries  and  increased  vessel 
intima-media  thickness
31-33.  These  vascular  abnormalities  are  accepted  markers  of 
asymptomatic atherosclerosis and predictors of future symptomatic CVD in adults with 
CKD
34, 35 and although no such data exists in paediatrics it raises a strong suspicion for 
a maladaptive cardiovascular system in children.  
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Over and beyond the presence of uraemia, there is a now a growing body of evidence 
incriminating HD as an independent contributor to endothelial dysfunction. HD is pro-
inflammatory presumably due to an immune mediated response to non-biocompatible 
membranes, blood contact with non-sterile dialysate solution and/or "back-leaking" of 
dialysate across the membrane. However the mechanisms by which CRP production is 
stimulated still eludes us. More frequent dialysis therapies are associated with improved 
CRP levels and other markers of inflammation
36, 37 but in contrast during conventional 
HD elevated C-reactive protein (CRP) levels correlate with dialysis vintage
38.  Not only 
is CRP a valid marker of cardiovascular impairment and atherosclerosis in ESRD but is 
itself  thought  to  pathogenic.  It  is  produced  specifically  by  coronary  artery  smooth 
muscle cells and directly contributes to vascular inflammation and atherosclerosis
39.. 
Finally  HD  is  also  associated  with  changes  in  blood  volume,  blood  viscosity  and 
laminar shear stress. This is an environment conducive to disordered endothelial cell 
dynamics and function and ischaemic injury. 
 
Cardiovascular disease in paediatric dialysis patients is driven by a variety of factors 
different to those in the general population: peripheral vascular changes, calcification, 
inflammation  and  possibly  the  dialysis  procedure  itself.  However  it  is  difficult  to 
distinguish what is cause or effect in the evolution of intradialytic hypotension and what 
part, if any, repetitive HD induced ischaemic injury plays in the pathogenic process in 
children.  
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1.5  Paediatric Haemodialysis 
Technically paediatric HD refers to the dialysis of children from birth to 18 years of 
age. The basic principles of dialysis are universal but the dialysis prescription has to be 
tailor-made for each child and is often adjusted according to the patient’s body surface 
area. A conventional paediatric HD schedule consists of four hour treatments, 3 times 
per week or three hour treatments, four times per week. Vascular access is achieved 
either through a tunneled, indwelling catheter such as a permcath or an arteriovenous 
fistula.  During  infant  dialysis  if  the  volume  of  the  extracorporeal  circuit  volume  is 
greater than 10% of the estimated total blood volume (TBV) a circuit prime with 5% 
albumin or blood is recommended.   
 
 
 
 
Figure 1.3: Schematic diagram of a haemodialysis circuit  
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With increasing blood flow, more solute is delivered to the dialyzer, resulting in higher 
dialyser clearance but this clearance advantage starts leveling off at blood flows of 250-
300mls/min and therefore where possible a blood flow rate as close to 300mls/min is 
used. In children however the effective blood flow rate is largely determined by the 
vascular access and adjusted to achieve a 4-6mls/kg/min urea clearance, approximating 
a Kt/V of > 1.2 
40, or in infants a minimum of 20mls/min to avoid the risk of clotting the 
circuit. The problem with small, high resistance double-lumen central venous catheters 
or occasionally single lumen catheters is an increased risk of high recirculation rates 
with inadequate dialysis on conventional dialysis regimens. This can be improved by 
changing the dialysis time by increasing the frequency or duration of treatment.  
 
As a general rule to maximise effective dialyser clearance the ratio between dialysis 
fluid and blood flow should be at least 1.5 to 2 and in children typically dialysis flow 
rates of 300-500mls/min are employed, even in infants with low blood flow rates. The 
dialysate  temperature  is  most  commonly  set  at  a  constant  temperature  of  37˚C. 
Bicarbonate  is  now  routinely  used  as  the  acid  buffer  and  intravenous  heparin 
anticoagulates the extracorporeal circuit. With a desired objective of achieving long-
term  solute  balance  the  dialysate  sodium,  magnesium,  calcium  and  potassium 
composition can be adjusted in accordance with the patient’s plasma levels.  
 
 
1.6  Cardiovascular Response to Haemodynamic Stress 
During HD both UF and plasma solute clearance induces fluid exchange that ultimately 
results  in  intravascular  fluid  depletion.  This  haemodynamic  stress  triggers  a  
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characteristic  compensatory  response  which  owing  to  differences  in  physiological 
maturity is age dependent but is ultimately aimed at restoring circulation adequacy.   
 
In  general  the  cardiac  output  is  predominantly  determined  by  the  heart’s  loading 
conditions. Preload is defined as the ventricular wall tension at the end of diastole and is 
largely derived from the circulating blood volume and venous capacitance. The velocity 
and  power  of  contraction  in  single  fibres  is  directly  related  to  fibre  length  at  the 
beginning of contraction (The Frank-Starling law). As the preload increases the stroke 
volume (SV) increases but there is a limit of preload reserve. Conversely, as is the case 
during HD, as the preload decreases the SV decreases. Afterload is the sum of forces 
opposing  ventricular  ejection  and  the  most  important  component  is  total  peripheral 
resistance (TPR) or systemic vascular resistance. SV decreases as afterload increases 
but by increasing the contractility of the heart some gain in SV can be achieved. Heart 
rate (HR) increases cardiac output but by reducing the time spent in diastole rapid rates 
can decrease SV by limiting ventricular filling and reducing coronary arteries perfusion. 
As SV increases the myocardial demand for oxygen rises and coronary blood flow must 
rise to compensate. Finally in a response to reduced cardiac output, vascular tone is 
increased in attempt to preserve the central blood pressure and maintain vital organ 
perfusion. 
 
Ventricular compliance is also an important component of cardiac output. Ventricular 
filling occurs in two stages, the rapid early filling which is associated with ventricular 
relaxation and then the slower later filling that is augmented by atrial contraction. As 
ventricular  compliance  decreases  the  end-diastolic  volume  for  a  given  end-diastolic 
pressure falls and is in these circumstances the slow phase dominates. An increase in  
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heart rate will accelerate the rate of relaxation and may precipitate a fall in cardiac 
output. Similarly ischaemia compromises the rate and extent of relaxation.  
 
Neonates at the time of birth have reduced inotropic and preload reserve and thus their 
dominant  response  to  a  haemodynamic  challenge  is  tachycardia.  The  sympathetic 
innervation of the neonatal heart is less well developed than the parasympathetic and 
thus they have a propensity for reflex bradycardia. Compared with older children any 
fall  in  HR  is  accompanied  by  an  attenuated  vasoconstriction  response  and 
disproportionately larger decreases in cardiac output. Therefore as afterload increases 
cardiac output falls but in the reverse as the afterload falls there is a less impressive gain 
in output. In infancy and childhood the myocardium adapts progressively and develops 
an increased reserve to B adrenergic stimulation. 
 
Stressors such as HD cause intravascular fluid depletion. As the effective circulating 
volume falls, the preload, SV and cardiac output would fall. In an attempt to maintain 
the central BP one would expect a local hormonal, metabolic and sympathetic stimulus 
increases  vascular  tone  and  total  peripheral  resistance.  In  the  presence  of  arteriolar 
constriction  the  distending  pressure  to  the  vein  is  reduced  and  blood  is  extruded 
centrally towards the heart to maintain cardiac refilling.  
 
Uraemia is associated with a maladaptive cardiovascular response but what is unknown 
in paediatrics is the extent to which the processes described above are abnormal. 
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1.7  Blood Volume Monitoring and Ultrafiltration 
On-line  non-invasive  blood  volume  monitors  (NIVM)  make  it  feasible  to  indirectly 
measure blood volume, both real-time and continuously throughout dialysis. They are 
based  on  the  principle  of  mass  conservation:  the  concentration  of  measured  blood 
constituents (haemoglobin/haematocrit/plasma protein) confined to the vascular space, 
change in proportion to changes in the vascular volume. It is also assumed that the total 
concentration of blood constituent in the circulation is constant with uniform mixing 
throughout the vascular space. NIVMs differ by the intrinsic sensing techniques that are 
used for monitoring. 
 
Optical: measures the optical absorbance of monochromatic light, via an optoprobe in 
the arterial line. The optical density of whole blood is really a measure of red blood cell 
(RBC) concentration - the haematocrit, rather than the haemoglobin content. Scattering 
of light from the surface of RBC yields a non-linear relationship between the measured 
optical density and hematocrit. The Crit-line (In-Line Diagnostics, Riverdale, Utah), a 
stand alone device, is however designed to correct for this while the Hemoscan (Hospal-
Dasco, Medolla, Italy) which forms part of the dialysis machine, adjusts for variations 
in oxygen saturation.   
 
Blood density: blood density is dependent on the total protein concentration (plasma 
protein concentration + mean cellular haemoglobin concentration). The Blood Volume 
Monitor  (BVM,  Fresenius  AG,  Bad  Homburg,  Germany)  measures  the  velocity  of 
sound through blood, by means of a cell inserted in the pre-pump segment of the arterial 
line, adjusted for temperature, a factor known to impact on both sound velocity and 
blood density.   
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Electrical  conductance:  conductivity  of  blood  depends  on  hematocrit,  temperature, 
plasma electrolytes and non-electrolyte concentrations. The difference of high and low 
frequency  conductivity  has  been  found  to  be  a  measure  of  hematocrit.  The 
extracorporeal  plasmatic  impedance  meter  (IPEC,  Laboratoire  Eugedia,  Chambly, 
France) translates changes in conductivity into relative changes in the plasma volume. 
 
All three devices report results as a percentage relative change of the blood volume 
(RBV),  and  in  some,  these  are  displayed  graphically.  Each  device  is  fitted  with 
computer software that  converts measured changes to percentage RBV based on an 
internal calibration reference points. These may differ between machines and therefore 
an absolute RBV value on one device may not read the same on another. Schneditz et al 
demonstrated  a  2%  difference  in  relative  blood  volume  changes  (BVM  2%  less 
reduction in blood volume compared to Crit-line), which developed approximately 1 hr 
into dialysis, and persisted thereafter 
41.   
 
NIVM measures the change in blood volume as fluid is being removed during UF and 
thereby  provides  additional  insight  into  vascular  refilling  ability.  Theoretically,  this 
could guide UF rates based on observed RBV changes as demonstrated by the four 
relative blood volume (RBV) curves shown in Figure 1.4.  
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Figure 1.4: Examples of relative blood volume curves taken during haemodialysis 
 
￿  Patient 1 has a flat line throughout dialysis and hence plasma refilling rate is 
able to fully compensate UF rates. In fact one could assume the patient has an 
excess of fluid in the interstitial space as refilling rates remain high throughout 
dialysis. It is thus probable that the patient will tolerate higher UF rates. 
￿  Patient 2 has a constant RBV curve during a first part of dialysis followed by a 
linear decrease. This would indicate compensated UF up to the point that the 
curve is flat but thereafter the plasma refilling rate is not able fully compensate 
UF rate and thus the RBV falls. 
￿  Patient 3 shows a linear decrease of RBV from the onset of dialysis with a 
constant declining slope.  In this patient the UF rate is  always exceeding the 
plasma refilling rate and therefore if the UF rate was to be increased there is a 
risk of precipitating decompensation.  
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￿  Patient 4 shows a linear decrease of RBV with a variable declining slope. In this 
patient  fluid  removal  is  too  rapid  at  the  onset  as  demonstrated  by  the  steep 
decline in RBV and the risk of symptoms secondary to hypovolaemia is high. 
The UF rate needs to be revised to reduce intradialytic morbibity. 
 
Steuer et al achieved a 2-fold reduction in intradialytic symptoms using NIVM in six 
hypotension  prone  adults,  without  changing  the  UF  volume  or  treatment  times
42. 
Additional benefits that have been reported in adults are an increase in the UF potential, 
lowering of the dry weight, improved patient well-being and reduced hospitalization 
due  to  fluid  overload.  Access  to  information  on  blood  volume  status  would  be 
particularly  helpful  in  the  paediatric  HD  setting  as  the  prevalence  of  intra-  and 
interdialytic morbidity can be higher when children do not often verbalize early warning 
symptoms and for differentiating between symptoms caused by aetiologies other than 
hypovolaemia.  Responding directly to RBV changes with RBV driven algorithms have 
shown  decreased  UF  associated  symptoms  and  antihypertensive  medication  burden, 
with the greatest impact on children weighing less than 35 kg
43-45. Michael et al defined 
a safe UF rate based RBV change of < 8 % per hour in the first 90 mins and then < 4 % 
thereafter, with no more than a 12 % net RBV change per dialysis session
44 but there is 
no data on the predictability of RBV levels of impending intradialytic symptoms or 
hypotension in paediatrics. Adult literature has been more comprehensive and results 
have been conflicting. Kim initially showed
46 that if RBV fell below a given threshold, 
arterial hypotension appeared. Subsequently, larger observational studies demonstrated 
that critical maximal RBV reduction had no predictive power but found that irregularity 
of the RBV curve and switching from an exponential to a linear decrease were the most 
powerful predictors of intradialytic hypotension
47, 48.   
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1.8  Myocardial Architecture and Function 
1.8.1   Myocardial Contraction 
The  muscle  of  the  heart  is  layered  in  a  helical  arrangement  with  complex  spatial 
organization  of  the  left  ventricle  (LV)  myocardial  fibres
49.  Cardiac  muscle  is  not  a 
homogeneous  muscle  mass,  but  shows  variations  at  a  microscopic  level  between 
individuals  and  further  changes  arise  from  disease  states.  Circumferentially  oriented 
myocardial fibres form the largest proportion of fibres and are primarily found in the 
midwall layer and longitudinally oriented fibres are primarily found in the endocardial 
and epicardial layers 
50(see figure 1.5). 
 
Three  perpendicular  axes  define  the  local  myocardial  fibre  direction  of  movement: 
radial  (R),  circumferential  (C),  and  longitudinal  (L)  as  shown  in  Figure  1.6.  The 
circumferential axis is tangent to the surface and oriented in the short-axis direction for 
both the epicardium and endocardium; the longitudinal axis is tangent to the surface and 
oriented in the cardiac long axis; and radial axis lies in the direction perpendicular to the 
wall and is tilted near the apex because of the taper of the LV. 
 
 
 
 
Figure 1.5: MRI reconstruction of ventricular muscle fibre orientation 
51  
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Figure 1.6: Diagram illustrating the direction of local myocardial fibre arrangement and 
resultant deformation 
52 
 
 
Myocardial  contraction  is  a  complex  three-dimensional  motion.  At  the  macroscopic 
level  a  combination  of  wall  (radial)  thickening,  circumferential  shortening,  and 
longitudinal shortening occurs. Consequently ejection is combined effect of the inward 
pressure generated from concentric forces when these muscle layers start to tense and 
longitudinal shortening. The LV apex rotates counter clockwise (as viewed from the 
apex) and the base rotates clockwise creating a torsional deformation from oppositely 
wound epicardial and endocardial myocardial fibres. Internal cardiac fibres moved to 
the outside and those on the outside move to the inside. The reverse happens in diastole. 
The resultant effect is a twisting motion, like a wet cloth being wrung out with the apex 
fixed  while  the  base  of  the  heart  ‘screws  down’  onto  the  apex.  Changes  in  the 
intracavity  volume  occur  as  a  result  of  the  inward  motion  and  deformation 
(circumferentially and longitudinally) of the endocardium. Both the circumferential and 
longitudinal shortenings contribute to the magnitude of the ejection fraction 
53 but in 
normal  individuals  midwall  circumferential  fibre  shortening  appear  to  be  the  most 
important component.   
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During systolic ventricular contraction the subendocardial coronary vessels, namely the 
vessels  that  enter  the  myocardium,  are  compressed  due  to  the  high  intraventricular 
pressures. However, the epicardial coronary vessels, the vessels that run along the outer 
surface of the heart, remain patent. Because of this, blood flow in the subendocardium 
stops. As a result most myocardial perfusion occurs during heart relaxation (diastole) 
when the subendocardial coronary vessels are patent and under low pressure. 
 
1.8.2  Coronary circulation 
The major vessels of the coronary circulation are the left main coronary that divides into 
left anterior descending and left circumflex branches, and the right main coronary 
artery. Both of these arteries originate from the root of the aorta, immediately behind the 
aortic valve leaflets,left coronary artery originates from the left aortic sinus, while the 
right coronary artery originates from the right aortic sinus.  
 
 
Figure 1.7: Coronary circulation  
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The  coronary  arteries  sub-divide  to  form  three  compartments.  Firstly  the  proximal 
compartment which constitutes the large epicardial coronary arteries. These lie on the 
surface  of  the  heart,  large  capacitance  function  and  offer  very  little  resistance  to 
coronary blood flow but are responsive to flow mediated dilatation. Their anatomical 
blood  supply  to  regions  of  the  heart  is  shown  in  Table  1.1;  nonetheless  the  exact 
anatomy can vary considerably between individuals, especially in the apical cap.  
 
Table 1.1: Anatomical blood supply to regions of the heart 
Anatomic Region of 
Heart 
Coronary Artery (most 
likely associated) 
Inferior 
Infero-septal 
Right coronary  
Anterior 
Antero-septal 
Left anterior descending 
Infero-lateral  
Antero-lateral 
Left circumflex 
 
The coronary arteries then divide into pre-arterioles. These vessels maintain the pressure 
within a narrow range when coronary flow or intravascular pressure varies. They are 
essentially  the  principle  site  of  autoregulation.  The  vessels  then  finally  divide  into 
intramural arterioles with diameters less than 100 m serve to ensure that myocardial 
blood supply adequately meets the metabolic demand of the heart. Their role is the 
metabolic regulation of coronary blood flow and these dilate in response to various 
metabolic stimuli.  
 
The  objective  of  the  combined  autoregulatory  mechanisms  within  the  coronary 
circulation is to match blood flow with myocardial oxygen consumption and this is done  
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principally by coordinating vascular tone and resistance. There is a degree of reserve 
within the system, the coronary flow reserve and this refers to the magnitude of the 
increase in coronary flow that can be achieved in going from basal coronary perfusion 
to maximal coronary dilatation. 
 
 
1.8.3  Echocardiography  
Two dimensional (2D) echocardiography use ultrasonic waves directed perpendicularly 
to the heart to provide real-time imaging of the heart. This also provides the means to 
assess cardiac function non-invasively. Global LV systolic function is usually assessed 
by the resting LV ejection fraction (LVEF), expressed as the ratio of the stroke volume 
divided by the end-diastolic volume.  
    Stroke volume (SV) = LV end-diastolic volume - LV end-systolic volume 
    LVEF (%) = (SV / LV end-diastolic volume) x 100 
 
 
In  order  to  assess  regional  LV  systolic  function  the  heart  has  to  be  divided  into 
segments.  A  standardised  17  segment  model  recommended  by  The  American  Heart 
Association (AHA)
54, names segments according to their location relative to the long 
axis of the ventricle and 360° circumferential
 locations on the short-axis views as shown 
in Figure 1.8.
 In spite of the probable variability in the coronary artery
 blood supply to 
myocardial segments, a consensus has been reached on assigning the 17 myocardial 
segments to the territories of the left anterior descending (LAD), right coronary artery 
(RCA), and the left circumflex coronary artery (LCX) (see Figure 1.9) with a note of 
caution that the greatest variability in myocardial blood supply occurs at the apical cap, 
segment 17.  
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Figure 1.8: Left ventricle Segmentation
54  
 
 
Figure 1.9: Assignment of the 17 myocardial segments to the territories of the left anterior 
descending (LAD), right coronary artery (RCA) and the left circumflex coronary artery (LCX). 
The greatest variability in myocardial
 blood supply occurs at the apical cap, segment 17 
54.   
 
41
Regional myocardial contractile function can be assessed by measuring myocardial wall 
motion  measurements  (displacement  and  velocity)  or  wall  deformation  (strain).  The 
term "strain" refers to the fractional or percentage change from the original, unstressed, 
dimension or the change in length corrected for the original length. In common terms, 
deformation of a heart fibre is akin to stretching of the heart fibre. Myocardial strain is 
dimensionless and usually shown as a percentage. Through the assessment of segmental 
myocardial  strain  the  contraction/relaxation  pattern  of  the  LV  can  be  followed  in  3 
planes;  longitudinal,  circumferential,  and  radial.  In  comparison  routine 
echocardiographic  assessment  of  regional  wall  motion  activity  will  only  provide 
information on longitudinal axis function.  
 
 
1.9  Myocardial Stunning  
1.9.1  Definition  
￿  Myocardial  stunning  is  defined  as  transient,  post-ischaemic,  left  ventricular 
dysfunction with normal or near- normal myocardial perfusion 
55 
￿  Episodes of transient myocardial ischaemia can be followed by reversible left 
ventricular (LV) dysfunction, namely reduced or absent contraction in global or 
discrete parts of the LV 
 
1.9.2  Evidence for haemodialysis induced myocardial stunning 
In order to establish whether HD induces myocardial stunning three criteria needed to 
fulfilled, intradialytic i) myocardial ischaemic injury, ii) reduced myocardial blood flow 
and iii) segmental or global LV dysfunction. I present the evidence for all three of these 
criteria in adult HD patients. 
  
 
42
Short  intermittent  HD  treatments  cause  significant  hypovolaemia  and  intradialytic 
hypotension  (IDH)
56,  57.  Acute  rise  of  cardiac  troponin-T  (cTnT)  levels  following 
dialysis has been speculated to indicate subclinical myocardial  cell injury
58,  59. This 
parallels several studies demonstrating silent ST segment depression during dialysis at 
rates that vary between 15 and 40%
60. In addition to cTNT, brain natriuretic peptide 
(BNP) is gaining increasing recognition as a marker of acute myocardial cell damage. 
There is evidence that a combination of elevated BNP, in combination with elevated 
markers of inflammation such as interleukin 6 (IL-6), predicts stunned myocardium, 
whereas  elevated  BNP  with  normal  IL-6  levels  correlate  with  non-viable,  infarcted 
myocardium
61. In addition, elevated BNP levels predict mortality in dialysis patients
62. 
Elevated biomarkers of myocardial damage have also been demonstrated in children 
with chronic kidney disease
63.  
 
Although  there  was  initial  debate  as  to  whether  these  biochemical  and 
electrocardiographic  abnormalities  reflect  silent  ischaemia  or  changes  in  electrolyte 
concentrations,  subsequent  studies  measuring  myocardial  blood  flow  strengthen  the 
case  for  ischaemia.  Using  single  photon  emission  computed  tomograghy  dialysis 
induced perfusion defects have been demonstrated
64. In a small cohort of patients with 
and without large vessel epicardial coronary disease, regional myocardial blood flow 
fell. The segments demonstrating, transient, intradialtyic LV dysfunction also exhibited 
the  greatest  reduction  in  regional  myocardial  blood  flow.  The  duration  of  LV 
dysfunction extended beyond the period of reduced perfusion and was thus more in 
keeping  with  myocardial  stunning  than  stress  cardiomyopathy  (see  Figure  1.10  and 
1.11).  
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Figure 1.10:  HD is associated with both reduced global and segmental myocardial blood flow 
(MBF) 
65  
 
 
 
 
Figure 1.11 Stunned myocardial segments exhibit significantly greater reduction in myocardial 
blood flow (MBF) 
65 
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One  method  of  examining  regional  LV  function  is  through  echocardiographic 
assessment  for  the  development  of  new  LV  regional  wall  motion  abnormalities 
(RWMA). New RWMAs are indicative of ischaemia and their onset precedes symptoms 
and  electrocardiographic  changes.  These  principles  form  the  basis  and  rationale  for 
dobutamine  stress  echocardiography
66.  In  75%  of  prevalent  adult  HD  patients  new 
RWMAs have been demonstrated, starting 2 hours into dialysis, peaking at the time of 
maximum stress at the end of dialysis, with 30% persisting 30 minutes postdialysis. A 
direct correlation is seen between both the number and intensity of stunning within 
segments and intradialytic BP changes and UF volume
67. A study of sequential positron 
emission tomography (PET) scans of adult during their HD treatment reported a 13% 
reduction in global myocardial blood flow 30 minutes into HD, a period of minimal UF. 
This was accompanied by a 5% fall in cardiac output but no change in systolic and 
diastolic BP or heart rate was observed. By 220 minutes the global myocardial blood 
flow had fallen on average by 26% with a corresponding 21% drop in cardiac output, a 
significant tachycardic response but again a non-significant fall in systolic and diastolic 
BP.  The  regions  of  the  heart  that  demonstrated  the  greatest  segmental  decline  in 
myocardial blood flow developed new LV RWMA by the end of dialysis (see Figure 
1.12)
68.  
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Figure 1.12: Relative change from baseline of the cardiac output (C) and myocardial blood flow 
(D) during haemodialysis
68 
 
 
This  study  illustrates  a  pronounced  fall  in  myocardial  blood  flow  that  occurs  early 
during the dialysis session, unrelated to hypovolaemia and is therefore more likely to be 
due  to  a  sequence  of  events  that  follow  connection  to  the  extracorporeal  circuit.  In 
patients commencing continuous renal replacement therapy, blood dialyser membrane 
incompatibility triggers a bradykinin response with resultant early onset hypotension
69. 
A similar inflammatory reaction is possible in the conventional HD patients however 
this alone does not explain the predominance of myocardial haemodynamic changes but 
raises  suspicion  about  the  integrity  of  myocardial  microcirculation.  This  study  also 
demonstrated that the reversible regional left ventricular dysfunction lasted beyond the 
period of reduced perfusion. This is essence completes the clinical evidence for HD 
induced myocardial stunning in adults. 
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Consequences of myocardial stunning  
The concept of myocardial stunning  was  first introduced in patients with ischaemic 
heart disease. Repeated episodes of ischaemia and stunning may lead to cumulative, 
more severe and prolonged stunning
70 eventually  progressing to the phenomenon of 
‘myocardial functional hibernation’, that is non-infarcted, scar free myocardium with 
fixed systolic dysfunction ranging from hypokinesia (depressed contraction), akinesia 
(no contraction) or dyskinesia (paradoxical contraction)
71. The extent and severity of 
LV dysfunction can vary considerably and untreated is predictive of morbidity. If a 
discrete region of the LV is involved the impact on ejection fraction can be minimal, 
however with more global involvement heart failure is inevitable.  
 
Myocardial  hibernation  is  thought  to  represent  a  functional  adaptation  to  chronic 
hypoperfusion with cardiac myocytes almost adopting an embryonic phenotype
72. There 
is conflicting evidence on whether myocardial blood flow to hibernating myocardium is 
normal
72, 73 or reduced
74 but what is clear is that the coronary flow reserve is severely 
reduced
75.  Importantly  the  chronic  LV  dysfunction  that  is  typical  in  hibernating 
myocardium can be reversed with restoration of regional myocardial blood flow
76. If 
this  fails  to  occur  the  hibernating  myocardium  is  highly  vulnerable  to  increases  in 
demand or reductions in oxygen supply and subsequent stresses are cumulative. The 
knock  on  effect  is  a  prolonged  period  to  recovery  following  revascularisation  or 
eventual apoptosis or necrosis and non-viable myocardium (see Figure 1.13).  
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In adults the physiological strain and haemodynamic stress during conventional HD is 
sufficient to cause transient myocardial ischaemia with resultant left ventricular (LV) 
dysfunction.  Conventional  HD  regimens  comprise  of  3  to  4  dialysis  treatments  per 
week,  every  week  of  the  year,  therefore  the  potential  for  repetitive  ischaemic 
myocardial  insults  is  both  significant  and  high.  Burton  et  al  have  undertaken  serial 
echocardiographic assessments of global and regional LV performance in prevalent HD 
patients,  twelve  months  apart.  They  found  a  significant  reduction  in  segmental 
shortening  fraction  SF  in  those  segments  that  had  developed  RWMAs  at  baseline 
(Figure 1.14) with 32% developing a fixed reduction in segmental function. 
 
 
Figure 1.14: Change in segmental shortening fraction (SF) in haemodialysis patients  
followed for 12 months
67  
 
 
 
Furthermore  patients  segments  with  fixed  systolic  reduction  of  >60%  showed  a 
significant decline in ejection fraction over 12 months both at rest and at peak stress 
during HD. There was no significant reduction in LVEF in patients who did not develop 
fixed reductions in segmental function (Figure 1.15)
67.  
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Figure 1.15: Change in ejection fraction (EF) at rest and during HD in patients with a fixed 
reduction in segmental function greater than 60% 
67 
 
 
 
Records from the US Renal Data System have shown that HD is an independent risk 
factor for the development of both de novo and recurrent heart failure with a two-year 
mortality after a diagnosis of congestive heart failure as high as 51% 
77. The aetiology 
of uraemic heart failure is elusive but evidence implicating HD induced myocardial 
stunning story is emerging. However what remains uncertain is whether children on HD 
are also vulnerable. 
 
 
1.10  Strategies for improving intradialytic morbidity 
1.10.1  Sodium profiling 
Following a sodium load, the mechanisms responsible for preserving plasma tonicity 
will  maintain  plasma  sodium  within  narrow  limits  by  changing  the  plasma  volume. 
During  HD,  dialysate  sodium  generates  a  crystalloid  osmotic  pressure  and  thus 
influences fluid shift between the different body compartments, but it also permeates the 
dialysis membrane and thus has the potential for becoming a sodium load.    
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One  of  the  primary  objectives  of  HD  is  restoration  of  sodium  and  fluid  balance.  
Sodium is predominantly cleared by convection with the excess water. Pure UF has 
approximately  the  same  sodium  activity  as  plasma  with  no  net  change  in  patient’s 
plasma  sodium  concentration.  Diffusive  sodium  transport  is  proportional  to  the 
difference  in  sodium  concentration  between  blood  and  dialysate  compartments. 
Dialysate  sodium  activity  is  approximately  equal  to  97%  of  the  measured  sodium 
concentration. Similarly the proportion of plasma sodium ions that are bound to protein 
and other anions, are unavailable for exchange. We can measure the free ionized plasma 
water  sodium  concentration  in  the  blood  by  using  direct  ionometry.  Plasma  sodium 
activity is further limited by the Donnan effect, whereby negatively charged proteins 
(mainly albumin) produce a small electrical potential difference across the membrane 
(negative on the plasma side) that prevents movement of the positively charged sodium 
ions.  Concentration  differences  between  interstitial  and  plasma  also  stem  from  the 
Donnan effect. In the absence of UF, we can approximate the concentration of dialysate 
sodium to achieve isotonic dialysis by correcting the blood sodium measured by direct 
ionometry for a Donnan factor of 0.967.  
 
Hyponatric  dialysis  causes  osmotic  fluid  shift  from  the  extracellular  to  intracellular 
compartment,  dialysis  disequilibrium  disorder  and  intradialytic  hypotension. 
Hypernatric  dialysis  transfers  sodium  to  the  patient,  causing  interstitial  oedema, 
interdialytic thirst, increased interdialytic weight gain and the worsening hypertension. 
A  therapeutic  advantage  can  be  gained  by  manipulating  the  dialysate  sodium 
concentration throughout dialysis. This is referred to sodium profiling, and typically 
utilizes a sodium concentration that falls in a step, linear or exponential fashion. The 
higher dialysate sodium at the start allows a diffusive sodium influx to counterbalance  
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the  rapid  decline  in  plasma  osmolarity  due  to  clearance  of  urea  and  other  small 
molecular weight solutes. Low dialysate sodium at the end aids diffusive clearance of 
the  sodium  load  and  minimizes  hypertonicity.  Compared  with  a  constant  dialysate 
sodium  bath  modelling  has  been  shown  to  increase  stability  of  intradialytic  blood 
volume,  and  reduce  both  intradialytic  cramps  and  interdialytic  fatigue  in  adults  and 
children
78. Outcomes have been better with the linear and step profiles compared with 
exponential. Step profiles are most effective at attenuating post-dialytic hypotension and 
early  intradialytic  hypotension  and  linear  profiles  best  reduced  cramps  and  late 
intradialytic  hypotension.  Sodium  profiling  is  also  indicated  in  the  prevention  of 
dialysis dysequilibrium with patients reporting a preference to it. However one of the 
major drawbacks of sodium profiling is the risk of a positive sodium balance by the end 
of each HD session.  
  
The challenge therefore with sodium profiling is finding the concentration gradient that 
offers the benefits of cardiovascular stability without exposing the patient to a small but 
repeated sodium load. A net sodium gain of 1mmol/l will result in a 1.3% expansion of 
the extracellular space. Based on concerns of inducing hypervolaemia the emphasis is 
shifting  to  neutral  sodium  balance  profiles.  Protocols  of  isonatriaemic  dialysate  are 
similar with time averaged dialysate sodium 2-3mEq/l lower (Donnan effect) than the 
predialysis sodium
79. Results indicate benefits comparable to sodium profiling with a 
significant decrease in the interdialytic weight gain and thirst score
80.  
 
Currently the decision to manipulate dialysate sodium relies heavily on conflicting adult 
literature and there is no comparison of its benefit over other commonly used strategies 
such as UF profiling in children.  
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1.10.2  UF profiling 
Modifying the UF rate throughout dialysis to allow adequate vascular refilling has the 
potential to increase the UF potential. This is the rationale behind UF profiles. The 
plasma refilling capacity increases proportionately with interstitial volume expansion. 
Decreasing stepwise or linear profiles start with high UF rates at the time of maximal 
tissue  hydration,  progressively  reducing  the  rate  in  line  with  decreasing  interstitial 
hydration in the hope of maintaining the crucial balance between fluid removal and 
vascular refilling. Intermittent profiles aim to provide periods of active mobilization of 
interstitial  fluid  into  the  vascular  space  when  UF  rates  are  low,  thereby  making  it 
amenable to removal during periods of high UF rates. Donauer et al reported lower 
symptomatic hypotension with the decreasing profiles, but the intermittent profile was 
associated with an increased incidence of symptomatic hypotension and post-dialysis 
fatigue
81. The incidence of intradialytic hypotension was highest with UF rates greater 
than 1.5 times the average. Ronco  et al   observed hypotension at  a rate of 6.7/100 
treatments when the UF rate was 0.3 ml/min/kg increasing to 15.8 at an UF rate of 0.4 
ml/min/kg, 25.6 at a rate of 0.5 ml/min/kg, and 67.4 at a rate of 0.6 ml/min/kg
82.  
 
Combining  UF  profiles  with  sodium  profiles  can  induce  plasma  hypertonicity.  The 
utilisation of a high UF rate with higher dialysate sodium conditions maximises plasma 
refilling and in adults has been shown to be superior to either sodium or UF profiles 
alone in attenuating intradialytic symptoms and cardiovascular instability. Ebel et al 
compared 3 regimens; i) constant dialysate sodium of 138mmol/l, ii) UF profile of 40% 
of the total UF goal in the first hour, 30% in the second hour, 30% in the subsequent 
90mins and then none in the last 30mins, iii) combined UF profile with a sodium profile 
with a dialysate sodium 10% higher than the pre-dialysis plasma sodium, decreased in 5  
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steps to 138 in the last hour. Both the stand alone UF and sodium profiles showed 
evidence  of  intracellular  fluid  shift  and  intravascular  hypovolaemia.  The  combined 
profiles showed higher refilling rates and net removal of fluid from the interstitium and 
reduced renin, aldosterone, epinephrine and norepinephrine levels
83, perhaps reflecting 
less marked hypovolaemia and improved vascular stability. Paediatric data on the use of 
UF profiles in isolation or in combination with sodium profiles is non-existent and thus 
efficacy large extrapolated from adult data. 
 
1.10.3  Biofeedback 
The  kidneys’  unique  ability  to  maintain  homeostasis  is  achieved  by  continuously 
adjusting purification in response to transfer of information through a complex system 
of sensing and feedback mechanisms. Until now we have been unable to simulate this 
because  traditional  HD  prescriptions  are  based  on  information  from  previous 
observations. Recently introduced biofeedback systems adjust the treatment prescription 
based on real-time repeated observations from an on-line monitoring system using a 
negative feedback system designed to return the deviating factor to a pre-set nominal 
value.    
 
Blood volume controlled feedback systems respond to RBV changes
84. At the start of 
therapy the treatment duration, UF goal, and a target for a maximum decline in BV is 
set.  The  feedback  programme  will  then  adjust  the  UF  rate  and  (when  using  the 
Hemocontrol module) dialysate conductivity to maintain RBV along this pre-set target 
thus  improving  RBV  preservation  with  a  more  physiological  reduction  in  the  RBV 
profile
85,  86.  Initial  results  report  a  reduced  incidence  of  intra-dialytic  hypotensive 
episodes  and  attenuation  of  post  dialysis  symptoms
87  with  a  partial  response  in  
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hypotension prone patients
84, 88. Again data in paediatrics is non-existent, nevertheless 
RBV driven UF algorithms have been used in children with success with reports of 
reduce antihypertensive medication burden and UF associated symptoms
89.   
 
1.10.4  Sequential dialysis 
Owing  to  anecdotal  experience  iso-osmotic  fluid  removal  during  sequential  dialysis 
techniques (pure UF followed by dialysis) is often used to achieve higher UF rates 
without  inducing  hemodynamic  instability  but  what  remains  unclear  is  how  this 
improvement  in  cardiovascular  stability  is  achieved  and  the  extent  of  the  benefit. 
Isolated UF can be performed by placing the HD machine in bypass or on the UF mode. 
As the patient is no longer being warmed by the dialysate their core temperature drops. 
Traditional thinking believed this to be problematic as patients developed symptoms 
related to cold. In light of emerging evidence the reverse is now believed to be true.  
Cooling over the extracorporeal circuit counteracts the heat generated during dialysis 
and  thus  prevents  an  increase  in  core  temperature,  peripheral  vasodilatation  and 
hypotension.  Others  have  postulated  that  the  improved  hemodynamic  stability  is 
secondary to decreased sodium clearance
90, 91. Based on personal experiences there is no 
doubt that sequential dialysis can be useful in meeting UF targets during paediatric HD 
but quantitative, comparative data has never been reported.  
 
1.10.5  Intradialytic mannitol  
Dialysis  discomfort  and  dysequilibrium  due  to  cellular  osmotic  distress  occurs  as  a 
result  of  changes  in  osmolarity  inducing  water  shifts  from  the  extracellular  to  the 
intracellular compartment across the highly permeable blood brain membrane. It was 
first described in 1962 and manifests during or immediately after HD as a self limiting  
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entity but recovery can take several days. Symptoms typically include nausea, vomiting, 
headache, blurred vision, hypertension, seizures and coma but others such as muscular 
cramps, anorexia, restlessness and dizziness have been reported.   
 
The exact pathophysiology of DDS remains unclear and two mechanisms have been 
proposed.  The first, the reverse urea effect, believes that urea clearance from plasma 
occurs more rapidly than brain tissue. This results in a transient osmotic gradient and 
net movement of water from plasma to brain causing cerebral oedema and occasionally 
due  to  loss  of  extracellular  water,  hypotension.  The  second  theory  relates  to 
intracerebral acidosis and emerged from evidence pertaining to a paradoxical acidaemia 
of CSF and cerebral cortical grey matter in patients and animals treated with rapid HD. 
This is accompanied by increased brain osmole activity due to displacement of sodium 
and potassium ions and enhanced organic acid production. The increased intracellular 
osmolarity induces fluid shifts with subsequent cytotoxic oedema. Both mechanisms 
allude to rapid changes in brain volume. This in turn is thought to damage the blood 
brain  barrier  and  disrupt  cerebral  autoregulation.  Patients  identified  as  high  risk  of 
developing DDS are new patients, those with a high pre-dialysis urea or high UF goal, 
children  and  patients  with  co-morbidites  such  as  pre-existing  neurological  disease, 
hyponatraemia, malignant hypertension and hypoglycaemia. 
 
Treatment options are both preventative and therapeutic.  The dialysis prescription can 
be adjusted to reduce the rate of plasma urea clearance by downgrading the surface area 
of the dialyser; decreasing the blood flow rate; minimized intradialytic fluid shifts with 
sodium profiles or higher dialysate sodium concentrations and if the patient is grossly 
fluid overloaded to treat using sequential HD with a initial period of UF alone followed  
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by  conventional  dialysis.  In  paediatrics  mannitol  is  used  almost  exclusively  as  a 
preventative and therapeutic agent.  It is osmotically active solute, and can therefore 
artificially  increase  plasma  osmolarity  at  the  time  of  rapid  urea  clearance. 
Therapeutically  it  rapidly  lowers  intracranial  hypertension  within  minutes  of 
administration,  with  a  maximal  effect  at  20-40mins.  Mannitol  accumulates  in  renal 
failure  (half-life:  36hrs)  and  therefore  a  maximal  intradialytic  dose  of  1g/kg  is 
recommended.   
 
One of the greatest challenges relating to DDS resides in the fact that the diagnosis is 
essentially one of exclusion, the main differential diagnosis being intravascular fluid 
depletion. In practice DDS is only treated when symptoms are typical and/or severe and 
therefore the true incidence in children is unknown. Similar to sequential dialysis the 
value of intradialytic mannitol in children has never been quantified, especially within 
the context of modifying the UF potential. 
 
1.10.6  Cooling 
By modifying skin blood flow we can control heat exchange between the body and the 
environment.    This  is  mediated  by  two  sympathetic  nervous  systems,  an  adrenergic 
vasoconstrictor  and a less well understood sympathetic vasodilator. During times of 
increased  body  core  temperature,  tonic  sympathetic  vasoconstriction  is  relaxed  and 
active  vasodilatation  is  initiated
92  and  with  heat  stress  the  skin  blood  flow  rate  can 
increase from a baseline of 200-500mls/min (5-10% of the total body cardiac output) to 
8l/min (approximately 60% of cardiac output)
93, 94. 
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Traditionally  dialysate  temperatures  have  been  set  around  37°C  based  on  presumed 
physiological normal values and to compensate for losses of heat in the extracorporeal 
circuit.  Both of these assumptions have in fact been found to be untrue. In a study of 
HD patients 62.5% of 128 HD adult patients had pre-dialysis body temp below 36.5, 
with marked inter- and intra-individual differences
95. There is growing evidence in both 
in adults and children of a net gain and not loss of heat during dialysis speculated to 
have  a  multifactorial  aetiology.  Firstly  transfer  of  heat  to  patients  from  the  warmer 
dialysate. As a result of a higher resting energy expenditure in HD patients compared to 
the normal population, especially in those with residual renal function
96. Thermogenesis 
as  direct  consequence  of  the  inflammatory  response  invoked  when  blood  comes  in 
contact  with  bioincompatible  dialysis  membranes.  Finally  UF  activates  increased 
sympathetic vasoconstriction, reducing skin blood flow and therefore heat exchange, 
demonstrated by a direct correlation between UF volume and net heat gain
97. If the 
accumulation  of  heat  causes  an  increase  in  the  body  core  temperature,  UF  induced 
vasoconstriction is overridden by active vasodilatation.  Blood is redistributed to the 
skin
98, the peripheral vascular resistance falls, causing decreased cardiac refilling and 
hypotension
99. Fine and Penner
95 showed that dialysis patients with subnormal body 
temperature (below 36°C) dialyzed against a 37°C dialysate had a 15.9% incidence of 
symptomatic hypotensive episodes, which fell to 3.4% with 35°C dialysate. Selby et al 
reported an improvement in the degree and severity of HD induced myocardial stunning 
in patients treated with cooled dialysate
100. This hemodynamic advantage of “cool” HD 
comes  at  a  price  with  symptoms  related  to  feeling  cold  and  a  theoretical  risk  of 
adversely affecting urea clearance as a result of compartmental dysequilibrium.  The 
application of ‘cooling’ can complex using a feedback control circuit or simple through 
the  manipulation  of  the  dialysate  temperature  based  on  the  patient’s  pre-dialysis  
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temperature.  In  adults  cooling  has  been  associated  with  improved  cardiovascular 
stability and reduced HD induced LV dysfunction
100.  
 
1.10.7  Quotidian haemodialysis 
Conversion  to  frequent  HD  has  been  shown  to  reduce  intra-  and  interdialytic 
hemodynamic instability. This may simply be the result of gentler and more gradual 
fluid. However, there is growing evidence indicating an improvement in a number of 
uraemic  cardiovascular  co-morbidities  in  association  with  superior  toxin  clearance. 
Quotidian dialysis improves EPO responsiveness and dialysis related inflammation
37; 
hypertension and LVH
101,  102; conduit artery stiffness and total peripheral resistance; 
endothelium-dependent vasodilatation
102; and baroreflex regulation of heart rate
103.  
 
Almost exclusively the reported literature features adult studies and paediatric data is 
almost  exclusively  gained  from  case  series  reports.  In  spite  of  this  the  collective 
experience has been positive with improved UF potential and dialysis quality and a 
reduction in intradialytic symptoms. One feature that is relevant in light of the work of 
this MD is that children converting to frequent, 8-10 hour dialysis treatments develop 
chronic asymptomatic pre- and post-dialysis hypotension
104. Again owing to a paucity 
of data we do not know whether this has serious implications in the short-term or in the 
future.    
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Chapter Two 
Hypotheses  
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Nature of the Studies 
Cardiovascular disease is prevalent and the most common cause of mortality in children 
with ESRD. Intradialytic hypotension is prevalent and in adults is a known risk factor 
for death. This raises a very valid question, are the two linked? The evidence for the 
cardiovascular burden of HD is growing stronger and with it the urgency for change in 
the way we dialyse our patients. The difficulty in paediatrics is the paucity of data to 
direct us. Studies examining the cardiovascular response to dialysis have been in adults 
and  extrapolated  to  children.  There  is  anecdotal  evidence  of  haemodialysis  induced 
haemodynamic disturbance and decompensation in children but the risk has not been 
quantified.  Young  adults  have  a  constellation  of  ischaemia  predisposing  factors 
including increased intima media thickness and pulse wave velocity, coronary artery 
and  valvular  calcification,  endothelial  dysfunction  and  early  atherosclerosis.  It  is 
therefore plausible that children may also display a similar pathophysiology of dialysis 
induced cardiac injury as adults.  
 
Objectives 
The objectives of this thesis are as follows: 
￿  To determine the prevalence of intradialytic hypotension during conventional 
paediatric HD treatments. 
￿  To investigate the haemodynamic response to HD in children 
￿  To  ascertain  whether  changes  in  intravascular  volume  are  predictive  of 
intradialytic hypotension during paediatric HD 
￿  To investigate global and segmental myocardial function during conventional 
paediatric HD treatments  
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￿  To determine the efficacy of sodium and UF profiles, sequential dialysis and 
intradialytic mannitol in attenuating intradialytic symptoms and hypotension. 
 
 
Original Hypotheses 
￿  The aetiology of intradialytic hypotension in children is due to variations in the 
compensatory haemodynamic response to intravascular volume changes during 
dialysis. The aetiology is multifactorial and not exclusively due to UF induced 
hypovolaemia. 
 
￿  Children  with  ESRD  have  developed  significant  cardiovascular  disease  that 
predisposes them to ischaemic injury. Conventional HD constitutes a significant 
haemodynamic  stress  and  as  such  is  a  procedure  associated  with  a  high 
metabolic  demand.  In  the  presence  of  repeated  episodes  of  intradialytic 
hypotension the resultant demand supply mismatch causes ischaemic myocardial 
injury and LV dysfunction. 
 
￿  Through  a  better  understanding  of  the  mechanism  involved  in  intradialytic 
hypotension the dialysis prescription can be modified to improve cardiovascular 
stability and intradialytic morbidity. 
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Chapter Three 
Haemodynamic Response to Paediatric Haemodialysis   
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3.1  Hypotheses 
￿  UF is associated with intravascular fluid depletion. 
￿  Intravascular hypovolaemia induces a compensatory cardiovascular response to 
maintain and support adequate circulation for vital organs. During paediatric HD 
the dominant response varies between patients. 
￿  Decompensation is prevented by mounting a tachycardia response, increasing 
cardiac contractility and stroke volume (SV) while the total peripheral resistance 
(TPR) rises to sustain central BP.  
￿  Intradialytic  hypotension  occurs  when  theses  compensatory  mechanisms  fail 
combined with changes in intravascular volume. 
￿  Temporal changes in relative blood volume (RBV) are not able to predict the 
development  of  intradialytic  symptoms  and  hypotension  in  children  but 
thresholds can help to discriminate between successful treatments and in those in 
which an adverse event occurs.  
 
 
3.2  Introduction  
Adults with ESRD have an altered and abnormal hemodynamic stress response
12, 105, 106 
and we assume the same to be true in children. In spite of this, with a desired objective 
of  maintaining  euvolemia  we  attempt  to  remove  large  volumes  of  fluid  during 
conventional 4 hour HD treatments. In paediatrics, UF volumes of up to 6% of the dry 
weight  are  prescribed  and  achieved  but  at  the  expense  of  inducing  intradialytic 
symptoms and hypotension. The aetiology of intradiayltic hypotension is complex and 
thought to be caused in part by an impaired cardiovascular compensatory response to 
fluid removal, although the precise mechanisms are still not entirely understood. Plasma  
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refilling  is  thought  to  be  an  important  mediator  and  an  imbalance  between  UF  and 
plasma refilling rates will eventually lead to hypovolaemia.   
 
The  introduction  of  non-invasive  blood  volume  monitors  (NIVM)  has  now  made  it 
possible to measure the relative changes in the blood volume real-time and repeatedly 
during  individual  dialysis  treatments.  In  addition  it  has  been  suggested  that  RBV 
parameters  may  predict  the  occurrence  of  adverse  intradialytic  events.  In  adults  a 
critical  level  of  RBV  reduction
46,  gradient  of  the  RBV  curve  or  switching  from  an 
exponential  to  a  linear  RBV  reduction  have  demonstrated  predictive  ability  for  the 
occurrence of intradialytic hypotension
46, 48. In children RBV literature is dominated by 
studies reporting on the merits of RBV algorithms in guiding UF
43, 89
  but the predictive 
and discriminating ability of RBV parameters have not been investigated.    
 
 
3.3  Subjects & Methods 
3.3.1   Non-invasive continuous haemodynamic monitoring 
Technique 
The finometer (Finapres Medical Systems, Arnhem, The Netherlands) is a tool designed 
for measuring BP and haemodynamic variables non-invasively, using continuous pulse-
wave analysis at the digital artery (Figure 3.1). Finger arterial pressure is measured 
using the finger-clamp method whereby changes in digital arterial diameter are detected 
by  infrared  photoplethysmograph
107  and  opposed  by  an  ultra-fast  pressure  servo 
controller that changes pressure in an inflatable air bladder, both mounted in a finger 
cuff. This generates an arterial waveform on a beat-to-beat basis form which is then  
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used  to  reconstruct  a  central  aortic  flow  waveform
108  and  calculate  a  number  of 
haemodynamic variables on a continuous basis (see Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Non-invasive continuous haemodynamic monitoring with the finometer 
 
 
Using  a  nonlinear,  self-adaptive,  three-element  Windkessel  model  of  aortic  input 
impedance  an  algorithm  computes  the  aortic  flow  waveform  from  an  arterial  blood 
pressure  pulsation.  Zo  is  characteristic  impedance  of  the  proximal  aorta;  Cw 
'Windkessel' the compliance of the arterial system; and Rp, total systemic peripheral 
resistance. The input is P(t), the arterial pressure waveform and output Q(t) blood flow 
as a function of time. 
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Figure 3.2: Modelling flow from measurements of arterial pressure.  
Left panel: input- the non-invasive pressure for one heartbeat.  
Middle panel: three-element model of aortic input impedance that is used to compute flow from 
pressure Right panel: output- aortic flow as a function of time 
 
 
 
An arm cuff is wrapped around the same arm as the finger cuff to undertake a “Return-
to-flow” calibration
109. When arm cuff pressure is supra-systolic, no pulsations can be 
sensed in the finger. The first slight pulsation signals return to flow and is sensed in the 
finger and detected by the software. The finger cuff pressure is read at that instant and 
calibrated against brachial readings. The Finometer has been validated against invasive 
haemodynamic  measurements  in  both  children  and  adults
110-114  and  shown  to  be 
accurate, reliable and reproducible.   
 
Patients & Method 
I prospectively selected all chronic HD patients treated at Great Ormond Street Hospital 
for Children, excluding those with overt cardiac disease. Ethics approval for this study 
was granted by the local research ethics board and informed consent was obtained from 
patients or their guardians. 
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The children aged from 11 to 17 years, had been dialysis dependent for 4-130 months. 
The net UF volume ranged from 5 to 61mls/kg. Using the finometer I measured the 
heart rate (HR), blood  pressure  (BP), stroke volume (SV), cardiac output (CO) and 
peripheral resistance (TPR) for the duration of the dialysis session. All the data was 
downloaded to a PC based analysis program to calculate average results over 5 minute 
time intervals.  
 
Dialysis Prescription 
All  patients  were  dialysed  using  Gambro  AK  95®  or  Gambro  AK100
®  dialysis 
monitors. Patients received HD for 4 hours, 3 times per week. All dialysis membranes 
were  high  flux  polysulfone  or  triacetate  cellulose  membranes,  sized  to  match  each 
patient’s body surface area. For all treatments, dialysate contained sodium 140 mmol/l, 
potassium 2mmol/l, calcium 1.75mmol/l, magnesium 0.5mmol/l, bicarbonate 34mmol/l 
with a small quantity of acetate in the acidic component to stabilise the dialysate. The 
dialysate solute concentrations were not formally analysed and verified but assumed to 
be correct based on the from the manufacturers labels. The dialysate temperatures were 
set at constant value of 37.0°C. Dialysate flow rates were maintained at 500mls/min and 
the  blood  pump  speed  varied  between  80mls/min  to  400mls/min  depending  on  the 
patients’ size.  
 
3.3.2  Non-invasive blood volume monitor 
Patients 
I included all children who had undergone at least one month of HD within the dialysis 
unit  at  the  Hospital  for  Sick  Children,  Toronto,  excluding  those  receiving  total 
parenteral nutrition or blood products (albumin, fresh frozen plasma, blood, platelets)  
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during their treatment and those who were acutely unwell. Patients were subdivided into 
2 groups for the presence or absence of ‘polyuria’, which was defined as a daily urine 
output >1.5mls/kg/hr. Ethics approval for this study was granted by the local research 
ethics board and informed consent was obtained from patients or their guardians. 
 
Baseline characteristics of the patients and dialytic treatments are listed in Table 3.1. 
The underlying renal disease was focal segmental glomerulosclerosis (FSGS)[1 patient], 
autosomal recessive polycystic kidney disease (ARPKD)[1 patient], renal dysplasia [4 
patients], chronic allograft nephropathy and BK virus nephropathy secondary following 
a  cardiac  transplant[1  patient],  membranous  glomerulonephritis  [1  patient],  anti-
neutrophil  cytoplasmic  antibodies  (ANCA)  negative  glomerulonephritis  [1  patient], 
unknown underlying  aetiology [2 patients]. Of the 11 patients 5 were polyuric, one 
patient  with  panhypopituitarism  was  prone  to  hypotensive  episodes,  1  patient  had  a 
chronic history of intradialytic cramping and 1 patient had been treated with a second 
heart transplant and had evidence of significant right ventricular dilatation on a peak 
dobutamine stress test but normal LV function at rest. 3 patients had LVH and 5 were 
hypertensive.     
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Table 3.1: Baseline characteristics of patients and their dialytic treatments 
 
Sex (M/F)  6/5 
Age (years)  12.8 [7 to 17] 
Dry weight (kg)  40.2 [18.5 to 69.4] 
Urine output (yes/no)  7/4 
Urine output (mls/kg/hr)  1.61 [0.2 to 2.9] 
Pre-dialysis plasma hemoglobin (g/l)  94.8 [114 to 84] 
Pre-dialysis plasma albumin (g/l)  35.8 [26.5 to 44] 
Pre-dialysis plasma ionized calcium (mmol/l)  1.24 [1.09 to 1.55] 
Mean gross UF (mls/session) 
          UF range in non-polyuric patients  
          UF range in polyuric patients 
1475 [500 to 3500] 
   [1123 to 3500] 
    [408 to 1600] 
Blood flow rate (mls/min)  120-350 
Dialysate flow rate (mls/min)  200-650 
Kt/V  1.71[1.36 to 2.14] 
Mean Systolic BP at the start of dialysis (mmHg)  113 [84 to 170] 
Mean Diastolic BP at the start of dialysis (mmHg)  68.1 [49 to 95] 
Mean Heart rate at the start of dialysis (beats/min)  100 [64 to 133] 
 
 
Dialysis Prescription 
All patients were dialysed using the Fresenius 2008K® or 2008H® for 3hrs, 4 times per 
week or for 4hrs, 3 times per week. In addition if patients arrived for their treatment 
grossly fluid overloaded and remained at least 1kg above their estimated dry weight (or 
0.5kg in a hypotensive prone patient) at the end of dialysis, they returned the following 
day for an additional 2 hr treatment. All dialysis membranes were high flux, triacetate 
cellulose  or  polysulfone  membranes.  Dialysis  flow  rates  varied  between  200  to 
650mls/min and blood flow rates were calculated to provide a urea clearance of 3 to 
5mls/kg/min. All patients received unfractionated heparin as standard anticoagulation. 
A  bolus  dose  of  15-20u/kg  was  administered  at  the  start  of  dialysis  followed  by  a  
 
70
continuous  infusion  of  15-20u/kg/hr,  stopping  the  heparin  infusion  over  the  last  30 
minutes of dialysis. The rate of infusion was adjusted to maintain the activated clotting 
time  (ACT)  at  20-50%  above  baseline,  with  a  maximum  ACT  of  220  seconds.  If 
patients were considered to be at a high risk of bleeding no heparin was given. Patients 
were dialysed against 35mmol/l bicarbonate and 1.25mmol/l calcium dialysate solutions 
with a small quantity of acetate in the acidic component to stabilise the dialysate. The 
dialysis water quality was tested monthly  and  met national standards.  The dialysate 
temperatures were set at constant value of 37.5˚C.  Patients were permitted to consume 
one meal during their treatments.   
 
All patients were dialysed with either step or linear, decreasing sodium profiles, starting 
with a sodium concentration of 148mmol/l that dropped to a final concentration of 138 
or 135mmol/l. This was combined with UF profiles (see Figure 3.3): 
-  constant UF rate profile [UF profile 0] 
-  decreasing step wise decline profile [UF profile 3] 
-  decreasing linear decline profile [UF profile 2]  
-  high UF rates interspersed between low rates [UF profile 6] 
The maximum UF rate for any profile did not exceed 1.5 times the average rate. The 
dialysis prescription was adjusted monthly to achieve a urea reduction rate between 65 
to 80% and an estimated Kt/V between 1.2 and 1.6
115.   
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Figure 3.3: UF profiles 
 
Study Protocol 
During a mid-week or end of the week dialysis session RBV changes were measured 
using the Blood Volume Monitor® (BVM, Fresenius AG, Bad Homburg, Germany). 
Data was recorded hourly throughout treatment, at the time of an ‘adverse event’ prior 
to any nursing intervention and upon recovery. Concurrently, the patient’s heart rate and 
BP, and gross UF volume were recorded. A single BP reading was taken in a sitting 
position  using  an  automated  Dinamapp  machine  with  a  cuff  adjusted  for  size.  An 
‘adverse  event’  was  defined  as  an  intradialytic  event  that  resulted  in  a  nursing 
intervention  (saline  bolus,  stopping  UF,  placing  the  patient  in  the  Trendelenburg 
position, arrest call). Treatment failure was defined as the occurrence of an intradialytic 
adverse event and/or the development of hypotension defined as the first Task Force 5th 
percentile systolic BP measurements
8. An exception was made for a hypotension prone 
patient  with  panhypopituitarism  patient  in  whom  the  cut-off  systolic  BP  was  set  at 
75mmHg. Finally the dry weight was assessed monthly from a clinical assessment of 
the patient’s volume status combined with a review of post-dialysis weights at which 
the  patient  displayed  no  symptoms  indicative  of  underhydration.  If  any  degree  of 
uncertainty remained the size of the cardiac silhouette and on a posterior-anterior view, 
post dialysis chest X-Ray.  
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Statistical analyses 
All values of continuous variables were presented as mean ± standard error. A paired t 
test  was  used  to  determine  whether  there  were  significant  differences  between 
continuous  variables  at  the  95th  confidence  interval  (CI),  corrected  for  multiple 
comparisons  using  Bonferroni.  In  order  to  assess  the  ability  of  RBV  changes  to 
discriminate between successful and failed treatments receiver operating characteristics 
(ROC) curves were constructed: 
￿  actual RBV measurement at the end of the first hour and treatment failure in the 
first or second hour of dialysis 
￿  actual RBV measurement at the end of the second hour and treatment failure in 
the second or third hour of dialysis 
￿  hourly  RBV  difference  during  the  second  hour  and  treatment  failure  in  the 
second or third hour of dialysis.  For example if the RBV was 90% at the start 
and 80% at the end of the second hour, the hourly RBV difference would be 
10%. 
￿  actual RBV measurement at the end of the third and treatment failure in the third 
or fourth hour of dialysis 
￿  hourly difference in RBV during the third hour and treatment failure in the third 
or fourth hour of dialysis  
￿  actual RBV measurement at the end of the fourth hour and treatment failure in 
the fourth hour of dialysis 
￿  hourly difference in RBV during the fourth hour and treatment failure in the 
fourth hour of dialysis 
￿  final RBV measurement at the end of dialysis and treatment failure  
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In the evaluation of actual RBV measurements, the ROCs were constructed taking low 
values to be ‘positive’ for treatment failure. For example, using a test threshold of 88%, 
the test is positive for a RBV of 88% or below and negative if the RBV is greater than 
88%. In the analyses of hourly differences in RBV as the discriminator, high values 
were taken to be ‘positive’ for treatment failure. For example, with a test threshold of 
10%, the test is positive if the hourly difference in RBV is greater or equal to 10% and 
negative if the hourly difference is less than 10%. Polyuric patients were excluded from 
the ROC analyses. 
 
A repeated measures ANOVA was used to determine whether the rate of RBV change 
over  time  or  the  shape  of  the  RBV  curve  differed  between  successful  and  failed 
treatments, testing for polyuria as a confounder. Measured RBV data from 60 minutes 
to the end of dialysis was entered into the analysis. Finally a logistic regression analysis, 
again with polyuria as a confounder, was conducted to test the relationship between 
treatment  outcome  (successful  or  failed  treatment)  and  the  predictors:  i)  final  RBV 
measurement at the end of treatment; ii) difference in systolic BP from the start to the 
end of treatment; iii) difference in diastolic BP from the start to the end of treatment; 
and iv) difference between final and initial heart rate.  For all four analyses ‘end of 
treatment’ was defined as the time of completing the prescribed dialysis treatment or the 
time at which an adverse intradialytic event occurred.   
 
All statistical tests were performed using the SAS statistical package (SAS 9.1, North 
Carolina, USA). All statistical tests were two tailed with a p-value less than or equal to 
0.05 taken to indicate significance. The internal correlation of observations from the 
same patients was taken into account by completing repeated measures analyses for all.  
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3.4  Results 
From the 11 patients, 74 RBV curves were recorded of which 15 records were from 
polyuric patients. I have no information on the number of dialysis treatments and thus 
the number of RBV curves that were generated by each patient as I was blinded to the 
selection  of  patients  for  RBV  analyses.  Intradialytic  hypotension  occurred  in  34% 
(26/74)  of  treatments,  associated  with  RBV  changes  of  up  to  30%.  Intradialytic 
symptoms  occurred  in  41%  (30/74)  of  the  treatments,  14%  (10/74)  were  stopped 
prematurely  and  only  53%  (39/74)  of  UF  targets  could  match  the  volume  of  the 
intradialytic weight gain.  
 
The  hemodynamic  response  during  HD  differed  between  patients  and  is  best 
demonstrated using specific examples. 
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Figure 3.4: Intradialytic haemodynamic response for Patient 1 
 
 
Patient  1  mounted  a  tachycardic  response  from  the  second  hour  of  dialysis.  She 
demonstrated  a slow  gradual decline in her SV and CO during the first 3 hours of 
dialysis with a sudden fall in both in the last hour of dialysis, associated with a drop in 
her BP. Her BP essentially mimicked the TPR and as her TPR became unstable in the  
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3
rd and 4
th hour her BP followed suit.  Within the group this was a common feature. The 
systolic BP appeared to be most influenced by the TPR and thus if the rise in vascular 
resistance was inadequate, a declining BP followed.                
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Figure 3.5: Intradialytic haemodynamic response for Patient 2  
 
Patient  2  was  haemodynamically  stable  for  the  first  2  hours  of  dialysis  and  then 
suddenly dropped his CO. This was preceded by a short-lived tachycardic response and 
followed by a fall in SV. The BP remained relatively stable up to this point and in fact 
increased at the same time as the patient became tachycardic.  As the heart rate fell so 
did the SV and BP. The BP then stabilized as the TPR increased. Within the group the 
drop  in  CO  was  greatest  featured  in  patients  that  failed  to  mount  an  adequate 
tachycardic response. 
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Figure 3.6: Intradialytic haemodynamic response for Patient 3 
 
 
Patient 3 was a 13 year old with FSGS, oliguria, significant proteinuria and relative 
hypoalbuminaemia. She demonstrated a rising CO and SV during the 2nd hr of dialysis 
presumably  due  to  refilling  from  the  interstitial  space.  In  spite  of  this,  a  delayed 
response in TPR resulted in a falling BP. The BP recovered as the TPR increased, in 
parallel with a rising CO. Please note in Patient 3 we were only able to capture data for 
the first 3 hours of dialysis as she did not tolerate the finometer.  
 
The limited number of paediatric specific finger cuffs placed an age restriction of 11 
years old, under which it was not possible to successfully collect data.  Previous studies 
on neonates have reported success on using larger finger cuffs over the patients’ wrists, 
however this method was also unsuccessful. The other major concern with the finometer 
was the fact that it was not tolerated by the children for long periods of time and it was 
only after a lot of cajoling and repeated efforts in some patients that I was able to 
complete the study.  
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The combined group trend, as illustrated below, showed a falling CO and SV and rising 
HR with time on dialysis.  As the systolic BP fell in the latter half of dialysis the TPR 
increased.  As a general rule hypotension was the result of a falling cardiac output (CO) 
combined with an insufficient rise in total peripheral resistance (TPR).                  
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Figure 3.7: Graphical representation of the combined group trend 
 
 
RBV as a Predictor of Outcome 
Regression analysis demonstrated a significant association between change in systolic 
BP during a HD session and final RBV measurement (p=0.05), excluding data from 
polyuric patients (see Figure 3.8).  
 
The presence of polyuria as a confounder had a highly significant effect on the final 
RBV  reduction  (p<0.0001),  such  that  polyuric  patients  had  higher  final  RBV 
measurements at the end of dialysis in both successful and failed treatments.  
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Figure 3.8: Graph of absolute final RBV reduction and intradialytic BP change 
 
Multivariate logistic regression was used to test potential predictors of treatment failure 
(Table  3.2).  The  only  variable  significantly  related  to  treatment  failure  was  the 
difference in heart rate and the presence of polyuria as a confounder was not statistically 
significant. For each beat per minute increase in heart rate during dialysis there was a 
5% increased risk of treatment failure (p=0.05). 
 
Table 3.2: Logistic regression of complication free treatments in multivariate analysis 
Group  p value  Odds 
ratio 
95% Confidence 
Interval 
Final RBV measurement at the end of dialysis 
(for each 1% increase) 
0.27  0.95  0.88 – 1.04 
Difference in systolic BP from the start to the 
end of dialysis (for each mmHg decrease) 
0.11  0.97  0.926 – 1.01 
Difference in diastolic BP from the start to the 
end of dialysis (for each mmHg decrease) 
0.47  1.02  0.97 – 1.07 
Difference between final and initial heart rate 
(for each beat/min increase) 
0.05  0.95  0.92 – 0.99 
 
R
2= 0.57  
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The repeated measures ANOVA found no statistically significant difference in the rates 
of change of the RBV from 1 hour to the end of treatment between successful and failed 
treatments (Figure 3.9).  
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Figure 3.9: Individual RBV curves with group trends for treatments with and without 
complications 
 
The cumulative data in the fourth hour was small and disproportionate, there was one 
treatment failure and 7 seven successful ones. To account for this bias we analyzed the 
data up to the end of the third hour and the fourth hour, but as the results were the same 
we have only reported on the analysis to the end of the third hour. The average RBV 
measurements were higher in the successful treatments but the shape of the RBV curve 
and the rate of RBV change from 1 hour to end of the third hour was not statistically 
significant if including all treatments (p= 0.50) and or after excluding treatments from 
polyuric  patients  (p=  0.75).  There  was  a  significant  difference  in  the  average  RBV 
measurement at the point of entry into the ANOVA analysis, namely the time intercept 
1 hour (see Figure 3.8). This translates to a statistically significant difference in the  
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average RBV measurement at 60 minutes of dialysis. Therefore the rate of RBV change 
during  the  first  hour  of  dialysis  between  the  successful  and  failed  treatments  was 
statistically significant with a steeper decline in the failed treatments (see Table 3.3).  
 
Table 3.3:  Differences in average absolute RBV measurements for treatments with and without 
complications at intradialytic time intercept 1 hour  
 
Repeated Measures ANOVA for dialysis time 
intercept 1hr 
Average 
RBV 
p 
Value 
95% 
Confidence 
Interval 
Including all RBV curves 
Complication free treatments  90.1  0.01  87.95 – 93.35 
Complicated treatments  86.1  0.01  83.96 - 88.21 
 
Excluding treatments from polyuric patients 
Complication free treatments  86.1  0.05  84.07 – 88.22 
Complicated treatments  83.6  0.05  82.05 – 85.07 
 
 
One factor that was present in all the patients that may have influenced RBV change 
was  the  consumption  of  food.  However  it  was  not  possible  to  test  the  relationship 
between the timing and the size of meal in the first hour and changes in RBD reduction 
as every patient consumed a meal and in 90% of cases patients tended to snack on foods 
such as crisps before or after their meal.  
 
 
RBV Reduction as a Discriminator of Successful and Failed Treatment 
We found actual RBV measurements at the end of each hour of dialysis to be better 
discriminators of outcome than hourly RBV differences. Using the hourly difference in 
RBV in the first, second, third and fourth hour, and final RBV measurement at the end  
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of treatment, the 95% CI for the ROC area under the curve (AUC) contained 0.5 (Table 
3.4). Thus these tests are redundant as their application would only provide a 50:50 
odds ratio of discriminating between outcomes and were thus excluded from any further 
analyses. ROC curves were only constructed for actual RBV measurements at the end 
of the first, second and third hours of dialysis. The ROC curves for the first hour can be 
seen in Figures 3.10 and 3.11 
 
Table 3.4: Proposed RBV diagnostic tests and the empirical Area Under Curve (AUC) 
analysis of their ROC curves 
 
Diagnostic Test  AUC  95% Confidence 
interval  of AUC 
Absolute RBV measurement at the end of the first hour  0.82  0.68 – 0.90 
Absolute RBV measurement at the end of the second hour  0.79  0.62 – 0.89 
Absolute RBV measurement at the end of the third hour  0.72  0.50 – 0.86 
Absolute RBV measurement at the end of the fourth hour  0.50  0.20 – 0.71 
Final absolute RBV measurement at the end of dialysis   0.50  0.34 – 0.63 
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Figure 3.10: Empirical ROC for absolute RBV change at the end of the first hour of HD  
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Figure 3.11: ROC curve of the absolute RBV change at the end of the first hour of HD based on 
the binormal assumption. 
 
The best cut point on these ROC curves represented a RBV cut-off threshold of 88% at 
the end of the first hour, 84% at the end of the second hour and 82% at the end of the 
third hour. The predictive value of these thresholds for determining treatment failure is 
shown in Table 3.5.   
 
Table 3.5: The predictive value of our ROC derived RBV thresholds testing for  
treatment complications  
 
RBV Threshold   Sensitivity  Specificity  PPV  NPV 
88% at the end of the 1
st hour of dialysis  63%  89%  86%  69% 
84% at the end of the 2
nd hour of dialysis  58%  94%  96%  52% 
82% at the end of the 3
rd hour of dialysis  78%  80%  91%  57% 
 
Test ‘Positive’ if less than or equal to RBV threshold 
Test ‘Negative’ if greater than RBV threshold 
 
PPV- positive predictive value, NPV- negative predictive value 
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3.5  Discussion 
The haemodynamic response during a 4 hour conventional HD treatment was different 
and  individual  to  each  child.  Similarly  there  was  an  intra-patient  and  inter-patient 
variation in RBV profiles confounded by differences between patients with and without 
significant residual renal function. The gradient of the RBV curve in the first hour and 
changes in intradialytic heart rate were the strongest predictors for the occurrence of 
intradialytic adverse events. 
 
The intradialytic blood volume is dependent on several distinct factors, the volume of 
the extracellular space, the dynamic balance between UF and vascular refilling during 
dialysis, vascular tone and the ability to mount an adequate cardiovascular response at 
times of decompensation. During the course of the dialysis session any one of these 
factors could predominate and therefore also be primarily responsible for precipitating 
hypotension. This would also explain the range of critical RBV thresholds that resulted 
in intradialytic morbidity or the variations in the nature of the compensatory response 
within patients. The analyses of the polyuric patients highlighted the relevance of an 
additional factor, the hydration status of a child. One can hypothesise that patients with 
a high urine output have minimal intradialytic volume expansion and their presenting 
weight is almost identical to their euvolaemic target weight. Therefore minor changes in 
the blood volume could result in hypovolaemia at higher RBV thresholds. At the other 
extreme, in fluid overloaded patients a poor correlation exists between changes in body 
weight and plasma volume with an inverse relationship between pre-dialysis BP and 
intradialytic changes in the plasma volume
116. Theoretically therefore, chronically fluid 
overloaded patients or those with an over-estimation of their dry weight should be able 
to achieve higher UF volumes without compromising their circulation.   
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The  cardiovascular  system  demonstrates  a  high  degree  of  intrinsic  autoregulation 
dependent on neural, hormonal and local metabolic control all of which are sensitive 
and  affected  by  disease.  Uraemia  alters  the  physiological  mechanisms  involved  in 
maintaining arteriolar tone and cardiac output. Tachycardia is an early and universal 
response  to  all  causes  of  intravascular  compromise
105  and  this  remains  true  during 
paediatric HD. The tachycardic response was important both in predicting intradialytic 
morbidity and supporting the cardiac output. This would suggest that in the presence of 
uraemia  the  chronotropic  response  dominated  over  the  ionotropic  response.  In  fact 
recent  adult  data  concurs  with  this  notion.  HD  induces  segmental  myocardial 
dysfunction and even in the presence of the significant haemodynamic stress imposed 
by UF the ejection fraction does not rise
117. These findings raise the possibility that HD 
negatively affects myocardial contractility not only in adults but perhaps in children too.  
 
Analogous  to  newborns,  patients  with  ESRD  have  increased  basal  level  peripheral 
sympathetic nervous system activity
118. In newborns this is associated with a relative 
resistance to the effects of catecholamines and thus increases in heart rate achieve little 
gain in cardiac output, and if excessive may even drop the cardiac output. If we apply 
the same physiology to uraemic children one can explain how the tachycardic response 
is useful in predicting adverse events during dialysis but on its own is unable to prevent 
hypotension from occurring. In reality this is all postulation as I have no evidence to 
support  whether  this  is  the  pathogenesis  for  the  limited  compensatory  response  in 
children on dialysis, nevertheless I present data that is clearly indicative of a change in 
cardiovascular phenotype in uraemic patients.  
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Children  with  ESRD  show  evidence  of  endothelial  dysfunction,  reduced  vessel 
compliance
24  and  vascular  calcification
119.  Above  this  baseline  risk  the  very  act  of 
dialysis is thought to initiate further endothelial dysfunction. Adult HD patients have 
elevated  levels  of  endothelial  cells  and  endothelial  microparticles
120,  reduced 
endothelial progenitor cell function
121 with preservation of smooth muscle progenitor 
cells
122. This translates to a vascular environment conducive to injury but without the 
capacity to repair, with triggers that are almost certainly multi-directional. Dialysis is 
recognised as a pro-inflammatory procedure but the mechanisms continue to elude us. 
UF with RBV  reductions as high  as 30% as demonstrated in this study alter blood 
viscosity and shear stress and this can adversely influence endothelial cell survival and 
quiescence.  Severe  reductions  in  afterload  during  dialysis  can  induce  ischaemic 
endothelial cell apoptosis with continued and repeated depletion of the body’s pool of 
endothelial  progenitor  cells.  The  resultant  endothelial  dysfunction  represents  a 
molecular state of activation and a switch from a quiescent phenotype towards to one 
that is procoagulant, pro-inflammatory and vasoconstrictive. This is  clearly  counter-
productive and in all likelihood responsible for the maladaptive regulation of vascular 
tone and the increased predisposition to hypotension. During paediatric HD this may be 
especially  important  as  peripheral  vascular  resistance  was  in  this  cohort  one  of  the 
strongest influences on systolic BP. 
 
Similar  to  findings  in  adults,  the  absolute  RBV  reduction  was  unable  to  predict 
intradialytic hypotension. Dasselar et al found a significant difference in RBV change 
measurements  by  different  NIVMs  (the  Crit-Line,  Hemoscan,  and  BVM)  and  those 
obtained from laboratory-derived haemoglobin changes
123.  This raises a suspicion of an 
inherent  flaw  within  all  NIVMs  that  produces  inaccuracies.    RBV  is  based  on  the  
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principle  of  mass  conservation  and  an  assumption  that  the  total  amount  of  blood 
constituent in the circulation is constant, with uniform mixing of red blood cells and 
plasma throughout the circulation or that the relative distribution of blood constituents 
over  different  vascular  beds  does  not  change  during  dialysis.  We  now  know  this 
assumption to be incorrect. Whole blood haematocrit is lower than arterial or venous 
haematocrit due to the dynamic reduction in microvascular haematocrit in capillaries 
and  venules  (Fahraeus  effect)
15.  The  difference  is  expressed  as  a  F-cell  ratio  and 
approximates 0.91 in the normal population
124. During HD, owing to the redistribution 
of the blood from the microcirculation to the central circulation the F-cell ratio increases 
and thus the observed  RBV change in theory  underestimates the whole body blood 
volume change
125. In fact Agarwal et al tested the diagnostic ability of the RBV slope in 
detecting volume excess and volume depletion. They found that the area under the ROC 
curve was 0.71 to predict volume excess and 0.55 to predict volume depletion
126 and 
hence RBV curves were superior in discriminating between volume excess than volume 
depletion.  Therefore the RBV curve lacks potential in predicting the critical point in 
intravascular volume reduction and the onset of decompensation and this may in part be 
explained by the delay in detecting real changes.  
 
This study may not have been able to identify a universal absolute RBV threshold that 
predicts intradialytic morbidity but I was able to determine and validate RBV thresholds 
that discriminated between treatments with and without adverse events. Jain et al have 
proposed  similar  RBV  driven  UF  algorithms  and  in  contrast  to  my  cut-off  RBV 
thresholds of 88% at the end of the first hour, 84% at the end of the second hour and 
82% at the end of the third hour, they defined safe UF with a RBV reduction less than 
8% per hour in the first 90 minutes and less than 4 % thereafter
43. The reality is that  
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both  may  in  fact  be  valid  and  the  discrepancy  relates  to  differences  in  the  dialysis 
prescription  and  choice  of  NIVM.  The  Blood  Volume  Monitor®  measures  the 
difference in blood density and is dependent on the total protein concentration and the 
Crit-line®, the device used by Jain measures the red blood cell concentration through 
assessment of the optical density of whole blood. There is no doubt that the accuracy of 
readings between the two devices is similar however the RBV measurements are not 
directly interchangeable. Schneditz et al demonstrated a 2% difference in relative blood 
volume changes (BVM 2% less reduction in blood volume compared to Crit-line) that 
developed  approximately  1  hr  into  dialysis,  and  persisted  thereafter
41.    The  dialysis 
prescription is also relevant to this discussion. Jain studied patients dialysed against a 
fixed dialysate sodium concentration of 140mEq/l and provided no details on UF rates. 
In contrast the objective of this study was to validate RBV thresholds over a range of 
dialysis sodium and UF prescriptions thus making it more broadly applicable clinically. 
The theoretical problem with this approach is that we know that dialysate sodium and 
UF rates influence dialysis quality and risk of intradialytic symptoms and hypotension
78, 
127. In an attempt to address this possible bias I tested the possibility of an independent 
effect of the dialysis prescription on the frequency of adverse events. By entering my 
data into a repeated measures Generalized Estimating Equations model I analysed the 
odds of adverse events between the UF profiles and two sodium profiles and found no 
statistically significant differences between the groups. Thus I present RBV thresholds 
that  have  the  potential  to  guide  safe  UF  but  would  recommend  against  prescriptive 
application of these thresholds as adjustments may be required with local differences in 
dialysis conditions.  
 
  
 
88
3.6  Study limitations  
First and foremost my study was performed in a small and heterogenous population. 
However as this was the formal first assessment of this kind in children my initial aim 
was not to be over restrictive on the recruitment process. In the world of paediatric HD 
where  single  centre  patient  numbers  rarely  exceed  20,  maintaining  such  a  broad 
inclusion criteria was necessary in order to achieve an adequate and appropriate cohort 
size. Clearly in the converse it also has the potential to introduce bias.  
 
Treatments were not standardized for patient factors such as postural changes during 
dialysis  and  food  intake  which  are  known  to  influence  the  accuracy  of  NIVM  and 
cardiovascular  dynamics.  Similarly  sodium  and  UF  profiles,  and  the  use  of  short 
intervals  of  isolated  UF  are  all  dialysis  factors  with  the  potential  to  influence 
cardiovascular  stability  during  dialysis.  The  results  should  therefore  be  interpreted 
within the limitations of its design. 
 
The  numbers  were  further  depleted  in  the  finometer  study  owing  to  the  restrictions 
imposed by the size limitations of the finger cuffs. The smallest finger cuff size was 
only suitable for children 11 years or over and hence we were unable to get any data on 
6 patients. Previous studies on neonates have reported success on using larger finger 
cuffs over the patient’s wrist, but in my hands this method failed to produce an adequate 
trace and was therefore abandoned. The other major concern with the finometer was the 
fact that it was not tolerated by the children for long periods of time. The cuff had to be 
wrapped tightly around the finger for the finger-clamp method to be effective and the 
longer  the  cuff  remained  in  place  the  greater  the  likelihood  of  adverse  symptoms. 
Children complained of the finger becoming numb, white and cold to touch. The wrist  
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strap that housed all the sensors and adaptors was also relatively heavy and cumbersome 
and this prompted several verbal complaints. The design of the finometer was such that 
it was reported to be able to cope with movements in the arm without having a hegative 
impact on the trace. However this did not match my own experience. Typically a child 
on  dialysis  would  eat  lunch,  watch  TV,  play  games  or  was  encouraged  to  do  their 
homework.  In  the  children  studies  the  resultant  movement  from  these  activities 
frequently resulted in sensor failure and repeated interruptions in the trace.  
 
Clearly a child’s cooperation is paramount to attaining finometer data and on reflection 
I feel that the method used in this study will require change during subsequent studies. 
The objective in dialysis studies is to measure changes in haemodynamic variables with 
time on dialysis. In theory this can also be achieved by attempting finometer traces for 
15-30minute intervals per hour of dialysis. If the first time aliquot starts prior to the 
patient  being  connected,  baseline  information  will  be  captured  while  the  final  30 
minutes will capture the period at the end of dialysis and hence the time of peak stress 
in addition to the recovery period during washback and disconnection from the dialysis 
circuit.  I  am  also  hoping  that  by  allowing  the  children  respite  time,  free  from  the 
finometer, compliance and co-operation may improve.    
 
The other major limitation of this study was the fact that the two arms of the study were 
conducted in different patients. The Hospital for Sick Children, Toronto had already 
invested in NIVMs and hence this study was possible there. In contrast Great Ormond 
Street Hospital had access to the finometer but not NIVMs. This preliminary data has 
been very useful in determining group trends and directing future studies but there is no 
doubt that to accurately assess trends in individual patients simultaneous data from both  
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the finometer and RBV monitoring is required. This would also be more in keeping with 
the future direction of HD treatments, that of individualised treatments.  
 
 
3.7  Conclusion 
In  conclusion  the  hemodynamic  response  to  conventional  HD  treatments  and  UF  is 
different and individual to each child.  The evolution of tachycardia and the gradient of 
decline of the RBV curve during the first hour of treatment can be useful in predicting 
the occurrence of intradialytic adverse events.  The blood volume profiles from patients 
with significant residual urine output were different from oligo-anuric patients.  
 
Cut-off RBV thresholds of 88% at the end of the first hour, 84% at the end of the 
second  hour  and  82%  at  the  end  of  the  third  hour  were  the  best  discriminators  of 
outcome with a high specificity and PPV for treatment failure but limited sensitivity and 
NPV.  Knowledge  of  patient  specific  adaptive  responses  may  allow  us  to  target 
interventions in supporting circulation during subsequent dialysis sessions.  
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Chapter Four 
Myocardial Consequences of Haemodialysis   
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4.1  Hypotheses 
￿  Uraemic children have a predisposition for demand ischaemia 
￿  The  extracorporeal  blood  volume  necessary  for  priming  the  HD  circuit 
combined  with  the  intravascular  fluid  depletion  during  UF  amounts  to  a 
significant haemodynamic stress. 
￿  The  resultant  effect  is  HD  induced  cardiac  perfusion  defects  and  regional 
myocardial dysfunction  
￿  Speckle tracking two-dimensional strain is more sensitive in detecting ischaemic 
myocardial dysfunction than assessment of regional wall motion activity. 
 
 
4.2  Introduction 
Cardiovascular  mortality  is  grossly  elevated  in  HD  patients.  CKD  have  a  30  fold 
increase in mortality than age-matched controls and an even higher risk of up to 800 
fold for dialysis and young adults
20. This excess of cardiovascular death is only partly 
explained by an increase in traditional risk factors, and several mechanisms of cardiac 
damage  specific  to  the  uraemic  milieu  have  been  identified.  It  is  also  becoming 
increasingly  apparent  that  HD  in  itself  confers  a  risk  but  the  pathophysiological 
mechanisms  remain  elusive.  In  adults  there  is  evidence  from  isotopic
65, 
electrocardiographic
60,  128,  biochemical
58,  59  and  echocardiographic
100,  117  studies 
implicating HD as a source of recurrent subclinical myocardial cell injury, even in the 
absence of pre-existing large vessel epicardial coronary artery disease (CAD). Single 
photon  emission  computed  tomography  (PET)  adult  data  has  demonstrated  acute 
reductions in global and segmental myocardial blood flow during HD, with matched 
reversible reductions in segmental contractile function
65, consistent with the definition  
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of myocardial stunning
55. The number of stunned segments and the intensity of stunning 
within segments correlate with intradialytic BP changes and UF volume
129. In the model 
of CAD, repeated stunning leads to myocardial hibernation with resultant heart failure
71. 
Within  dialysis  patients  transient  myocardial  ischemia  precipitates  cardiac 
arrhythmias
130 and progresses to fixed regional systolic dysfunction and reduced global 
systolic function 
67. 
 
Uraemic  children  and  young  adults  have  a  similar  constellation  of  ischaemia 
predisposing factors to adults, including increased intima media thickness and pulse 
wave velocity, vascular calcification, early atherosclerosis and endothelial dysfunction 
24,  119,  but  without  significant  atheromatous  CAD.  In  the  previous  study  I  have 
demonstrated  that  the  incidence  of  HD  induced  haemodynamic  disturbance  is 
comparable to adults, with a 20-30% incidence of intradialytic hypotension associated 
with a relative blood volume reduction of 20-25%. It is therefore plausible that children 
may also display a similar pathophysiology of dialysis induced cardiac injury as a result 
of characteristic uraemic cardiovascular abnormalities. 
 
Regional  wall  motion  assessment  (RWMA)  is  primarily  an  assessment  in  the 
longitudinal axis and uses the inward motion of endocardial borders as the sole marker 
of  abnormal  contraction.  In  contrast  2D  speckle  tracking  provides  a  multi-axis 
assessment of LV function employing functional components that are not visible to the 
naked eye. Speckle tracking strain is also both translation and angle independent with 
lower  inter  and  intra-operator  variability  compared  with  RWMA
131  in  adults.  This 
makes  it  a  very  promising  novel  technique  for  detecting  regional  LV  dysfunction,  
 
94
especially within this context. Uraemic children have no evidence of epicardial coronary 
artery disease and thus the extent of ischaemic injury may be mild and findings subtle.   
 
 
4.3  Method 
4.3.1  Patients 
All patients at Great Ormond Street Hospital that had been on HD for at least one month 
were considered for inclusion within the study. I excluded those patients with congenital 
heart  disease,  a  concurrent  respiratory  illness  or  if  it  was  not  possible  to  obtain 
echocardiographic images of sufficient quality to allow meaningful analysis owing to 
poor windows for visualizing the heart.  Ethics approval for this study was granted by 
the local research ethics board and informed consent was obtained from patients or their 
guardians.  
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Table 4.1: Patient Demographics 
 
n/a: not available 
 
AV fistula: arteriovenous fistula 
LV: left ventricle 
 
* Patients recruited for the Regional wall motion Study 
§  Patients recruited for the 2D strain Study 
 
Patient 
Age 
(yrs) 
Time 
on HD 
(mths) 
Cause of ESRD  AV 
fistula 
LV 
septum 
[Z-score] 
LV 
Posterior 
wall 
[Z-score] 
*
§ 1   5  4  Renal dysplasia  yes  1.3  1.7 
*
§ 2   17  89  Cystinosis  yes  1.6  0.3 
*
§ 3   15  43  Focal segmental  
glomerulosclerosis  yes  0.1  1.4 
*
§ 4   15  4  Renal dysplasia  yes  0.3  0.2 
*
§ 5   15  32  Focal segmental  
glomerulosclerosis  yes  2.6  1.9 
*
§ 6   13  4  Renal dysplasia  no  5.9  6.3 
*
§ 7   11  35  Renal dysplasia  yes  0.5  -0.6 
*
§ 8   13  15  Focal segmental  
glomerulosclerosis  no  0.6  -1.1 
*
§ 9   2  7  Glomerulocystic disease  no  1.5  1.7 
* 10   17  12  Reflux nephropathy  yes  1.9  1.7 
* 11   7  62  Autosomal recessive 
polycystic kidney disease  yes  1.0  0.3 
*
§ 12   14  6  Cystic dysplasia  yes  2.6  1.2 
§ 13  13  2  Focal segmental  
glomerulosclerosis  no  0.4  03 
§ 14  2  2  Nephronophthisis  no  1.2  1.3 
§ 15  1  2  Oxalosis  no  0.7  0.8 
§ 16  8  24  Congenital nephrotic 
syndrome  no  n/a  n/a 
§ 17  15  2  Renal dysplasia  no  1.4  1.6  
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Of  the  17  patients  9  had  AV  fistulae  as  their  dialysis  vascular  access  and  in  the 
remainder central tunnelled venous catheters were used. 5 patients had previous failed 
transplants and 2 patients had three months of peritoneal dialysis prior to HD. Residual 
urine output varied amongst the study group, 7 patients were anuric, 5 patients passed 
less  than  1ml/kg/hr  of  urine  and  5  patients  passed  between  1-2  mls/kg/hr.  At  their 
baseline  examinations  only  one  patient  had  LV  hypertrophy  and  three  patients  had 
borderline hypertrophy (see Table 4.1 
 
 
4.3.2  Dialysis Prescription 
All patients were dialysed using Gambro 200S® dialysis monitors. Patients received 
HD for 4 hours, 3 times per week. All dialysis membranes were high flux polysulfone 
or triacetate cellulose membranes using sizes that at minimum were equivalent to each 
patient’s  body  surface  area.  For  all  treatments  the  dialysate  contained  sodium140 
mmol/l, potassium 2mmol/l, calcium 1.75mmol/l, magnesium 0.5mmol/l, bicarbonate 
34mmol/l  with  a  small  quantity  of  acetate  in  the  acidic  component  to  stabilise  the 
dialysate. The dialysate temperature was set at a constant value of 37.0˚C. Dialysate 
flow  rates  were  maintained  at  500mls/min  and  blood  pump  speeds  varied  between 
80mls/min to 400mls/min depending on the patients’ size. The dialysis prescription was 
adjusted monthly to achieve a urea reduction ratio greater than 65% and Kt/V urea 
greater  than  1.2  (calculated  from  Daugiradas  single  pool  kinetics)
115.  All  patients 
received unfractionated heparin as required. Patients were permitted to consume one 
meal during their treatment. For each session, net fluid removal was set on an individual 
basis and adjusted to restore the patient to their ideal dry weight (clinically determined) 
by the end of the dialysis session. UF took place in parallel with dialysis using constant  
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UF  rates  unless  patients  had  higher  than  normal  UF  requirements.  In  these 
circumstances patients received 30 minutes of isolated UF at the beginning and/or the 
end of the HD session. 
 
 
4.3.3  Regional wall motion assessment 
Technique 
Using 2-dimensional (2D) echocardiography standard apical 2-chamber and 4-chamber 
views are taken to visualise the LV endocardial border in 2 planes at 90 degrees to each 
other. These images are then copied onto CDs in DICOM format for off-line analysis 
using a personal computer based digitising programme (Echo-CMS, MEDIS, Leiden, 
The Netherlands)
132. Three consecutive heartbeats were analysed for each time point 
(extrasystolic beats were excluded). Endocardial borders (excluding papillary muscles) 
were traced semi-automatically for each videoframe of the 3-beat sequence, and any 
anomalies corrected manually. Maximal displacement of the endocardial border from a 
centre point was then measured over each of 100 chords around the LV wall, corrected 
for  end-diastolic  LV  circumference  (see  Figure  4.1)  and  expressed  as  percentage 
shortening fraction (SF). Each apical view was divided into 5 segments and SF for the 
chords in each segment was averaged so 10 regions of the LV were assessed at each 
time point. Any segmental endocardial border that was not clearly visible was excluded 
from  analysis.  Segmental  reduced  regional  wall  motion  (RRWM)  was  defined  as  a 
decline in SF of >20% from baseline and degrees of hyperkinesis 20% and 50% were 
defined  as  those  segments  that  demonstrated  a  increase  in  SF  of  >20%  and  >50% 
respectively.  I  calculated  the  mean  SF  for  all  ten  segments  (SF[Overall]),  for  those 
segments  that  developed  new  RRWM  (SF[RRWA])  and  those  segments  that  did  not  
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develop RRWM (SF[Non-RRWM]). Ejection fraction (EF) was calculated from the apical 
four chamber and 2 chamber view by the Simpson’s rule. The LV posterior and septal 
wall  thickness  was  measured  from  parasternal  long  axis  M-mode  images,  and 
represented as Z-scores after adjusting for age and body surface area.  
Figure 4.1: Assessment of regional wall motion activity by Echo CMS.  
On the left panel highlighted in blue is an example of a semi-automatic tracing of the 
endocardial border. On the right panel each red line represents a measurement of the regional 
endocardial border movement.   
 
 
Study Protocol 
For each monitored dialysis treatment, serial echocardiography was performed at the 
start of dialysis (baseline), 2 hours into the dialysis session, the end of the dialysis 
session and at recovery 15mins after dialysis, once a saline wash-back had been given 
and  the  patients  had  been  disconnected  from  the  machine.  Ideally  I  would  have 
preferred a longer period post dialysis prior to re-assess the cardiac function, but owing 
to travel times and other social reasons patients refused. Blood samples were collected 
before  and  after  each  session  in  lithium  heparin  and  EDTA  tubes,  and  biochemical  
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analysis  performed  on  a  multichannel  autoanalyser  for  routine  electrochemical,  full 
blood count and high sensitivity C-reactive protein (hsCRP). Cardiac troponin-I (cTnI) 
analysis  was  preformed  using  a  chemiluminescent  assay  on  a  Beckman  Access 
Immunoassay analyser. Pre dialysis blood tests were drawn immediately after insertion 
of access needles or catheter connection, and post levels were taken from the arterial 
line after reducing the blood pump speed to 50ml/min. During each dialysis session the 
net  UF  volume  and  intradialytic  symptoms  with  corresponding  heart  rate  and  BP 
measurements  were  recorded.  For  each  patient  echocardiography  data  was  collected 
during  two  separate  dialysis  sessions,  separated  by  no  more  than  four  weeks.  The 
primary endpoint of HD induced myocardial stunning was determined from the degree 
of change in LV segmental SF, and the number of segments involved. The secondary 
endpoint was to assess whether a relationship existed between reduced segmental LV 
function and intradialytic BP and UF volume. 
 
Statistical analyses 
The data comprised of 2 data sets of 12 from the same patients. Therefore in order to 
determine the prevalence of myocardial stunning only one data set was used, selected at 
random, by tossing a coin. To test the association between dialysis and patient related 
factors and the severity of stunning I was able to combine the data sets by incorporating 
a repeated measures analysis into the analysis. 
 
The results were expressed as mean ± SD if parametric or the median and interquartile 
range  (IQR)  if  non-parametric.  Echocardiographic  and  haemodynamic  data  were 
analysed  using  one-way  analysis  of  variance  (ANOVA),  with  a  design  for  repeated 
measures. Depending on Gaussian distribution, all other data were analysed using either  
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the paired or unpaired t tests or the Mann-Whitney or Wilcoxon matched pair tests. To 
test  for  the  association  between  both  the  mean  %SF[RRWM]  and  SF[non-RRWM]  at  240 
minutes  against dialysis related factors (UF volume-mls/kg dry weight, intradialytic 
BP)  and  patients  related  factors  (dialysis  vintage,  age)  I  used  univariate  regression 
analysis  adjusting  for  repeated  measures.  I  did  not  attempt  multivariate  logistic 
regression analysis due to the relatively small sample size. In all analyses, an alpha error 
at p<0.05 was judged to be significant. 
 
 
4.3.4  Speckle tracking two-dimensional strain assessment 
Technique 
The speckle tracking strain software analyzes motion by tracking ‘speckles’ from frame 
to frame in 2D echocardiogram images. Speckles are natural acoustic markers of 20-40 
pixels  that  are  equally  distributed  throughout  the  myocardium.  By  following  the 
movement of each speckle throughout a single cardiac cycle a temporal assessment of 
myocardial muscle deformation is achieved (see Figure 4.2).  
 
Standard  grayscale  2D  images  were  acquired  in  the  4-chamber  apical  views  and 
parasternal short-axis views at the level of the papillary muscles (the level of mid wall 
contraction) using frame rates of 50 frames per second minimum. The apical images 
were required to assess peak longitudinal strain and the parasternal images for radial 
and circumferential strain. The images were stored digitally in raw format for analysis 
later.  From  an  end-systolic  single  frame  a  region  of  interest  was  traced  on  the 
endocardial  border  by  a  point-and-click  approach.  The  2D  strain  algorithm  then 
automatically evaluates the tracking quality at each myocardial region over time and  
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assigns each segment an ‘acceptable’ or non-acceptable’ label. For each image that was 
analysed  the  region  of  interest  was  manually  adjusted  until  all  the  segments  had 
acceptable tracking quality. The specialist software then processed and generated LV 
segmental  time-strain  curves  from  which  the  timing  and  value  of  peak  strain  per 
segment were extracted.  For the purpose of 2D speckle tracking the LV was divided 
into 6 segments as shown in Figure 4.3. 
 
 
Figure 4.2: LV segmentation in the long axis (left) and short axis (right) for the purpose of 
regional strain measurements.  
 
 
Speckle tracking for assessment of cardiac motion and dyssynchrony has been validated 
in adults with intraobserver and interobserver variability of 3.6% to 5.3%
131 but the 
experience in children is extremely limited
133.  
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Figure 4.3: Two-Dimensional Strain Imaging.  
In the left panels the strain images are represented. The arrows highlights the type of deformation 
assessed in each view: radial thickening (A), circumferential shortening (B), and longitudinal shortening 
(C). The right panel demonstrate the segmental time-strain curves for a synchronous left ventricle AVC 
refers to aortic valve closure and represents the end of systole. [Adapted from Delgado
134]. 
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Study Protocol 
For each monitored dialysis treatment, echocardiography was performed at the start of 
dialysis (baseline) and again at the end of the dialysis session, the time of peak stress. 
During each dialysis session intradialytic symptoms with corresponding heart rate and 
BP measurements were recorded in addition to the net UF volume at the end of each 
treatment.  The images were then analysed with specialist 2D speckle tracking software 
to generate segmental longitudinal, radial and circumferential time strain curves. For 
each time point the peak segmental strain was recorded. To test for dyssynchrony two 
parameters were used, i) the maximal time delay between peak strain of 2 segments and 
ii) asynchrony index, which was derived by calculating the standard deviation of time to 
peak strain over the 6 segments. 
 
Finally speckle tracking 2D strain assessments were performed on age matched controls 
at rest using longitudinal and parasternal (papillary muscle level) 2D echocardiographic 
grayscale images.  
 
Statistical analyses 
Echocardiographic and haemodynamic data differences within patients at the start and 
end of HD were analysed using ANOVA, with a design for repeated measures. Pearsons 
correlation analyses were performed to assess the relation between intradialytic strain 
reduction and dialysis related factors (UF volume-mls/kg dry weight, intradialytic BP) 
and patients related factors (dialysis vintage, age). Univariate linear regression analyses 
were used to determine predictors of intradialytic BP change. In all analyses, an alpha 
error at p<0.05 was judged to be significant. 
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4.4  Results 
4.4.1  Regional wall motion assessment 
Global & Segmental Ventricular Function 
The median LVEF was 51.8%, range 38.2 to 68.1 at baseline, 55.7% (44.2 to 66.7) at 
120mins of HD, 53.21% (37.8 to 71.5) at 240mins and 55% (43.5 to 64) on recovery 15 
minutes after dialysis (see Figure 4.4), but the differences between all the time points 
were not statistically significant (p=0.56). At the start of dialysis 4 patients had LVEF 
below the lower limit of normal, namely 50%. 
 
Figure 4.4: Changes in global and segmental LV function during HD 
 
 
* Ejection fraction is represented as mean and standard deviation. The difference at the 4 time points was 
not statistically significant (p=0.56) 
† Mean segmental %SF[Overall] represented as the cohort mean and box plot of the individual results. The 
difference between the baseline and both 120m and 240m was statistically significant (p<0.05) 
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All 12 patients developed segments with RRWM in 1-5 segments (see Figure 4.5), with 
co-existing  20%  hyperkinesis  in  1-4  non  stunned  segments  in  11/12  patients  from 
120mins  that  persisted  into  recovery.  In  addition  9/12  patients  exhibited  50% 
hyperkinesis in as many as 3 segments. Again this was evident at 120mins and persisted 
into  recovery  (see  Figure  4.5),  Of  the  35/120  segments  that  stunned  mid-cavity 
segments dominated followed by basal and then apical segments.  
 
Figure 4.5: Segmental RRWM and hyperkinesis during HD 
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 The resultant effect on segmental shortening fraction was a fall of the mean segmental 
%SF[Overall] from 2.2 ± 0.4 (mean ± standard deviation)  at baseline to 1.9 ± 0.3 by 
120mins, 1.8 ± 0.4 at 240mins with an increase to 2.1 ± 0.5 post dialysis (see Figure 
4.6). The difference was statistically significant when comparing baseline segmental 
%SF[Overall] to that at 120mins and 240mins (p<0.05) but did not reach significance on 
comparing  %SF[Overall]  at  120mins,  240mins  (p=0.34)  and  at  recovery.  There  was  a   
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statistically significant fall in the mean segmental %SF[RRWM] from 2.7 ± 1.1 at baseline, 
1.9 ± 0.7 at 120mins, 1.4  ± 0.6 at 240mins, and 2.2 ± 0.7 at recovery (p<0.05) (see 
Figure 4.7).  
 
Figure 4.6: Differences in mean segmental percentage SF in those developing RRWM 
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Figure 4.7: Mean segmental percentage SF in those developing RRWM 
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10/12  patients  showed  evidence  of  resolution  of  RRWM  on  recovery,  as  early  as 
15mins after completing dialysis (see Figure 4.8). The mean segmental %SF[nonRRWM]  
increased from baseline to 240mins, 2.0 ± 0.6 to 2.3 ± 0.6 but did not reach statistical 
significance (p=0.07) (see Figure 4.8). The mean segmental %SF in the segments that 
developed RRWM was higher at baseline compared with those that did not (2.35 ± 0.52 
versus 1.98 ±0.63) (see Figure 4.8). 
 
 
Figure 4.8: Mean Segmental Percentage Shortening Fraction Relative to Time On HD 
 
 
 
 
 
 
 
 
 
 
·  Significant difference between %SF[Overall] {baseline v 120m} 
·   and {baseline v 240m} (p<0.05) 
 
† Significant difference between %SF[RRWM] {baseline v 120m}, {baseline v 240m}, {120m v 240m} and 
{240m v recovery} (p<0.05) 
‡ In the remaining groups the difference was not statistically significant 
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This pattern of dialysis induced segmental RRWM is consistent with the definition of 
myocardial stunning. Pictorial representation of serial regional wall motion assessment 
from 2 patients illustrates the transient regional myocardial dysfunction that is seen 
during a HD treatment (see Figures 4.9 and 4.10).   
 
Figure 4.9: Serial regional wall motion assessment from Patient 7 during HD 
 
 
 
Figure 4.10: Serial regional wall motion assessment from Patient 9 during HD 
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Factors Associated With The Development Of Myocardial Stunning 
The  median  intradialytic  systolic  BP  fall  for  the  group  was  25  mmHg  (range  6-
90mmHg)  and  the  lowest  intradialytic  systolic  dialysis  BP  ranged  from  58  to 
110mmHg. A strong correlation was seen between intradialytic systolic BP change and 
mean segmental %SF[RRWM] (r = 0.56, p<0.05) as shown on figure 4.11. Similarly on 
univariate  linear  regression  analysis  there  was  a  significant  association  between 
intradialytic  systolic  BP  changes  and  mean  segmental  %SF[RRWM]  (p<0.05),  but  not 
against lowest intradialytic systolic BP (p=0.68). 
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Figure 4.11: Graph of intradialytic blood pressure change and LV mean segmental shortening 
fraction 
 
The median UF volume for the group was 29.4mls/kg (range 2-94mls/kg), and in one 
patient no UF was attempted. There was no significant association between UF volume 
and the number of segments that developed RRWM, or the mean segmental %SF[RRWM]. 
Likewise on univariate linear regression analysis there was no association between UF 
volumes and mean segmental %SF[RRWM] (p=0.6). When considering both intradialytic  
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BP change and UF against the mean segmental %SF[RRWM] the relationship between 
intradialytic BP change and the mean segmental %SF[RRWM] disappeared (p=0.24). In 
this patient group UF volume correlated with change in BP during HD (r=0.56, p<0.05) 
as shown in Figure 4.12. Similarly on univariate linear regression there was a significant 
association between systolic BP change and UF volume (p<0.05, r
2 0.32).     
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Figure 4.12: Graph illustrating the relationship between Systolic BP change and UF volume 
 
I  found  no  significant  relationship  between  the  number  or  intensity  of  RRWM  as 
measured  by  the  mean  %SF[RRWM]  against  patient  age,  dialysis  vintage,  pre-dialysis 
plasma  urea  levels,  anaemia,  LV  mass,  hsCRP  or  cTnI  and  the  presence  of  a 
arteriovenous fistula. I could not test for the relationship between the absolute or change 
in heart rate during dialysis and RRWM as it was impossible to separate the tachycardic 
response that evolved as part of the haemodynamic response to HD and that as a direct 
result of the children, especially the infants, getting upset and crying during their echo 
assessments.   
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Hematological &Biochemical Profile& Markers of Cardiac Injury  
The  biochemical  and  hematological  profile  was  typical  of  HD  patients,  showing  a 
prevalence of anaemia (n= 5), hyperparathyroidism (n=7), hyperphosphataemia (n= 5) 
and acidosis (n=4). Routine laboratory values and dialysis adequacy are summarised in 
Table 4.2. Values for hsCRP exceeded 1 g/l in 6 patients post-dialysis and 3 g/l in one 
patient post-dialysis. In 8/12 patients the post-dialysis cardiac troponin I (cTnI) levels 
remained the same as pre-dialysis levels of <0.04 g/l. In the remaining 4 patients the 
cTnI levels increased post dialysis to up to 0.07 g/l (see Table 4.3). 
 
 
Table 4.2: Biochemical and Haematological Profile 
  Mean ± Standard Deviation  Range 
Pre-dialysis Urea (mmol/l)  22.5 ± 4.2  15.2 to 28.2 
Post-dialysis Urea (mmol/l)  4.5 ± 1.5  1.5 to 6.9 
KT/V urea  2.0 ± 0.5  0.5 to 3.1 
URR (%)  80 ± 6  72 to 91 
Haemoglobin (g/dl)  11.5 ± 1.4  9.1 to 13.1 
Potassium (mmol/l)  5.3 ± 0.7  3.7 to 6.4 
Phosphate (mmol/l)  1.5 ± 0.6  0.6 to 2.9 
Albumin (g/l)  38.3 ± 2.5  34 to 41 
PTH (pmol/l)  22.4 ± 22.9  0.3 to 89 
Ionised Calcium (mmol/l)  1.2 ± 0.1  1.09 to 1.44 
Bicarbonate (mmol/l)  23.9 ± 2.4  20 to 27 
hs CRP ( g/l  1.9 ± 1.5  0.4 to 5.5 
 
 
URR:   urea reduction rate 
PTH:  parathyroid hormone  
hsCRP: highly sensitive C-reactive protein  
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Table 4.3: Cardiac Troponin I levels pre and post dialysis 
Patient  Baseline cTNI ( g/l)  Post dialysis cTNI ( g/l) 
1  <0.04  0.04 
2  0.05  0.07 
3  <0.04  0.04 
4  <0.04  <0.04 
5  <0.04  <0.04 
6  <0.04  <0.04 
7  <0.04  <0.04 
8  <0.04  0.04 
9  <0.04  <0.04 
10  Not available  Not available 
11  <0.04  <0.04 
12  <0.04  <0.04 
 
cTNI: Cardiac Troponin I 
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4.4.2   
Speckle tracking two-dimensional strain assessment 
For each patient speckle tracking 2D strain echo images were acquired during a single 
HD. However during the data analysis and thus assessment of peak strain and 
asynchrony three cardiac cycles were analysed per patient at each time point.  
 
Peak Segmental Strain 
Compared with age matched controls the peak segmental longitudinal strain was lower 
in uraemic patients at the start of dialysis. The difference was statistically significant in 
the baso-septal, mid-septal, mid-lateral and baso-lateral segments. During dialysis the 
peak longitudinal strain fell and the difference was statistically significant in all the 
segments (see Table 4.4). 
 
There was no segmental difference in peak circumferential strain between the controls 
and uraemic patients pre-dialysis. During dialysis the peak circumferential strain fell 
and the difference was statistically significant in the lateral and posterior segments. The 
exception was the antero-septal segments in which the peak circumferential strain was 
significantly higher (see Table 4.5). 
 
Segmental peak radial strain was lower in uraemic children pre-dialysis compared with 
age  matched  controls.  The  difference  was  statistically  significant  in  the  anterior, 
posterior, inferior and lateral segments. During dialysis the peak radial strain increased 
in  all  the  segments  but  the  difference  only  achieved  statistical  significance  in  the 
posterior segments (see Table 4.6).   
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Inter-segmental Synchronicity 
The asynchrony index or standard deviation of time to peak strain over the 6 segments 
was significantly higher pre-dialysis compared with the controls and higher still post 
dialysis in all 3 axes.  Similarly the maximum inter-segmental time difference to peak 
strain progressively increased from the age matched controls to uraemic patients pre-
dialysis and higher still in the post dialysis patients. The difference was statistically 
significant in the longitudinal, circumferential and radial axes (see Table 4.4 to 4.6).  
 
Figures 4.13 and 4.14 represent longitudinal time strain curves for patients 7 and 9, the 
same patients whose regional wall motion assessments were shown in Figures 4.9 and 
4.10 earlier in this chapter. The longitudinal strain curves demonstrate a reduction in 
peak longitudinal strain post dialysis and variations in the time to peak strain between 
the 6 segments.  
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Table 4.4: LV segmental longitudinal strain 
 
  Pre-dialysis 
Mean 
[95% CI] 
Post-dialysis 
Mean 
[95% CI] 
§ 
Control 
Mean 
[95% CI] * 
Peak basal-septal strain 
-17.93 
[-18.75 to -17.11] 
-16.10 
[-17.30 to -14.89] 
§ p<0.05 
-20.10 
[-21.29 to -18.92] 
* p<0.05 
Peak mid-septal strain 
-19.01 
[-19.73 to -18.30] 
-17.35 
[-18.22 to -16.47] 
§ p<0.05 
-21.40 
[-22.27 to -20.53] 
* p<0.05 
Peak apical-septal 
strain 
-21.20 
[-22.32 to -20.07] 
-16.69 
[-18.13 to -15.24] 
§ p<0.05 
-21.42 
[-22.79 to -20.06] 
* p=0.73 
Peak apical-lateral 
strain 
-17.24 
[-18.72 to -15.77] 
-14.08 
[-15.58 to -12.59] 
§ p<0.05 
-17.33 
[-19.12 to -15.54] 
* p=0.16 
Peak mid-lateral strain 
-15.02 
[-16.22 to -13.81] 
-12.45 
[-13.83 to -11.07] 
§ p<0.05 
-17.75 
[-19.11 to -16.38] 
* p<0.05 
Peak basal-lateral strain 
-17.60 
[-19.11 to -16.10] 
-15.00 
[-16.40 to -13.60] 
§ p<0.05 
-21.41 
[-23.1 to -19.73] 
 * p<0.05 
Time of peak segmental 
strain [Inter-segmental 
time SD] 
45.60 
[41.43 to 49.77] 
51.85 
[44.53 to 59.16] 
§ p<0.05 
34.95 
[29.45 to 40.46] 
* p<0.05 
Time of peak segmental 
strain [Inter-segmental 
time difference] 
108.02 msecs 
[96.47 to 119.56] 
129.22 msecs 
[107.51 to 
150.94] 
§ p<0.05 
81.07 msecs 
[65.83 to 96.30] 
* p<0.05 
 
 
§ Difference between pre- and post-dialysis patients 
* Difference between pre-dialysis patients and controls  
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Table 4.5: LV segmental circumferential strain 
 
  Pre-dialysis 
Mean 
[95% CI] 
Post-dialysis 
Mean 
[95% CI] 
§ 
Control 
Mean 
[95% CI] * 
Peak antero-septal 
strain 
-25.75 
[-28.55 to -22.95] 
-27.93 
[-30.64 to -25.23] 
§ p<0.05 
-24.75 
[-27.78 to -21.71] 
* p=0.63 
Peak anterior strain 
-22.00 
[-24.30 to -19.70] 
-20.75 
[-22.94 to -18.58] 
§ p=0.20 
-20.50 
[-22.84 to -18.16] 
* p=0.24 
Peak lateral strain 
-17.54 
[-19.99 to -15.10] 
-12.24 
[-13.88 to -10.59]  
§ p<0.05 
-17.35 
[-19.99 to -14.70] 
* p=0.37 
Peak posterior strain 
-12.92 
[-15.62 to -10.22] 
-12.63 
[-15.47 to -9.78] 
§ p<0.05 
-14.23 
[-16.77 to -11.69] 
* p=0.27 
Peak inferior strain 
-16.99 
[-19.04 to -14.95] 
-16.75 
[-18.67 to -14.82] 
§ p=0.21 
-17.79 
[-20.66 to -14.92] 
* p=0.64 
Peak septal strain 
-23.45 
[-25.22 to -21.67] 
-23.15 
[-25.39 to -20.91] 
§ p=0.31 
-22.65 
[--26.72 to -
18.59] 
* p=0.71 
Time of peak segmental 
strain [Inter-segmental 
time SD] 
63.02 
[50.64 to 75.39] 
55.95 
[47.90 to 64.00] 
§ p<0.05 
35.34 
[28.10 to 42.58] 
* p<0.05 
Time of peak segmental 
strain [Inter-segmental 
time difference] 
164.27 msecs 
[125.49 to 
203.06] 
138.12 msecs 
[117.49 to 
158.75] 
§ p<0.05 
84.41 msecs 
[64.82 to 103.99] 
* p<0.05 
 
 
§ Difference between pre- and post-dialysis patients 
* Difference between pre-dialysis patients and controls  
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Table 4.6: LV segmental radial strain 
 
  Pre-dialysis 
Mean 
[95% CI] 
Post-dialysis 
Mean 
[95% CI] 
§ 
Control 
Mean 
[95% CI] * 
Peak antero-septal strain 
36.16 
[30.36 to 41.96] 
47.81 
[35.99 to 59.62] 
§ p=0.13 
43.44 
[36.27 to 50.62] 
*  p=0.11  
Peak anterior strain 
41.13 
[34.32 to 47.93] 
45.11 
[39.12 to 51.10] 
§ p= 0..88 
54.57 
[47.21 to 61.93] 
* p<0.05 
Peak lateral strain 
46.50 
[37.82 to 55.18] 
46.93 
[40.58 to 53.28] 
§ p=0.07 
62.20 
[55.29 to 69.11] 
* p<0.05 
Peak posterior strain 
45.25 
[36.64 to 53.86] 
47.17 
[40.24 to 54.10] 
§p<0.05 
63.15 
[55.83 to 70.47] 
* p<0.05 
Peak inferior strain 
40.78 
[34.39 to 47.12] 
44.56 
[37.74 to 51.37] 
§ p= 0.2 
55.59 
[47.01 to 64.16] 
* p<0.05 
Peak septal strain 
36.04 
[30.46 to 41.63] 
41.57  
[35.33 to 47.82] 
§ p=0.08 
43.37 
[35.41 to 51.33] 
* p=0.12 
Time of peak segmental 
strain [Inter-segmental 
time SD] 
34.94 
[25.79 to 44.09] 
35.09 
[25.14 to 45.04] 
§ p=0.05 
22.07 
[15.27 to 28.86] 
* p<0.05 
Time of peak segmental 
strain [Inter-segmental 
time difference] 
81.59 msecs 
[58.72 to 104.46] 
79.07 msecs 
[53.75 to 104.39] 
§ p<0.05 
48.43 msecs 
[32.22 to 64.64] 
* p<0.05 
 
 
§  Difference between pre- and post-dialysis patients 
* Difference between pre-dialysis patients and controls 
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Figure 4.13: Longitudinal time strain curves for patient 7. The top panel is pre-dialysis and the 
lower panel post dialysis.  
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Figure 4.14: Longitudinal time strain curves for patient 9. The top panel is pre-dialysis and the 
lower panel post dialysis.  
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Factors Associated with Strain Reduction 
Intradialytic peak longitudinal strain reduction was significantly associated with systolic 
BP, change in systolic BP during dialysis and the UF volume (see Table 4.7). During 
HD neither peak  circumferential nor peak radial strain reductions were  found to be 
significantly  associated  with  intradialytic  BP,  UF  volumes  or  dialysis  vintage  (see 
Tables 4.8 and 4.9). 
   
 
Table 4.7: Factors associated with peak longitudinal strain reduction during HD 
 
  Pearson’s 
Correlation 
R
2  p-value  Logistical 
Regression 
Coefficient 
p-value 
Absolute systolic BP  -0.26  0.07  p<0.05  0.22  0.41 
Intradialytic systolic BP change  0.317  0.10  p<0.05  -0.18  0.54 
UF (mls/kg)  0.30  0.09  p<0.05  0.09  0.76 
Months on HD  0.05  0.002  p=0.71  0.13  0.80 
 
 
 
 
Table 4.8: Factors associated with peak circumferential strain reduction during HD 
 
  Pearson’s 
Correlation 
R
2  p-value  Logistical 
Regression 
Coefficient 
p-value 
Absolute systolic BP  0.20  0.04  p=0.18  0.04  0.9 
Intradialytic systolic BP change  -0.03  0.001  p=0.87  -0.09  0.71 
UF (mls/kg)  0.14  0.02  p=0.34  0.04  0.9 
Months on HD  -0.26  0.07  p=0.09  -0.88  0.13 
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Table 4.9: Factors associated with peak radial strain reduction during HD 
 
  Pearson’s 
Correlation 
R
2  p-value  Logistical 
Regression 
Coefficient 
p-value 
Absolute systolic BP  0.07  0.005  p=0.73  0.03  0.89 
Intradialytic systolic BP change  -0.15  0.02  p=0.44  0.18  0.28 
UF (mls/kg)  -0.22  0.05  p=0.91  0.05  0.81 
Months on HD  -0.08  0.006  p=0.70  0.16  0.72 
 
 
 
Predictors of Intradialytic Systolic BP 
Within the cohort of 15 patients the UF volume ranged from 3mls/kg/hr to 86mls/kg/hr. 
The lowest documented intradialytic systolic BP ranged from 58mmHg to 140mmHg. 
On univariate linear regression analyses percentage strain reduction was not predictive 
of intradialytic BP (see Table 4.10).  
 
Table 4.10: Predictors of intradialytic systolic BP 
  Correlation 
Coefficient 
Significance 
% Reduction in peak longitudinal strain during HD  0.42  p=0.19 
% Reduction in peak circumferential strain during HD  0.19  p= 0.52 
% Reduction in peak radial strain during HD  0.03  p=0.91 
 
 
 
The intradialytic systolic BP reduction ranged from 6mmHg to 90mmHg. On univariate 
linear regression analyses both the percentage reduction in longitudinal strain and radial 
strain were significantly predictive of intradialytic systolic BP fall (see Table 4.11). 
Percentage reduction in longitudinal strain showed a positive correlation but radial 
strain showed a negative correlation, namely a greater fall in BP is seen in patients 
where peak radial strain shows little change during dialysis.  
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Table 4.11: Predictors of intradialytic systolic BP fall 
  Correlation 
Coefficient 
Significance 
% Reduction in peak longitudinal strain during HD  0.66  p<0.05 
% Reduction in peak circumferential strain during HD  -0.32  p=0.19 
% Rise in peak radial strain during HD  -0.70  P<0.05 
 
 
 
4.5  Discussion 
The prevalence of myocardial stunning in patients with CAD is high, cumulative and 
associated  with  an  attendant  risk  of  increased  CV  events  and  mortality.  The  same 
phenomenon has now been demonstrated in prevalent adult dialysis patients
117 and ‘low 
risk’  non-diabetic,  non-cardiac  adult  HD  patients
68  but  until  now  there  has  been  no 
evaluation  of  the  risk  in  children.  Compared  with  age  matched  controls  I  have 
demonstrated altered baseline myocardial function in uraemic children aged between 1 
to 17 years. During conventional 4 hour HD the myocardial function deteriorates further 
with biochemical evidence of ischaemic injury. The effect is global across all segments 
as  opposed  to  a  segmental  distribution  specific  to  an  isolated  coronary  artery.  The 
adverse impact on myocardial fibres within the LV wall is however specific with a 
predisposition to LV longitudinal shortening. The degree of myocardial dysfunction is 
associated with intradialytic blood pressure change and UF volumes. Nonetheless owing 
to an early compensatory hyperkinetic response in regions of the LV, preservation of 
circumferential shortening and increased radial thickening, the global LVEF did not fall, 
but  arguably  neither  did  it  rise  as  one  would  expect  following  a  significant 
hemodynamic challenge.  
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Left ventricular contraction relies on the co-ordinated shortening action of myocardial 
fibres  in  multiple  directions:  longitudinal  shortening,  radial  thickening  and 
circumferential shortening combined with torsion of the heart. The alignment of heart 
fibres and resultant patterns of regional strain is heterogeneous. The coronary blood 
supply to segments of the heart also shows significant variation. In this study regional 
wall motion assessment (RWMA) demonstrated significant dialysis induced regional 
myocardial dysfunction with preponderance for basal and apical segments. The strain 
analyses showed a reduction in peak strain but the difference was only significant in the 
longitudinal  axis  and  all  the  segments  were  involved.  With  this  discrepancy  in 
segmental involvement there is an implication that 2D strain may be more sensitive 
measure than wall motion of mild segmental LV dysfunction. RWMA assessment is 
primarily  an  assessment  in  the  longitudinal  axis  and  uses  the  inward  motion  of 
endocardial borders as the sole marker of abnormal contraction.  However the visual 
estimation of wall motion can be very subjective and does not take into account wall 
thickening, twisting or transmyocardial heterogeneity. In contrast 2D speckle tracking 
provides a multi-axis assessment of LV function employing functional components that 
are not visible to the naked eye. The motion of myocardial tissue is measured indirectly 
by the motion pattern of speckles tracking along the direction of the wall, not along the 
ultrasound beam. This makes it both translation and angle independent with lower inter 
and  intra-operator  variability  compared  with  RWMA
131.  Furthermore  in  a  direct 
comparison of the two, assessments of wall motion cannot differentiate between active 
and passive movement of a myocardial segment whereas deformation has the ability to 
discriminate. In the heart this is particularly important as ventricular wall motion is 
position dependent. As the apical parts of the ventricle pull down the ventricular base, 
the wall motion increases from apex to base and thus some of the measured wall motion  
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effect in the base is the combined effect of contraction and also apical tethering. Thus 
even completely passive segments can show motion but not deformation. 2D speckle 
tracking is a novel method for assessing regional myocardial function with minimal 
experience  in  children.  In  adults  however  myocardial  strain  quantification  has  been 
validated against tagged cardiac magnetic resonance imaging
135 and has been shown to 
be accurate and it is fast becoming the tool of choice in evaluating patients prior to 
cardiac  resynchronisation,  differentiating  between  hibernating  myocardium  and 
infracted  myocardium.  My  limited  experience  in  children  was  very  positive  and 
parallels these reports in adults. 
 
Longitudinally  directed  fibres  are  mainly  located  in  the  subepicardium  and 
subendocardium  regions  of  the  LV.  They  only  form  a  small  proportion  of  the  total 
ventricular myocardial mass but play a major role in the maintenance of normal ejection 
fraction. I found a selective reduction in longitudinal strain during HD. In simple terms 
this can be explained away by the heterogeneity of the heart architecture, however the 
apparent vulnerability of longitudinal shortening is not too dissimilar to other disease 
states and therefore unlikely to be either a coincidence or a normal variation. A degree 
of  long-axis  systolic  dysfunction  has  been  frequently  reported  in  conjunction  with 
diastolic  dysfunction
136.  Regional  reduction  in  the  extent  and  velocity  of  long  axis 
shortening  has  been  shown  to  be  a  sensitive  and  specific  finding  after  myocardial 
infarction
137, 138. In hypertensive patients LV long axis function abnormalities have been 
found to present even before the onset of hypertension, but circumferential fractional 
shortening  remain  unchanged
137.  Both  hypertension  and  diastolic  dysfunction  are 
features  common  to  children  on  dialysis
22,  27,  139  and  their  presence  may  in  part  be  
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responsible  for  the  findings  or  they  share  a  common  pathogenic  pathway  for 
longitudinal axis dysfunction dominance.   
 
One  feature  that  distinguishes  children  from  adults  is  the  absence  of  significant 
epicardial atheromatous CAD. They do however share a high prevalence of risk factors 
for adult-type cardiovascular disease that have been associated with a reduced coronary 
flow  reserve  and  thus  a  propensity  to  demand  ischaemia
140.  Of  these,  hypertension, 
anaemia, hyperparathyroidism and hyperphosphataemia were significantly prevalent in 
these  patients.  Children  can  also  display  a  constellation  of  altered  functional  and 
morphological cardiovascular features that predisposes them to ischaemic insults. LVH 
for example progresses to maladaptive cardiac remodeling characterized by decreased 
capillary  density,  subendothelial  perfusion
141  and  decreased  coronary  contractile 
reserve
142. Overt LVH was present in one patient and borderline hypertrophy in another 
3 patients. 5/17 of the patients were common to a study conducted by Shroff et al.
119 
reporting  findings  of  diminished  arterial  wall  compliance  and  coronary  and  carotid 
artery calcification. Such vascular abnormalities are accepted markers of asymptomatic 
arteriosclerosis  and  mortality
143  and  perhaps  indicative  of  coronary  microcirculation 
abnormalities. Evidence for inappropriately raised sympathetic nerve activity in dialysis 
patients
118  raises  the  possibility  of  an  alternative  explanation  for  the  regional  LV 
dysfunction, namely takotsubo or ’stress’ cardiomyopathy
144. However Dasselaar et al 
demonstrated a fall in regional and global myocardial blood flow, 30 minutes into a HD 
session,  in  the  absence  of  UF  that  preceded  regional  LV  dysfunction
68.  This  is  the 
inverse of the causal sequence of takotsubo or ‘stress’ cardiomyopathy. In addition the 
children  showed  no  evidence  of  apical  ballooning,  a  feature  typical  of  classical 
takotsubo cardiomyopathy. Nevertheless the effects of raised sympathetic nerve activity  
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may be relevant by mediating microvasculature derangement and vasospasm. I found no 
significant association between biochemical and cardiac risk factors and the severity of 
myocardial stunning. This is most likely due to the fact cardio-renal performance is 
influenced by a number of humoral and genetic factors
145 that act collectively to exert 
an effect  but in isolation, particularly in paediatrics,  are too small to be detectable from 
our sample size.  
 
The major determinant of intradialytic BP is cardiac output and end diastolic volume 
146 
but  clearly  regional  LV  function  is  important  as  evidenced  by  reports  of  reduced 
haemodynamic  stability  in  patients  developing  myocardial  stunning  despite  below 
average  UF  volumes
129.  Shoji  et  al  found  BP  reduction  during  dialysis  and  not 
hypertension in adult HD patients as a factor that influenced survival negatively
147. I 
found the UF volume and both the reduction and absolute intradialytic systolic BP to be 
related  to  dialysis  induced  longitudinal  axis  LV  dysfunction,  but  only  reduction  in 
systolic BP was significantly associated with abnormalities in regional  wall motion. 
These differences are most likely related to technique differences. 2D speckle tracking 
is slowly gaining credence over RWMA with improved accuracy and reproducibility 
qualities. It also has the ability to detect subtle and milder abnormalities in regional LV 
dysfunction, particularly those secondary to ischaemia, and thus even weak correlations 
became more apparent. Peak segmental strain was not predictive of absolute systolic BP 
but percentage changes in LV longitudinal shortening and radial thickening were both 
found to be predictive of intradialytic blood pressure changes.  The implication is that 
actual BP is not as important as the failure to maintain BP in initiating and propagating 
myocardial stunning during dialysis. Children appear to be different to adults, with a 
more direct relationship between BP and UF volumes. In addition, as a consequence of  
 
127
residual renal function, some exist closer to their dry weight and are thus very sensitive 
to fluid shifts during dialysis. Combined with a poorly compliant left ventricle
27 and 
peripheral  conduit  vessels
32,  33,  abnormal  vascular  tone,  UF  mediates  a  reduction  in 
cardiac output and BP. In the face of an attenuated coronary reserve, ischemia prevails 
when  the  hemodynamic  demand  of  HD  is  not  met  by  an  adequate  increase  in 
myocardial blood flow.  
 
There is considerable evidence alluding to the value of both CRP 
39 and baseline cardiac 
troponin as markers of cardiovascular disease and mortality in ESRD. An acute rise in 
cardiac  troponin  levels  in  HD  patients  is  also  indicative  of  sub-clinical  myocardial 
ischaemic injury 
58, 59, 63. I found elevated levels of high sensitivity CRP in half of the 
dialysis patients that were tested and a rise in cardiac Troponin I (cTnI) levels in 25%. 
Elevated plasma cardiac troponins levels  are usually only  seen 6-12 hours after the 
acute injury. However in this study post-dialysis plasma samples were taken 15minutes 
after the end of the HD session and this may explain my failure to demonstrate a rise in 
cardiac troponin I levels in more of the patients. In the patients that did demonstrate a 
rise in plasma cardiac enzmyes levels it is conceivable that the cardiac insult occurred 
early in the 4hour HD session and thus levels were detectable post-dialysis. An earlier, 
alternative marker of cardiac injury is mechanical synchronisation of LV contraction. 
Dssynchronous left ventricular long axis function is common in patients with chronic 
stable coronary artery disease
136. In fact the presence and localisation of asynchrony 
correlates  closely  with  reversible  abnormalities  on  thallium  myocardial  perfusion 
scanning
138 and precedes ECG changes or symptoms and changes in myocardial systolic 
amplitude  of  motion.  Asynchrony  is  believed  to  a  sensitive  and  earlier  marker  of 
ischaemia
148.  I  observed  an  exaggerated  dssynchrony  index  in  longitudinal,  
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circumferential shortening and radial thickening at the end of HD. This may reflect 
ischaemic injury that was detected earlier than more traditional biochemical markers of 
cardiac injury. Within this context it has the potential for becoming very useful in the 
clinical environment in identifying ‘at risk’ patients. 
 
 
4.6  Study Limitations 
This was a preliminary study looking at regional LV dysfunction in children on HD and 
the  sample  size  was  small.  Nevertheless  the  study  was  adequately  powered  for  the 
primary outcome. RWMA and analysis was repeated twice in the same patient and the 
results  showed  concordance  in  the  localization  of  abnormalities  but  the  number  of 
segments involved differed. This may indicate poor reproducibility or conversely is the 
consequence of differences in intra-patient UF volumes and intradialytic hemodynamic 
parameters between treatments. 2D speckle tracking analyses of the same patients were 
again consistent with findings from RWMA but the prevalence of segmental myocardial 
dysfunction was higher. This is likely to be due to the fact that 2D speckle tracking 
screened  LV  function  in  3  axes  and  the  assessment  incorporated  an  additional 
parameter, dyssynchrony index, and was thus a more sensitive test. 
 
I  have  already  alluded  to  the  limitations  of  RWMA.  However  looking  specifically 
within  the  context  of  children,  2D  speckle  analyses  are  also  at  risk  of  inaccuracy. 
Normally, the resting heart rate is influenced by the age of the child and the younger the 
child the higher their resting heart rate. During dialysis patients become tachycardic. 
The  optimal  frame  rate  for  speckle  tracking  seems  to  be  50–70  frames  per  second, 
however in the face of tachycardia this could result in under sampling. In an attempt to 
manage this problem I tried to use higher frame rates but this resulted in a reduction of  
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spatial resolution and in some patients this had to be abandoned as a result of less than 
optimal speckle tracking. In essence neither assessment is perfect but the gold standard 
for assessing functional change, magnetic resonance imaging, is technically impossible 
in patients while they are receiving HD. Of the two assessments speckle tracking shows 
more promise in detecting regional LV function, however prior to recommending it for 
general application 2D speckle tracking use must be validated in children. 
 
In this study I have made two assumptions. Firstly, having extrapolated from adult data, 
I have implied that HD in children is also associated with reduced myocardial blood 
flow. I have also assumed based both on negative findings or the absence of reports in 
the literature that none of the children in the cohort had significant epicardial CAD. 
Both  of  these  questions  could  have  been  answered  by  subjecting  the  children  to 
angiography  or  perfusion  imaging  but  I  elected  not  to  do  this  due  to  the  practical 
implications and severe reluctance from both the patients and dialysis nurses. Of the 
two,  perfusion  imaging  may  be  considered  to  be  less  invasive,  however  adult  data 
suggests that myocardial scintigraphy is imperfect in detecting CAD in patients with 
ESRD [De Lima JJ,03] and indeed doubts about applicability in patients with more 
severe CKD has led to renal disease currently not being categorised in the most recent 
‘Appropriateness Criteria for Stress Echocardiography’ recommendations
149.  
 
 
4.7    Conclusion 
I have shown for the first time that paediatric patients receiving conventional HD suffer 
from dialysis induced myocardial stunning. As in adults, this reflects the degree of HD 
induced  haemodynamic  instability.  This  data,  in  combination  with  previous  adult  
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studies  suggest  that  even  in  the  absence  of  conventional  epicardial  coronary  artery 
disease the characteristic cardiovascular phenotype in uraemic HD patients is severe 
enough to limit the microvasculature response to haemodynamic stress and predisposes 
to significant demand myocardial ischemia. 
 
Myocardial  stunning  is  progressive  with  raised  attendant  mortality.  In  any  serious 
attempt  to  modify  the  cardiovascular  burden  in  dialysis  patients  we  will  require  an 
accurate method for detecting ischaemic myocardial injury. In my limited experience 
the  novel  method  of  2D  speckle  tracking  was  superior  to  the  traditional  method  of 
regional wall motion assessment as it is able to offer a more comprehensive assessment 
of LV function combined with the possibility of detecting ischaemic myocardial injury 
in its early stages.   
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Chapter Five 
Moderators of Intradialytic Morbidity  
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5.1  Hypotheses 
￿  Manipulating the HD prescription can improve  intradialytic morbidity during 
paediatric dialysis 
￿   The use of sodium and UF profiles improves cardiovascular stability 
￿  The prescribing of intradialytic mannitol reduces the frequency and severity of 
intradialytic symptoms 
￿   The application of sequential dialysis during the course of the dialysis treatment 
improves the UF potential  
 
 
5.2  Introduction 
The development of intradialytic symptoms and hypotension can result in premature 
discontinuation  of  treatment  and  delivery  of  sub-optimal  dialysis  with  an  attendant 
adverse impact on health
150. Broadly speaking dialysis failure (in the absence of clotting 
the extracorporeal circuit) has two aetiologies, dialysis dysequilibrium and UF mediated 
cardiovascular  decompensation.  The  challenge  is  that  during  an  acute  episode 
symptoms can be non-discriminatory and their pathophysiological mechanisms obscure. 
Thus developing strategies to prevent or manage dialysis failure is both difficult and 
may  have  variable  results.  The  recognised  measures  for  improving  haemodynamic 
stability during HD, such as avoiding food during dialysis
151 and treating intradialytic 
hypocalcaemia
16 are of limited value. Experience with newer methods such as sodium 
and UF profiles
78 and intradialytic mannitol are inconsistent and limited in paediatrics. 
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5.3 Subjects and Methods 
5.3.1  Prevalent chronic HD patients 
I developed a standardized practice for prescribing chronic HD at the Hospital for Sick 
Children, Toronto. After 8 months the data from these dialysis treatments was collected 
and analysed. I included all children on HD for a minimum of one month, excluding 
those patients receiving nocturnal HD and those that were acutely unwell and/or in the 
paediatric intensive care unit. Ethics approval for this study was granted by the local 
research  ethics  board  and  informed  consent  was  obtained  from  patients  or  their 
guardians. 
 
Patients 
Baseline characteristics of the patients and dialytic treatments are listed in Table 5.1. A 
total of 11 patients were studied, 5 female and 6 male. The underlying renal disease was 
focal segmental glomerulosclerosis (1 patient), autosomal recessive polycystic kidney 
disease  (1  patient),  renal  dysplasia  (4  patients),  chronic  drug  toxicity  and  BK  virus 
nephropathy  secondary  to  cardiac  transplant  (1  patient),  membranous 
glomerulonephritis  (1  patient),  ANCA  negative  glomerulonephritis  (1  patient), 
unknown (2 patients). 5/11 patients were polyuric (daily urine output >1.5mls/kg/hr); 
one had panhypopituitarism; one had a chronic history of intradialytic cramping; one 
had been treated with a second heart transplant and had evidence of significant right 
ventricular  dilatation  on  a  peak  dobutamine  stress  test  but  normal  right  and  left 
ventricular function at rest. The resting heart rate was no different between the cardiac 
transplant  patients  and  the  remaining  patients.  Throughout  the  observation  period  6 
patients were normotensive without medication, 2 patients were on one antihypertensive  
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and 3 patients were on two antihypertensives. 3/11 patients had evidence of ventricular 
or septal hypertrophy. 
 
Table 5.1: Baseline characteristics of patients and their dialytic treatments 
 
Sex (M/F)  5/5 
Age (years)  12.8 ± 2.93 
Dry weight (kg)  40.2 ± 15.6 
Urine output (yes/no)  5/5 
Urine output (mls/kg/hr)  1.61 ± 0.81 
Pre-dialysis plasma haemoglobin (g/l)  94.8 ± 11.9 
Pre-dialysis plasma albumin (g/l)  35.8 ± 4.63 
Pre-dialysis plasma ionised calcium (mmol/l)  1.24 ± 0.16 
Mean gross UF (mls/session)  1475 ± 937 
Mean gross UF (%body weight /session)  4.77 ± 2.09 
Blood flow rate (mls/min)  120-350 
Dialysate flow rate (mls/min)  200-650 
Kt/V  1.71 ± 0.27 
Mean Systolic BP at the start of dialysis (mmHg)  113 ± 20.5 
Mean Diastolic BP at the start of dialysis (mmHg)  68.1 ± 12.3 
Mean Heart rate at the start of dialysis (beats/min)  100 ± 19.2 
 
 
 
The Standardised HD Prescription 
All patients were dialysed using the Fresenius 2008K® or 2008H®. Patients received 
HD for 3hrs, 4 times per week or for 4hrs, 3 times per week. All dialysis membranes 
were  high  flux,  triacetate  cellulose  or  polysulfone  membranes.  Dialysis  flow  rates 
varied between 200 to 650mls/min but were kept constant by a dialysate to blood flow 
ratio  of  2  to  2.5.  Blood  flow  rates  were  calculated  to  provide  an  estimated  urea 
clearance of 4mls/kg/min. The dialysis prescription was adjusted monthly to achieve a   
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urea reduction ratio between 65 to 80% and Kt/V urea between 1.2 and 1.6 (calculated 
from  Daugiradas  single  pool  kinetics)
115.  All  patients  received  heparin  as  standard 
anticoagulation or no heparin if they were at a risk of bleeding. Patients were dialysed 
against 35mmol/l bicarbonate, 1.25mmol/l calcium, with a small quantity of acetate in 
the acidic component to stabilise the dialysate. The dialysate temperatures were set at 
constant value of 37.5˚C. Patients were permitted to consume one meal during the first 
hour  of  their  treatment.  Mannitol  was  given  if  the  pre-dialysis  plasma  urea 
concentration  was  greater  than  35mmol/l  or  if  the  patient  experienced  symptoms 
suggestive  of  dialysis  dysequilibrium  (severe  headaches  or  altered  levels  of 
consciousness) on at least two separate occasions during previous dialysis treatments. 
For these patients 1g/kg mannitol was administered intravenously during the first hour 
of the first weekly dialysis session or 0.5g/kg during two dialysis sessions per week. 
 
UF Profiles 
The prescribed UF rate was determined from the interdialytic weight gain plus the 
volume of fluid given during the dialysis treatment including priming fluid, blood 
products and nutrition. Pre-programmed Fresenius 2008K UF profile patterns outlined 
in Figure 5.1 were used (when the Fresenius 2008H machine was used the UF profiles 
were adjusted to match those on the 2008K model). As shown profile 3 was a 
decreasing step pattern, profile 6 an alternating high/low UF rate and profile 2 a 
decreasing linear pattern. The maximum UF rate in any programme did not exceed 1.5 
times the average rate. 
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Figure 5.1: UF profiles 
 
 
Dialysate Sodium Ramping 
All  standard  treatments  were  prescribed  a  universal  dialysate  sodium  gradient  of 
148mmol/l at the start of dialysis, ending with a concentration of 138mmol/l. During the 
linear sodium profile the dialysate sodium was decreased at a linear but constant rate to 
the  final  concentration.  During  the  step  profile  the  starting  dialysate  sodium  was 
continued until the last 30 minutes of dialysis and then dropped in one step to the final 
concentration.   
 
Study Protocol 
A step wise approach to sodium and UF profiling was introduced for all the patients.  
Step 1: linear sodium profile + UF profile 3 for one week, followed by one week of step 
sodium profile + UF profile 3. The patient was then continued on the regimen with the 
least intradialytic symptoms, unless 2 treatment failures occurred, as defined below. In 
the event of two treatment failures the patient moved to Step 2, namely: linear sodium 
profile + UF profile 6 for one week, followed by one week of step sodium profile + UF 
profile  6.  The  patient  again  continued  on  the  regimen  with  the  least  intradialytic 
symptoms, unless a further 2 treatment failures occurred. The patient then moved to  
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Step 3: linear sodium profile + UF profile 2 for one week, followed by one week of step 
sodium  profile  +  UF  profile  2.  This  was  continued  on  the  regimen  with  the  least 
intradialytic  symptoms,  unless  2  treatment  failures  occurred.  Finally  Step  4:  linear 
sodium profile + UF profile 0 (constant UF rate) for 1 week, followed by one week of 
step sodium profile + UF 0. This was continued on the regimen with the least intra-
dialytic symptoms, unless 2 treatment failures occurred. At this point the patient exited 
form the study protocol.   
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 Treatment failure was defined as, i) premature discontinuation of the dialysis session, 
ii) intradialytic hypotension requiring a fluid bolus and iii) failure to achieve the dry 
weight only if the UF goal was less than or equal to 5% of the dry weight. 
 
During each dialysis treatment the patient’s heart rate, gross UF volume and BP was 
recorded hourly, at the time of an adverse event prior to any nursing intervention, and 
after recovering from it. A single BP reading was taken with an automated Dinamapp 
machine and a cuff adjusted for size. The first Task Force 5th percentile systolic blood 
pressure  measurements,  adjusted  for  age  and  sex
8  were  used  to  define  intradialytic 
hypotension except in a single patient with co-existing panhypopituitarism in whom the 
cut-off  systolic  blood  pressure  was  set  at  75mmHg.  In  the  event  of  a  hypotensive 
episode UF was stopped and if the BP failed to recover after 15 minutes or the patient 
began to clinically deteriorate, a bolus of normal saline was administered.  
 
In addition the following information was recorded during each treatment: i) description 
of intradialytic symptoms, ii) nature of any dialysis nurse intervention, iii) changes to 
the UF rate, and iv) administration of mannitol, blood products, or fluid boluses. At the 
end of the dialysis treatment the patient’s weight and final UF volume was recorded. 
The dry weight was assessed monthly by a clinical assessment combined with a review 
of  post-dialysis  weights  at  which  the  patient  displayed  no  symptoms  indicative  of 
under-hydration at the end of their treatment.  
   
Outcome Measures 
The outcome measures were categorized into 4 distinct groups: 
OUTCOME 1 - occurrence of intradialytic symptoms and/or temporary suspension UF   
 
140
OUTCOME 2 - administration of saline bolus and/or episode of hypotension 
OUTCOME 3 - success in achieving the desired dry weight 
OUTCOME 4 - UF volume expressed as a percentage of the dry weight calculated from 
the gross UF volume as the denominator  
 
The primary endpoints were a comparison of sodium ramping and UF profiles 2,3 and 6 
against  the  defined  outcome  measures  and  to  determine  the  effects  of  intradialytic 
mannitol on these outcomes. The secondary endpoint was determining the volume of 
UF that was achievable by our standardized dialysis prescription. Polyuric patients were 
excluded from the analyses for OUTCOMES 3 and 4. 
 
Statistical Analyses 
All values of continuous variables were presented as mean ± standard error or 95% 
confidence interval. A paired t test was used to determine whether there were significant 
differences between continuous variables at the 95th confidence interval. The incidence 
of  observed  events  was  expressed  as  a  percentage,  dividing  the  number  of  sessions 
during which an event occurred over the total number of sessions. For a more robust 
statistical comparison of the impact of the different treatments on outcome, a repeated 
measures Generalized Estimating Equations model was fitted to the data to account for 
the internal correlation structure of the data as a result of having repeated measures per 
subject. Treatment comparisons of linear versus step, 4 different sodium profiles, UF 
profile  0  versus  2,  3  and  6  and  mannitol  versus  no  mannitol  were  analysed  and 
expressed  as  an  odds  ratio.  A  repeated  measures  ANOVA  model  was  fitted  to  the 
percent dry weight data, our only continuous outcome. All statistical tests were two 
tailed with a p-value less than or equal to 0.05 taken to indicate significance.  
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5.3.2  Children prone to dialysis failure 
Patients 
During the previous study any child that had premature discontinuation of their dialysis 
treatment at minimum once weekly, on 3 separate occasions per treatment month, was 
selected. Of the 11 children, 6 were identified as being prone to severe intradialytic 
symptoms or hypotension and recruited for this study. The patient demographics are 
shown in Table 5.2. Ethics approval for this study was granted by the local research 
ethics board and informed consent was obtained from patients or their guardians. 
 
Dialysis Prescriptions 
All  patients  were  dialysed  against  the  standardised  HD  prescription  for  3  hours  4 
times/week or 4 hours 3 times/week using high flux membranes with dialysis flow rates 
between 200 to 650mls/min and blood flow rates adjusted to provide an estimated urea 
clearance of 4mls/kg/min. All patients were dialysed against 35mmol/l bicarbonate with 
a small quantity of acetate in the acidic component to stabilise the dialysate, 1.25mmol/l 
calcium solution and decreasing sodium profiles of 145-148mmol/l at the onset falling 
to 135-138mmol/l in a step-wise manner. The dialysate temperature was set at 37.5˚C 
and treatments were programmed using a constant UF (UF profile 0).  
 
All 6 patients underwent a trial of prophylactic mannitol and sequential dialysis.  
Mannitol  was  given  if  the  pre-dialysis  plasma  urea  concentration  was  greater  than 
35mmol/l or if the patient experienced symptoms suggestive of dialysis dysequilibrium 
(severe headaches or altered levels of consciousness) on at least two separate occasions 
during previous dialysis treatments. For these patients 1g/kg mannitol was administered 
intravenously during the first hour of the first weekly dialysis session or 0.5g/kg during  
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two dialysis sessions per week. Mannitol was diluted in saline using 50mls of normal 
saline per 10g of mannitol. In children with repeated episodes of UF failure sequential 
dialysis was prescribed at the start or end, for 30 minutes during 3hr treatments or 60 
minutes during 4hr treatments. 
 
Table 5.2: Children prone to dialysis failure: patient demographics 
 
VSD: ventricular septal defect 
  ASD: atrioseptal defect 
  LVH: left ventricular hypertrophy 
 
Patient  Age  Primary Renal 
Disease 
Co-morbidities  Urine 
Output 
(mls/kg/d) 
Cardiac 
Echocardiogram 
[Antihypertensives] 
1  11  Membranous 
glomerulonephritis 
Developmental delay 
Syndromic 
Bone marrow suppression 
Panhypopituitarism 
0  Normal 
 
[None] 
2  16  ANCA positive 
glomerulonephritis  
Absence seizures 
Poor adherence 
0  Mild septal LVH 
 
[Amlodipine & 
Atenolol] 
3  7  ? Nephronophthisis  G6PD deficiency 
Hepatic fibrosis 
Subdural effusions with 
cerebroperitoneal shunt 
in-situ 
Intradialytic hypertension 
2.9  Normal 
 
[Atenolol & 
Enalapril] 
4  15  Hypo-
complementemic  
glomerulonephritis  
Biliary hypoplasia  
Failed liver transplant 
Splenomegaly & portal 
hypertension. Recurrent 
haematemesis secondary 
to oesophageal varices 
Pancytopenia 
Scurvy and  malnourished 
0.2  Mild concentric 
LVH 
 
[None] 
5  14  Autosomal 
recessive 
polycystic kidney 
disease 
Caroli’s disease with 
hepatic fibrosis & retinal 
dystrophy 
Splenomegaly & portal 
hypertension 
Pancytopenia 
0  Normal 
 
[None] 
6  11  Solitary ectopic 
dysplastic kidney 
Female hypospadius 
Poor adherence 
ASD, VSD 
Scoliosis 
1.8  Small restrictive 
VSD. No LVH 
 
[None]  
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Study Protocol 
During  dialysis  the  patient’s  heart  rate  and  BP  was  recorded  hourly  throughout 
treatment,  at  the  time  of  symptoms  and  upon  recovery.  The  first  Task  Force  5th 
percentile systolic BP measurements
8 defined intradialytic hypotension except in Patient 
1 whose cut-off systolic BP was set at 75mmHg. In the event of a hypotensive episode 
UF was stopped and if the BP failed to recover after 15 minutes or the patient began to 
clinically  deteriorate,  a  bolus  of  normal  saline  was  administered.  At  the  end  of  the 
dialysis treatment the patient’s weight and final gross UF volume was recorded. The dry 
weight was assessed monthly and qualified from a clinical assessment combined with a 
review  of  the  post-dialysis  weight  and  the  onset  of  symptoms  indicative  of  under-
hydration following dialysis.  
 
Outcome Measures 
The outcome measures were categorized into 3 groups:  
OUTCOME 1 -  intradialytic  symptoms  (abdominal  pain,  cramps,  headaches,  loss  of 
consciousness or change in behaviour) 
OUTCOME 2 - hypotension or premature discontinuation of dialysis, due to persistence 
of hypotension/ symptoms in spite of a single fluid bolus 
OUTCOME 3 - percentage dry weight removed (calculated as gross UF volume divided 
by the estimated dry weight). 
 
Statistical Analyses 
All values of continuous variables were presented as mean ± standard error.  A paired t 
test  was  used  to  determine  whether  there  were  significant  differences  between 
continuous variables at the 95
th confidence interval. For a statistical comparison of the  
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impact  of  the  different  treatments  on  outcome,  a  repeated  measures  Generalized 
Estimating Equations model was fitted to the data to account for the internal correlation 
structure of the data as a result of having repeated measures per subject. A repeated 
measures ANOVA model was fitted to the percent dry weight data, our only continuous 
outcome. All statistical tests were two tailed with a p-value less than or equal to 0.05 
taken to indicate significance. 
 
 
5.4 Results 
5.4.1  Prevalent chronic HD patients 
A total of 506 dialysis treatments were reviewed with 162/506 (32%) from polyuric 
patients.  A  linear  sodium  profile  of  148mmol/l  to  138mmol/l  was  used  in  219/506 
(43%) treatments and a step profile in 287/506 (57%). UF profile 2 was used in 103/506 
(20%) treatments, UF profile 3 in 137/506 (27%) treatments, UF profile 6 in 19/506 
(4%)  treatments  and  no  UF  profile  in  287/506  (57%)  treatments.  Mannitol  was 
prescribed in 48/502 (9%) treatments.  
 
The  prevalence  of  intradialytic  symptoms  (OUTCOME  1)  was  26%.  Intradialytic 
hypotension or administration of a fluid bolus (OUTCOME 2) occurred in 19%. The 
desired  dry  weight  was  achieved  in  124/344  (36%)  treatments  from  non-polyuric 
patients.  Using  our  standardized  dialysis  prescription  combining  sodium  and  UF 
profiling and intra-dialytic mannitol we achieved UF goals ranging from 3.2% to 9.7% 
of the dry weight (OUTCOME 4). Analysed individually the mean UF volume for all 
the  interventions  were  greater  than  the  current  recommendations  of  5%  from  the  
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European Haemodialysis Guidelines
152 with mannitol achieving the highest mean UF 
volume (see Table 5.3). 
 
The overall treatment failure rate was 33% (167/506 treatments). Treatment failure due 
to premature discontinuation of the dialysis session occurred in 20/506 treatments and 
of these 5 were due to hypotension episodes and 15 due to intradialytic symptoms. 
Failure due to the development of intradialytic  hypotension requiring  a saline bolus 
occurred in 37/506 treatments. Finally 115/506 treatments failed to achieve the desired 
dry weight, despite a target UF goal less than 5%. The treatment protocol resulted in 
significant  morbidity  in  one  patient  who  had  a  history  of  panhypopituitarism,  bone 
marrow failure and was prone to hypotensive episodes. He became unconscious during 
4 dialysis treatments. This was associated with marked hypotension and bradycardia 
and was thought to be secondary to a Bezold-Jarisch reflex. Owing to the severity of his 
symptoms he was excluded from the protocol prematurely but his data was included and 
analysed  up  to  and  including  the  4th  episode.  One  patient  developed  intradialytic 
symptoms  and  interdialytic  fatigue  with  UF  profile  6  on  two  consecutive  dialysis 
sessions and refused further treatments with UF profile 6.   
 
Linear Versus Step Sodium Ramping 
There was no significant difference between linear and step sodium ramping and the 
onset  of  intradialytic  symptoms.  Compared  with  the  step  profile  the  linear  profile 
increased the odds of hypotensive episodes or premature discontinuation of treatment by 
27%  (see  Table  5.4).  The  likelihood  of  achieving  the  dry  weight  was  no  different 
between the step and linear sodium profiles and the mean UF volume for both was 
virtually identical at 5.4% of estimated dry weight (see Table 5.3).     
 
146
UF Profiles 
The UF profiles were no better than a constant UF rate (UF profile 0) in preventing 
intradialytic symptoms, hypotensive episodes or premature discontinuation of dialysis 
(see Table 5.4). UF profile 2 was the least effective in achieving the desired dry weight, 
reducing the odds by 40% when compared to a constant UF rate, reducing the odds by 
60% compared with profile 3 and reducing the odds by 36% when compared against UF 
profile 6. The latter was not statistically different and neither were the remaining UF 
profile comparisons. Profile 3 increased the odds of achieving the dry weight by 50% 
compared with a constant rate and UF profile 6 was virtually identical to a constant UF 
rate (see Table 5.4). The mean UF was however higher with all 3 profiles compared to 
UF  profile  0,  but  only  the  difference  between  profile  2  and  0  were  statistically 
significant (Table 5.3). Therefore all 3 UF profiles had mean UF volumes greater than 
5% of the dry weight but none of them significantly increased the odds of achieving the 
dry weight.  
 
Mannitol 
Compared  to  dialysis  treatments  without  mannitol,  the  administration  of  mannitol 
reduced the odds of intradialytic symptoms by 64% (p<0.05) but did not improve the 
odds of preventing intradialytic hypotension or achievement of the desired dry weight 
(see Table 5.4). The mean UF volume was statistically greater with mannitol compared 
to those without, with a mean of 6.2% of the dry weight (see Table 5.3). 
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Table 5.3:  Comparison of the Percentage Dry Weight Removed  
 
 
 
 
 
 
 
 
 
 
 
 
 
A : the difference between UF profile 0 and profile 2 was significant (p<0.05) 
* : the difference between mannitol versus no mannitol was significant (p<0.05) 
[For the remainder the differences were not statistically significant] 
 
 
Table 5.4: Odds ratios of defined outcomes against each dialytic intervention 
 
 
 
 
 
 
  
 
 
 
 
 
 
Outcome 1:  Odds of intradialytic symptoms 
Outcome 2:  Odds of hypotensive episode and /or administration of saline bolus  
Outcome 3:  Odds of successfully achieving the desired dry weight 
  All patients excluding those with polyuria 
 Mean [95% CI] 
Linear sodium  5.41  [4.97 – 5.86] 
Step sodium  5.37  [4.96 – 5.78] 
UF profile 0  5.03  [4.68 - 5.38] 
A 
UF profile 2  5.99  [5.49 – 6.49] 
UF profile 3  5.61  [4.98 – 6.25] 
UF profile 6  6.11  [5.26 – 6.96] 
Mannitol  6.18  [5.39 – 6.9] * 
OVERALL  5.39  [5.07 – 5.71] 
  OUTCOME 1  OUTCOME 2  OUTCOME 3 
Linear v Step sodium  1.61  (p=0.10)  1.27  (p=0.05)  1.25  (p=0.54) 
UF profile 2 v 0  1.58  (p=0.16)  0.77  (p=0.28)  0.60  (p<0.05) 
UF profile 3 v 0  1.66  (p=0.28)  0.91  (p=0.81)  1.46  (p=0.24) 
UF profile 6 v 0  1.47  (p=0.6)  1.50  (p=0.21)  0.95  (p=0.82) 
UF profile 2 v 3  0.95  (p=0.87)  0.85  (p=0.78)  0.41  (p<0.05) 
UF profile 2 v 6  1.08  (p=0.9)  0.51  (p=0.23)  0.64  (p=0.07) 
UF profile 3 v 6  1.13  (p=0.74)  0.61  (p=0.11)  1.54  (p=0.14) 
Mannitol v no mannitol  0.36  (p<0.05)  1.06  (p=0.89)  1.15  (p=0.82)  
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5.4.2   Children prone to dialysis failure 
Of 399 dialysis treatments intradialytic mannitol was given in 57 (17%) and sequential 
dialysis in 44 (11%). Intradialytic mannitol significantly increased mean treatment UF 
volume  (see  Table  5.5),  86%  of  the  treatments  achieved  UF  volumes  greater  than 
average for that individual patient and one third achieved their dry weight. Mannitol 
halved the odds of intradialytic symptoms and hypotension/premature discontinuation 
of  dialysis  (see  Table  5.6).  Sequential  dialysis  also  halved  the  odds  of  intradialytic 
symptoms (see Table 5.6). Intradialytic hypotension developed in 50% of the treatments 
but dialysis was only prematurely discontinued in 2% of treatments and 2 out of 3 
treatments achieved UF volumes greater than the average for an individual patient (see 
Table 5.5).  
 
 
Table 5.5: Prevalence rates of intradialytic morbidity and achieving the desired UF goal with 
intradialytic mannitol and sequential dialysis  
 
Intervention  Symptoms 
 
Hypotension 
 
Premature 
discontinuation 
of treatment 
Dry Weight 
Achieved 
UF as Percentage 
Dry Weight 
Mean [95% CI] 
Mannitol  6/57(11%)  3/57 (5%)  3/57 (5%)  * 9/29(31%)  5.55 
[5.04 – 6.06] 
Sequential  1/44 (2%)  23/44 (53%)  1/44 (2%)  18/44 (41%) 
10/21(48%) 
4.23 
[3.66 – 4.80] 
 
 
† Average UF volume for each patient was calculated from the total number of dialysis  
session over a 6 month period.  
 
* excluding polyuric patients  
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Table 5.6: Impact of mannitol and sequential dialysis on intradialytic symptoms and 
hypotension  
 
 
 
 
 
Outcome 1:  Odds of intradialytic symptoms 
Outcome 2:  Odds of premature dialysis discontinuation and/or administration of saline bolus  
and/or episode of hypotension 
 
 
Table 5.7: Chi-squared analysis of interventions mannitol and sequential dialysis and outcomes 
 
 
 
 
 
 
Degrees of freedom: 1 
p value is the probability of the null hypothesis being true 
 
Outcome 1:  Odds of intradialytic symptoms 
Outcome 2:  Odds of premature dialysis discontinuation and/or administration of saline bolus  
and/or episode of hypotension 
 
 
In patient 1 the odds of intradialytic hypotension was 23 times greater than the group 
risk. His pre-dialysis systolic BP ranged between 85-105mmHg and his interdialytic 
weight gain frequently exceeded 5% his dry weight. The patient’s predisposition for 
hypotension was often during the second hour of dialysis and was often associated with 
bradycardia. Sequential dialysis reduced intradialytic symptoms but not hypotension. 
Twice weekly mannitol reduced the odds of symptoms and hypotensive episodes but the 
  OUTCOME 1  OUTCOME 2 
Mannitol v no mannitol  0.44  (p<0.05)  0.56  (p<0.05) 
Sequential v no sequential  0.47  (p<0.05)  2.45  (p<0.05) 
  OUTCOME 1  OUTCOME 2 
Mannitol   2.64   
(p=0.10) 
0.35  
(p=0.18) 
Sequential   1.16  
(p=0.20) 
1.61  
(p=0.28)  
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UF potential was unchanged. As an isolated case I then elected to trial intradialytic 
midodrine. In the event of a declining BP 2.5mg of oral midodrine was given. If the BP 
failed to improve within 30 minutes or fell below 75mmHg a further 2.5mg dose was 
given. A cut-off of 7.5mg total dose was applied per 3 hour treatment and no midodrine 
was given in the final 30 minutes irrespective of BP. On using intradialytic midodrine 
no intradialytic symptoms were observed and the mean treatment UF volume increased 
from  3.74%  to  3.96%,  achieving  higher  than  average  UF  volumes  in  95%  of  the 
treatments and the desired dry weight in one third of the treatments (see Table 5.6). 
During 18 of 20 observed dialysis sessions a 2.5mg oral dose of midodrine produced a 
10-15mmHg increase in the systolic BP within 30 minutes of administration and no 
adverse effects were reported in the intradialytic or interdialytic period.   
 
 
5.5 Discussion 
The  uraemic  milieu  impairs  compensatory  responses  to  haemodynamic  stress  with 
ineffective venoconstriction, inadequate cardiac refilling, reduced plasma refilling and 
activation  of  the  sympaticoinhibitory  Bezold–Jarisch  reflex  leading  to  sudden 
hypotension
153.  In  paediatrics  more  often  than  not  we  are  faced  with  the  additional 
challenge of large UF goals. During standard 4 hour HD sessions this combination can 
result in decompensation and morbidity. I have shown both in prevalent dialysis patients 
and  in  high  risk  children  that  are  prone  to  hypotension  that  manipulation  of 
conventional HD prescriptions can improve the dialysis experience. 
 
Children  may  not  understand  or  appreciate  the  long-term  implications  of  chronic 
hypervolaemia and are often non-adherent to their fluid restrictions. The excess fluid  
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accumulates  both  in  the  intravascular  and  extravascular  compartments,  but  only  the 
former is amenable to UF during dialysis. During their treatments they often do not 
voice  the  onset  of  symptoms  until  they  are  severe  or  associated  with  hypotension. 
Children  have  compliant  high  capacitance  vessels  and  hypovolaemia  may  occur 
suddenly with little warning. This reduces the opportunity to change the UF rates before 
the intravascular volume becomes compromised. As a result, cautious UF goals of 5% 
of the dry weight have been recommended
152. In paediatrics, Jain et al were the first to 
challenge  this  recommendation  by  introducing  the  concept  of  adjusting  UF  rates 
according to changes in RBV
43. They reported reduced dialysis associated morbidity 
providing the UF volumes did not result in a blood volume change greater than 8% in 
the first hour and 12% over the dialysis session. In comparison I have demonstrated that 
through  the  use  of  dialysis  regimens  combining  sodium  ramping,  UF  profiles  and 
intravenous mannitol, UF volumes of up to 9% of the dry weight can be achieved.  
The  intravascular  compartment  is  continuously  changing  during  dialysis  as  fluid  is 
removed  by  UF  but  refilled  from  the  interstitial  compartment.  The  total  circulating 
blood  volume  during  a  dialysis  treatment  is  therefore  greater  than  that  of  a 
normovolaemic individual with a significant inter-patient and intra-patient variation in 
the pattern of RBV change
151. Therefore any dialytic measure that promotes vascular 
refilling  or  improve  cardiovascular  stability  should  in  theory  help  to  restore 
normovolaemia  and  increase  the  UF  potential  in  dialysis  patients.  Sodium  profiling 
provides a diffusive sodium influx at the start of dialysis to counterbalance the rapid 
decline  in  plasma  osmolarity  from  clearance  of  uraemic  solutes,  ending  with  a  low 
dialysate sodium concentration to encourage diffusive clearance of the sodium load. 
Compared with a constant dialysate sodium concentration, ramps have been associated 
with  increased  stability  of  the  intradialytic  blood  volume  and  reduced  intradialytic  
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cramps and interdialytic fatigue in adults
78, 127 and in older children
78. This is in keeping 
with  the  findings  of  this  study,  whereby  the  odds  of  intradialytic  hypotension  were 
reduced with a step ramp compared to a linear ramp. This is most likely due to a longer 
period  of  increased  plasma  osmolarity  that  promoted  vascular  refilling.  There  is  in 
theory  a  price  to  be  paid  with  a  potential  of  chronic  sodium  loading  driving  thirst, 
chronic water expansion and increasing interdialytic weight gain. In this study no long 
term data pertaining to interdialytic symptoms or weight gain was measured.   
 
The RBV at the point of decompensation shows large intra-patient and inter-patient 
variability but the vascular refilling capacity is always proportionately higher when the 
interstitial volume is expanded. This provides the rationale for UF profiles. Donauer et 
al reported a reduction in symptomatic hypotension episodes on profiles with decreasing 
UF rates with time on HD
81. The outcomes of this study have been less favourable, I 
found no difference between profiling and a constant UF rate in preventing intradialytic 
symptoms  or  hypotension  and  in  fact  found  that  UF  profile  2  reduced  the  odds  of 
achieving the desired dry weight. The mean UF volumes were greater in the UF profile 
groups  compared  with  treatments  applying  constant  UF  rates,  but  the  gain  was 
insufficient to increase the ability to achieve the desired dry weight. These contradictory 
results may be a reflection of the small sample size that was under-powered to reveal 
small differences. Alternatively the results are valid and are indicative of the problem of 
high UF rates that are characteristic to UF profiles. These periods of higher than average 
UF rates, or variable duration may exceed the body’s capacity to compensate, offering 
very limited reserve for variations in refilling capacity and thus at best only achieve 
minor gains in dialysis quality. In truth attempting to address the issue of large UF goals 
with techniques focusing on UF rates alone without consideration to refilling rates are in  
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reality destined to fail. In comparison automated RBV biofeedback techniques or more 
simply, RBV driven algorithms
89 that adjust UF rates according to RBV changes are 
successful in achieving equivalent or higher UF volumes with reduced cardiovascular 
instability.  
 
Mannitol is a drug traditionally used in the management of dialysis disequilibrium as it 
can  artificially  increase  plasma  osmolarity.  In  prevalent  dialysis  patients,  treatments 
prescribed mannitol achieved the highest mean UF volumes coupled with a significant 
reduction  in  the  odds  of  symptoms,  hypotensive  episodes  and  the  premature 
discontinuation of dialysis. Such positive outcomes were mirrored in the patients prone 
to hypotension. Mannitol requires dilution in saline prior to administration. Every 10g 
of  mannitol  is  diluted  in  100mls  of  normal  saline  and  thus  concurrently  delivers 
15mmol of sodium to the intravascular compartment during the infusion. Therefore one 
could simply attribute its benefits to the fluid bolus that is inadvertently given and the 
increased gross UF volumes could be the result of filtering this fluid load. The counter-
argument to this is that the benefits of mannitol exceed that of a saline bolus. Mannitol 
also differs in the fact that it is an osmotically active solute that unlike sodium does not 
leak into the interstitium and thus provides a more sustained oncotic effect. On a note of 
caution this osmotic effect could theoretically be counter-productive as it runs a risk of 
inducing thirst in the interdialytic period with resultant escalating hypervolaemia. An 
alternative  explanation  to  mannitol’s  success  is  that  it  successfully  treated  milder 
degrees of disequilibrium, thus allowing treatments to proceed to completion. The true 
incidence of dysequilibrium is unknown but children, by virtue of their age, are deemed 
high risk. One patient also had an additional risk from co-existing neurological disease. 
It is also conceivable that within this context, the benefits of mannitol may have been  
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more pronounced as children are less likely to communicate symptoms until they are 
severe. 
 
Abnormal  baroreflex  sensitivity,  altered  vascular  physiology,  reduced  coronary  flow 
reserve  are  integral  to  cardiovascular  decompensation  during  dialysis
150,  154.  The 
resultant  effect  is  failure  to  preserve  the  central  blood  volume  and  myocardial 
dysfunction secondary to a reduction in global and regional myocardial blood flow
65. 
During HD, UF activates sympathetic vasoconstriction, reducing skin blood flow and 
therefore heat exchange, with a direct correlation between UF volume and the amount 
of  heat  gained
97.  During  isolated  filtration  there  is  significant  cooling  over  the 
extracorporeal  circuit  and  this  attenuates  the  increase  in  core  temperature
98,  155.  In 
patients prone to hypotension short-periods of sequential dialysis reduced intradialytic 
symptoms and half of the patients achieved their dry weight by the end of dialysis, but 
the  risk  of  hypotension  was  unchanged.  If  we  are  to  believe  that  the  benefits  of 
sequential dialysis are related to cooling then one can understand how short bursts of 
isolated UF have limited gain as the remainder of the dialysis time is spent at dialysate 
temperatures of 37.5˚C. This would negate any changes in core temperature that may 
have  been  achieved  during  sequential  dialysis.  Furthermore  it  is  probable  that  with 
longer periods of sequential dialysis or by reducing the dialysate temperatures during 
the remainder of the treatment outcomes may have improved further. 
 
Midodrine was not part of the study protocol but was used as rescue therapy in one of 
the patients and hence deserves to be part of this discussion. Midodrine is a prodrug of 
desglymidodrine, a specific a-1 adrenergic agonist that increases intradialytic BP by 
mediating constriction of both arterial and venous capacitance vessels, thus preventing  
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venous  pooling  while  supporting  central  BP.    Oral  administration  in  our  patient 
achieved  peak  levels  within  1hr  and  I  saw  no  evidence  of  prolonged  hypertension 
beyond the period of dialysis in spite of pharmacokinetic data indicating a half-life of 
3hrs. Minor adverse reactions such as scalp paraesthesia, heartburn, flushing, headache, 
weakness and neck soreness have been described
156 but no such adverse effects were 
witnessed. Adult nephrologists have the greatest experience with midodrine and report 
variable success but our results mirror those of Blowey et al reporting a benefit in an 18 
year old
157. This single experience in a very difficult patient was very encouraging and 
certainly places midodrine in a position of priority for future research.  
 
 
5.6  Study Limitations 
The patient cohort was a small, heterogeneous group. In addition by virtue of the study 
protocol  the  exposure  to  the  different  interventions  also  varied  between  patients 
reducing  intervention  specific  numbers  further.  Therefore  my  findings  may  be  a 
reflection of the fact that the study was underpowered for small differences between the 
interventions and the results may have been different in a larger cohort. In a bid not to 
restrict numbers further all prevalent dialysis patients were recruited, including those 
with congenital heart defects. We know that the structural and physiological properties 
of the cardiovascular system are susceptible to change with disease. All of the cardiac 
patients were found to be susceptible to intradialytic symptoms and hypotension and 
hence they may have introduced a bias in the study of prevalent dialysis patients. Their 
inclusion  within  the  second  study  with  other  high  risk  patients  was  probably  more 
appropriate  and  encouragingly  the  results  were  no  different.  In  paediatric  HD,  the 
prevalent dialysis patients tend to be children unsuitable for peritoneal dialysis, with  
 
156
several co-morbidities, therefore even from the very onset of this study a selection bias 
was introduced. This also raises an important question on whether the baseline risk for 
cardiovascular compromise in prevalent HD patients differs from stable uncomplicated 
uraemic children. 
 
Within the study protocol it was impossible to control the UF prescription per dialysis 
treatment as this would have compromised patient well being. However there is a clear 
relationship between UF volumes and the risk of intradialytic morbidity. The problem is 
confounded further by the fact that tolerance to UF varies between patients and between 
treatments as illustrated in Chapter 3. Therefore even if statistical adjustments of the 
analyses for UF volumes were attempted this bias could not have been eliminated in this 
study.   
 
This  is  a  preliminary  study  and  being  conscious  of  time  and  the  relatively  quick 
turnover  of  patients  within  paediatric  dialysis  units  I  did  not  elect  to  introduce 
interventions  separately.  For  example  sodium  ramping  was  part  of  the  standard 
prescription in the study of patients prone to hypotension and was used in combination 
with the UF profiles in the prevalent dialysis patients study. As a consequence it is hard 
to know whether the results achieved were exclusively attributable to the intervention in 
question or due to the synergistic effect of all the interventions that were present per 
dialysis treatment. 
 
Finally on a number of occasions in the discussion I have raised concerns of the long 
term effects of some of these interventions such as sodium profiling and intradialytic 
mannitol and the theoretical risk of chronic volume expansion. Follow up within this  
 
157
study was short and data primarily concentrated on the intradialytic period and not the 
interdialytic period. In the battle against UF failure, preventative measures that limit salt 
and  water  intake  are  equally  important,  if  not  more  important  than  intradialytic 
strategies aimed at treating salt and water excess. The lack of data on the long-term 
consequences of these interventions is a shortcoming of this study and is certainly an 
area thus needs to be explored in future studies. 
 
 
5.7  Conclusion 
During standard 4 hour HD regimens the evidence for the cardiovascular burden of HD 
is  growing  stronger  and  with  it  the  urgency  for  change  in  the  way  we  dialyse  our 
patients. Improving dialysis failure is essential for patient well-being and will only be 
achieved  following  a  better  understanding  of  the  underlying  mechanism.  Through  a 
multidirectional  approach,  utilising  strategies  that  improved  plasma  refilling  and 
supported  the  central  blood  volume  I  have  demonstrated  an  attenuated  risk  of 
intradialytic morbidity in both prevalent dialysis patients and children that are prone to 
hypotension.  In  our  most  resistant  case  oral  midodrine  was  the  only  viable  rescue 
option, nonetheless experience with midodrine in paediatrics is still very limited and its 
efficacy needs to validated in larger, randomised trials prior to recommending it for 
general use. 
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Chapter Six 
Thesis Summation  
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Paediatric HD patients are typically children that are unsuitable for home peritoneal 
dialysis, the default mode of dialysis, owing to social and/or medical co-morbidities. 
Whether this translates to a higher baseline risk of cardiovascular disease is unknown 
but  what  has  become  apparent  from  this  research  are  the  similarities  in  adverse 
outcomes related to in-centre, conventional HD sessions between children and adult HD 
patients. 
 
During conventional 4 hour paediatric HD treatments the prevalence of intradialytic 
hypotension ranged between 20-30%, a rate that is comparable to adult HD patients. In 
an attempt to restore euvolaemia at the end of each of their dialysis treatments UF goals 
as high as 9% of the dry weight were successfully attempted in the children but this was 
associated with a RBV reduction of 30%. More commonly UF goals of up to 6% of the 
dry  weight  were  prescribed  and  this  resulted  in  a  marked  inter-  and  intra-patient 
variability of RBV change that was not predictive of the onset of adverse intradialytic 
events. This supports the concept that decompensation during HD is not just related to 
changes in intravascular blood volume but other factors are also important. Tachycardia, 
a signal for the onset of compensatory mechanisms, and the severity of RBV change 
during the first hour of dialysis were significantly predictive of impending intradialytic 
symptoms or hypotension. 
 
 It is clear from this data that conventional HD places a significant haemodynamic stress 
on the child and one that triggers compensatory cardiovascular mechanisms aimed at 
maintaining  circulation  adequacy.  However  the  nature  of  these  responses  varied 
between the patients studied. Nonetheless a pattern emerged. The cardiac output was 
more  dependent  on  a  chronotropic  response  than  ionotropic  response  while  the  
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intradialytic BP mirrored changes in peripheral vascular resistance. This also raised a 
suspicion  that  uraemic  children  have  an  attenuated  ability  to  increase  myocardial 
contractility during the course of HD.  
 
In children aged between 1 and 17 years there is functional and biochemical evidence of 
cardiac  injury  during  conventional  4hour  HD  manifesting  as  transient,  regional  LV 
myocardial dysfunction in association with an elevation of plasma cardiac enzymes in 
one quarter of patients. The degree of dysfunction was related to the UF volume and 
intradialytic  blood  BP.  In  addition  the  percentage  decline  in  LV  function  in  the 
longitudinal axis was predictive of changes in systolic BP during dialysis. I postulate 
that  the  characteristic  cardiovascular  phenotype  in  HD  patients  predisposes  to 
significant demand ischemia as illustrated in Figure 6.1. Conventional 4 hours HD is 
associated with increasing tachycardia and hypotension with a potential to cause an 
acute  fall  in  coronary  blood  flow.  Ordinarily  this  physiological  stress  is  met  and 
overcome by a  complex network of autoregulatory mechanisms within the coronary 
circulation  that  supports  and  maintains  an  appropriate  blood  supply  to  the  heart.  
However  owing  to  the  underlying  constellation  of  cardiovascular  disease  that  is 
typically found in uraemic children, the coronary reserve flow is impaired. Thus in the 
presence  of  an  increased  metabolic  demand,  such  as  dialysis,  the  limited  ability  to 
increase the oxygen supply to the heart results in a demand supply mismatch. Ischaemia 
prevails and this manifests as regional myocardial dysfunction. Owing to the design of 
the study it is impossible to decipher what factor takes the leads, the hypotension or the 
myocardial dysfunction. Regardless of the initiator, it is highly probable that the two are 
self-perpetuating.  
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The technique of speckle tracking 2D strain was superior to assessments of regional 
wall motion activity in detecting acute abnormalities in regional myocardial function. 
2D speckle tracking was both angle and translation independent and was therefore less 
influenced by intra-observer variability between images, improving its accuracy. It also 
provided  two  parameters  of  assessments,  the  peak  strain  and  inter-segmental 
synchronicity index. The latter is particularly sensitive in detecting ischeamic cardiac 
injury  and  therefore  in  this  setting  has  the  potential  for  becoming  a  screening  tool, 
looking for early evidence of dialysis induced cardiac injury and with it a window of 
opportunity to intervene before the myocardial injury becomes severe.  
 
The evidence for the cardiovascular burden of HD is growing stronger and with it the 
urgency for change in the way we dialyse our patients. Armed with greater details of the 
altered physiological responses during dialysis, a more directed approach to managing 
intradialytic morbidity is conceivable. During paediatric HD, patients are largely able to 
mount a tachycardic response but support is required to increase peripheral vascular 
resistance,  expand  the  central  blood  volume  and  augment  myocardial  contractility. 
Sodium  profiles  and  intradialytic  mannitol  encourage  plasma  refilling,  sequential 
dialysis prevents blood from being diverted away from the central blood volume and 
midodrine  increases  vascular  resistance.  All  four  interventions  were  shown  to  be 
effective  in  moderating  intradialytic  symptoms  and  hypotension,  midodrine  and 
sequential dialysis exclusively in high risk, hypotension prone patients.    
 
 
  
 
163
 
 
 
Chapter Seven 
Future Work  
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All the research that has been reported in this thesis is based on studies of a small 
cohort of HD patients from a single centre. First and foremost the results require 
validation from larger scale, long-term studies. The haemodynamic study (Chapter 
3) would benefit from a larger population base as this will allow the patients to be 
divided into relevant groups based on urine output, underlying renal disease and 
baseline risk of decompensation. These are factors that are likely to influence the 
compensatory  response  during  dialysis  and  any  information  gained  will  provide 
additional insight into any variations that exist and help direct focused strategies to 
improve HD related morbidity.  
 
The study examining the myocardial effects of dialysis (Chapter 4) was limited to 
the  acute  effects  on  the  heart  from  single  dialysis  sessions.  However  both  adult 
dialysis  data  and  the  model  of  coronary  artery  disease  allude  to  the  progressive 
nature  of  myocardial  stunning.  This  strengthens  the  case  for  gaining  long-term 
follow up data in children. In addition data following them longitudinally once they 
change renal replacement therapy, such as transplantation will provide invaluable 
information on the degree of reversibility of dialysis induced myocardial injury and 
the  risk  of  myocardial  injury  between  the  different  forms  of  renal  replacement 
therapies.  
 
The dialysis intervention study (chapter 5) measured the efficacy of various dialysis 
interventions in modifying intradialytic symptoms and prevalence of hypotension. 
One  battle  that  is  in  the  forefront  of  all  nephrologists  is  that  of  salt  and  water 
balance.  However  in  order  to  win,  strategies  have  to  be  directed  towards  the 
interdialytic period as well as the intradialytic period that was exclusively examined  
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here. Interventions such as sodium profiles and intradialytic mannitol increase the 
osmotic load during dialysis and this may have a knock on effect on chronic fluid 
and BP management. Long-term follow up is required to ascertain the impact of 
these dialysis interventions on the immediate and late interdialytic period both in 
terms of patient symptoms and volume status. Furthermore this work could also be 
extended  laterally  by  examining  differences  in  RBV  and  dialysis  induced 
myocardial dysfunction between the different interventions. Finally following on 
from the example set here and the success of midodrine in treating a very resistant 
case of intradialytic hypotension, its role in paediatric HD needs to be  explored 
further.  I  would  propose  a  randomised,  cross-over  trial  of  children  prone  to 
hypotension, supported by finometer, RBV change and regional myocardial function 
data.   
 
This thesis has introduced the concept of myocardial stunning in uraemic children 
and now additional work is necessary to understand the extent of the problem within 
the  paediatric  nephrology  population  base.  The  non-invasive  technique  of  2D 
speckle tracking lends itself well to these investigations.  
￿  I would like to start by investigating whether the chronicity of renal failure is 
important  in  medicating  myocardial  dysfunction.  I  plan  to  examine  this  by 
studying  patients  with  acute  renal  failure  on  continuous  renal  replacement 
therapy.  
￿  At present it is difficult to know whether ‘uraemia’ or the haemodynamic stress 
related  to  dialysis  is  the  dominant  factor  in  dialysis  induced  myocardial 
dysfunction.  Peritoneal  dialysis  (PD)  is  a  gentler  form  of  dialysis  that  is 
generally not associated with a large haemodynamic burden. An investigation of  
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children  on  PD  would  provide  further  insight  on  the  relationship  between 
uraemia and myocardial stunning.  
￿  At  Great  Ormond  Street  Hospital  for  Children,  we  have  initiated  plans  to 
develop a paediatric home HD programme. Frequent HD has been shown to be 
superior to conventional HD both in fluid management, BP control, intradialytic 
haemodynamic stability and dialysis quality, but the mechanisms remain elusive. 
I would like to use this opportunity to explore the potential role of myocardial 
stunning in the reported cardiovascular advantages linked to this patient cohort.  
￿  Sequential dialysis utilizes the principle of cooling to improve cardiovascular 
stability during paediatric HD but is adversely association with sodium loading. 
Applied  independently  within  conventional  HD  prescriptions,  cooling  of  the 
dialysate has cardiovascular benefits but the duration and intensity of cooling is 
limited  by  the  onset  of  symptoms  related  to  feeling  cold.  I  propose  a 
randomised,  cross-over  study  to  determine  the  optimal  paediatric  dialysate 
temperature for abrogation of intradialytic morbidity without inducing adverse 
symptoms. This study could potentially provide a widely applicable and cost-
effective intervention for reducing the cardiovascular burden that children carry 
into adulthood.   
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List of Abbreviations 
 
2D     two-dimensional  
AHA    The American Heart Association 
ANCA    anti-neutrophil cytoplasmic antibodies 
ANOVA    one-way analysis of variance 
ARPKD    autosomal recessive polycystic kidney disease 
BNP    brain natriuretic peptide 
BP     blood pressure 
CRP    C-reactive protein  
cTnI    cardiac troponin-I 
cTnT    cardiac troponin-T 
CO     cardiac output 
CAD    coronary artery disease 
CKD    chronic kidney disease 
CI      confidence interval 
EF     ejection fraction 
ESRD    end stage renal disease 
FSGS    focal segmental glomerulosclerosis 
hsCRP    high sensitivity C-reactive protein 
HD     haemodialysis 
HR     heart rate 
IL-6    interleukin 6 
LV     left ventricle 
LVH    left ventricular hypertrophy  
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MBF    myocardial blood flow 
NIVM    non-invasive blood volume monitors 
PD     peritoneal dialysis 
PET    photon emission computed tomography 
ROC    receiver operating characteristics curve 
RBC    red blood cell 
RBV    relative blood volume 
RWMA    regional wall motion abnormalities 
SV     stroke volume 
TPR    total peripheral resistance 
UF     ultrafiltration 
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